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Introduction
The incidence and prevalence of neurodegenerative diseases - defined
as early loss of specific neurons (Graeber and Moran, 2002) - rises with age
(Muangpaisan et al., 2011), representing a major burden in a worldwide ag-
ing society. Indeed, 10 to 13 per 100,000 persons yearly are diagnosed with
Parkinson’s disease (Muangpaisan et al., 2011). Parkinsonian syndromes
are often misdiagnosed and mixed up in clinical diagnosis, especially in
the early beginning of the disease. Generally, diagnostic decision-making
primarily depends on clinical variables. Hence, generalized, quantifiable
image-based markers to independently and accurately diagnose patients
are missing. In parkinsonian syndromes, if included at all, imaging is used
as supportive or exclusion criterion. In other neurodegenerative disease,
diagnostic criteria are amended and include recent findings of disease-
related brain alterations (Albert et al., 2011; Dubois et al., 2014; Gorno-
Tempini et al., 2011; Rascovsky et al., 2011). Parkinson’s disease rep-
resents the typical appearance of parkinsonian syndromes. Parkinsonism
describes the core symptoms of Parkinson’s disease: bradykinesia and ad-
ditionally rest tremor or rigidity. Slowness of movements and a decrease
in speed during performance of movements characterizes bradykinesia,
rest tremor is described by a shaking when inactive, and rigidity refers to
resistance to superficially imposed limb movements (Williams and Litvan,
2013). Further, non-motor symptoms such as mild cognitive impairment,
fatigue, and visual hallucinations can be present. Concerning diagnos-
tic decision-making, only dopaminergic imaging is well-established, other
imaging biomarkers have not been validated yet, even though they could
improve diagnostic accuracy. Stratified into several subgroups, parkinso-
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nian syndromes encompass diseases with similar clinical features but vary-
ing neuropathologies. This network includes scarce entities such as corti-
cobasal degeneration and progressive supranuclear palsy: atypical parkin-
sonian syndromes and neurodegenerative diseases, only confirmed by their
tau protein-based histopathology. Motor features of postural instability, early
falls, and eye-movement impairment indicate progressive supranuclear pal-
sy (McFarland, 2016). A well-known but not yet validated pathognomonic
marker is atrophy in the midbrain and cerebellar pedunculi. Recently, clin-
ical diagnostic criteria were amended (Höglinger et al., 2017), only con-
sidering ’predominant midbrain atrophy or hypometabolism’ as a support-
ive imaging criterion . Hence, diagnosis of progressive supranuclear palsy
mainly depends on clinical evaluation. Corticobasal degeneration is clin-
ically described by corticobasal syndrome. However, only 25% to 56%
of corticobasal degeneration cases are predicted ante-mortem (Armstrong
et al., 2013). Most frequent motor symptoms in post-mortem proven corti-
cobasal degeneration include limb rigidity and bradykinesia but also cogni-
tive decline and behavioral changes are common (Armstrong et al., 2013).
A really specific and peculiar symptom is the alien/anarchic limb pheno-
menon. About 30% of patients with corticobasal syndrome experience
an extremity as rogue or foreign, which performs well-executed but pur-
poseless movements. Identifying disease-specific features of corticobasal
degeneration remains ongoing research, restricting the ability to develop
definitive clinical criteria foreseeing the pathology. The clinical diagnostic
criteria were recently revisited, yet, imaging as a criterion to support diag-
nosis was not included (Armstrong et al., 2013).
My aim was to investigate objective neuroimaging biomarkers in parkin-
sonian syndromes, which could be used to increase diagnostic accuracy. I
apply three approaches to extract the neural correlates and disease-specific
patterns: (1) meta-analysis to find convergence among smaller cohort stud-
ies, (2) voxel-based morphometry to identify structural differences between
patients and controls, and (3) support-vector machine classification to pre-
dict the disease individually. We hypothesized to find disease-specific atro-
phy that disentangle the parkinsonian syndromes.
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Identifying Disease-Specific Patterns by Meta-Analyses. To find con-
vergence of the literature concerning disease-specific patterns with a pow-
erful statistical evaluation, we conducted meta-analyses. We investigated
the prototypical neural correlates of 1,767 patients with Parkinson’s disease
and 210 patients with progressive supranuclear palsy (Study 1 & 2, Albrecht
et al. (2018, 2019a)). In Parkinson’s disease [18F]-fluorodeoxyglucose -
positron emission tomography (FDG-PET) revealed glucose hypometabo-
lism in bilateral inferior parietal cortex and left caudate nucleus. Minor fo-
cal gray matter atrophy in the middle occipital gyrus was detected by the
means of whole-brain structural magnetic resonance imaging (MRI). In pro-
gressive supranuclear palsy meta-analyses identified gray matter atrophy of
the midbrain and white matter atrophy of the cerebral/cerebellar pedunculi
and midbrain. In Parkinson’s disease we evidenced that FDG-PET over-
comes MRI as potential biomarker. In progressive supranuclear palsy we
validated pathognomonic markers, which can be seen as disease-specific,
as we compared results with other published meta-analyses on neurode-
generative diseases. Our studies create a novel conceptual framework to
investigate disease-specific alterations for application in clinical routine by
data-driven meta-analytic approaches.
Obtaining Disease-Related Regions and Classifying the Disease by
Voxel-Based Morphometry and Support-Vector Machine. To individ-
ualize diagnostic and treatment protocols, we investigated neural corre-
lates and discriminated disease and clinical syndrome in single patients.
Multi-centric group data of patients with the clinical phenotype of corti-
cobasal syndrome and corticobasal syndrome with a unique symptom -
alien/ anarchic limb phenomenon - was acquired. 3T T1-weighted struc-
tural MR images of 25 corticobasal syndrome patients, 8 patients with cor-
ticobasal syndrome and alien/ anarchic limb phenomenon, and 25 healthy
controls were analyzed. To identify neural underpinnings, we performed
voxel-based morphometry: a widely used method to investigate structural
alterations like atrophy in patients. A multivariate pattern recognition al-
gorithm - support-vector machine classification - was trained to predict (i)
corticobasal syndrome patients and healthy controls and to differentiate (ii)
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between patients just having corticobasal syndrome and patients with corti-
cobasal syndrome having alien/ anarchic limb syndrome. Voxel-based mor-
phometry revealed gray matter volume differences between patients and
controls in asymmetric frontotemporal and occipital regions, motor areas,
and the insulae. The frontoparietal gyrus including the supplementary mo-
tor area contralateral to the side of the affected limb was specific for alien/
anarchic limb syndrome. The prediction of the disease among controls was
79.0% accurate. The prediction of the specific syndrome within a disease
reached an accuracy of 81.3%. Applying a meta-analytical mask lead to
similar stable results (Albrecht et al. (2017)). Because of two classification
groups, 50% represents chance level. We reliably classified patients and
controls by objective pattern recognition. Moreover, we were able to pre-
dict a specific clinical syndrome within a disease, shown even in a small
sample.
Discussion
By systematic and quantitative meta-analyses we statistically validated
convergence of published results for neurodegenerative diseases. In Parkin-
son’s disease glucose hypometabolism in bilateral inferior parietal cortex
and left caudate nucleus is more specific than structural brain atrophy.
In progressive supranuclear palsy we verified that midbrain and cerebral/
cerebellar pedunculi atrophy can be seen as disease-characteristic. By
applying machine learning we identified diseased and healthy individuals
as well as predict a symptom within a clinical syndrome. Additionally for
classification, we implemented a meta-analytical mask from a former study,
which lead to the same stable results (Albrecht et al. (2017)).
So far, disease diagnosis relies on experts and careful observation of
patients and their disease progression. Especially, atypical parkinsonian
syndromes are often misdiagnosed in the beginning of the disease course.
Correct and also early diagnosis plays a crucial role for treatment-decision
and hence symptom relief. A plethora of diagnostic criteria were already
updated by including disease-specific brain alterations (Albert et al., 2011;
Dubois et al., 2014; Gorno-Tempini et al., 2011; Rascovsky et al., 2011).
Diagnostic criteria for Parkinson’s disease, progressive supranuclear palsy,
and corticobasal degeneration have been revisited recently but only include
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the factor of objective medical imaging as supportive or exclusion crite-
ria. Including our proposed regional-atrophy patterns would considerably
advance disease diagnosis. Indeed, in frontotemporal lobar degeneration
and Alzheimer’s disease studies evidence that for both diseases the neu-
roimaging patterns considerably increased diagnostic accuracy as com-
pared to clinical evaluation (Rascovsky et al., 2002; Dubois et al., 2007;
Kipps et al., 2009). Hence, incorporation into diagnostic criteria was ad-
vised. The proposed neuroimaging biomarker still need to be validated in
independent cohorts and on a single-patient level. An example where imag-
ing criteria have been verified is primary progressive aphasia: diagnostic
imaging criteria were proposed by Gorno-Tempini et al. (2011) based on
previous neuroimaging studies and later statistically validated by indepen-
dent meta-analyses (Bisenius et al., 2016). In primary progressive aphasia,
imaging-supported diagnosis is even considered as the next level of clas-
sification. Hence, patients need to meet clinical criteria plus showing the
neuroimaging patterns. Bisenius et al. (2016) confirmed that concerning
MRI changes, the neuroimaging criteria are highly distinctive.
Conclusion
My thesis contributes objective disease-specific patterns and their ap-
plication to better disease diagnosis. For progressive supranuclear palsy
we proposed regional atrophy in midbrain and cerebral/ cerebellar pedun-
culi as specific disease-related pattern, supporting the incorporation into
diagnostic criteria. In Parkinson’s disease hypometabolism is more sen-
sitive than structural atrophy, nevertheless not disease-specific. By using
disease-specific patterns as mask and whole-brain data, we showed stable
classification results, discriminating patients from controls and even pre-
dicting symptoms within clinical syndromes.
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Einleitung
Inzidenz und Prävalenz neurodegenerativer Erkrankungen, definiert als vor-
zeitger Verlust spezifischer Neurone (Graeber and Moran, 2002), steigen
mit dem Alter (Muangpaisan et al., 2011). Jährlich werden bei 10 bis
13 von 100.000 Personen die idiopathische Parkinson-Krankheit diagnos-
tiziert (Muangpaisan et al., 2011). Der Parkinsonismus beschreibt die Kar-
dinalsymptome des Parkinson-Syndroms: Bradykinese und zusätzlicher
Ruhetremor oder Rigor. Eine Bradykinese ist charakterisiert durch ver-
langsamte Bewegungen, Ruhetremor beschreibt Zittern bei Inaktivität und
Rigor ist eine Art Muskelsteifheit bzw. Starre (Williams and Litvan, 2013).
Darüber hinaus können auch nicht-motorische Symptome wie eine leichte
kognitive Beeinträchtigung und visuelle Halluzinationen auftreten. Bezüglich
der Diagnose ist nur die dopaminerge Bildgebung ein routinemäßig an-
erkanntes Bildgebungsverfahren. Weitere Bildgebungsmarker wurden bis
jetzt noch nicht systematisch validiert, trotz ihres möglichen Potentials die
Diagnosegenauigkeit zu erhöhen. Das idiopathische Parkinson-Syndrom
stellt die typische und häufigste Erkrankung innerhalb des Spektrums der
Parkinson-Syndrome dar. Diese Syndrome werden in Gruppen unterteilt,
die ähnliche klinische Eigenschaften teilen, aber in der Neuropathologie
variieren. Das Spektrum umfasst seltene Erkrankungen wie die kortiko-
basale Degeneration und die progressive supranukleäre Blicklähmung. Sie
sind atypische Parkinson-Syndrome und neurodegenerative Erkrankungen,
welche nur histologisch durch ihre Tau-Protein Pathologie diagnostiziert
werden können. Motorische Symptome wie die posturale Instabilität, frühzeit-
ige Stürze und Augenmotorikstörungen weisen auf die progressive supranuk-
leäre Blicklähmung hin (McFarland, 2016). Ein bekannter, aber nicht sys-
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tematisch validierter, pathognomonischer Marker ist die Atrophie des Mit-
telhirns. In die kürzlich revidierten Diagnosekriterien wurde nur eine „prä-
dominante Mittelhirnatrophie oder Hypometabolismus“ als unterstützendes
Bildgebungskriterium aufgenommen (Höglinger et al., 2017). Daher beruht
die Diagnose der progressiven supranukleären Blicklähmung weiterhin auf
der klinischen Einschätzung. Die kortikobasale Degeneration ist klinisch
als kortikobasales Syndrom definiert. Es werden nur 25% bis 56% der
Fälle kortikobasaler Degeneration tatsächlich ante mortem prädiziert (Arm-
strong et al., 2013). Zu den Symptomen post mortem validierter, kor-
tikobasaler Degeneration zählen Rigor der Extremitäten, Bradykinese, aber
auch kognitive Beeinträchtigungen und Verhaltensänderungen (Armstrong
et al., 2013). Ein spezifisches und außergewöhnliches Symptom stellt das
Alien/ anarchische Extremitäten-Phänomen dar. Circa 30% der Patien-
ten mit kortikobasalem Syndrom beschreiben solch eine fremde/ selbst-
ständige Extremität, die zielgerichtete, aber zwecklose Bewegungen aus-
führt. Auch diese klinischen Kriterien wurden revidiert, wobei jedoch die
Bildgebung für die Diagnose unberücksichtigt gelassen wurde (Armstrong
et al., 2013). Generell bleibt die Diagnose hauptsächlich von klinisch er-
fassten Variablen abhängig. Daher gilt es generalisierbare, bildgebende
Marker zur objektiven und akkuraten Diagnose zu validieren. Besonders
bezüglich der Parkinson-Syndrome ist, wenn überhaupt, die Bildgebung
nur als unterstützendes oder Ausschlußriterium vertreten. Die kürzlich re-
vidierten Kriterien anderer neurodegenerativer Erkrankungen schließen je-
doch in die Diagnostik aktuelle Ergebnisse krankheitsspezifischer Hirnverän-
derungen ein (Albert et al., 2011; Dubois et al., 2014; Gorno-Tempini et al.,
2011; Rascovsky et al., 2011). Die vorliegende Arbeit untersucht objek-
tive, neurologische, Bildgebungsmarker, welche die Diagnosegenauigkeit
für Parkinson-Syndrome erhöhen könnten. Für die Identifikation neuraler
Korrelate und krankheitsspezifischer Muster verwendet diese Arbeit: (1)
Metaanalysen, um die Konvergenz zwischen Studien mit kleinen Gruppen-
größen zu finden, (2) voxel-basierte Morphometrie, um strukturelle Unter-
schiede zwischen Patienten und Kontrollen zu identifizieren und (3) Sup-
port Vector Machine-Klassifikation, um Erkrankungen individuell zu prä-
dizieren.
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Identifikation von krankheitsspezifischen Mustern mittels Metaanaly-
sen: Durch Metaanalysen evaluierten wir statistisch die Konvergenz der
Literatur zu krankheitsspezifischen Mustern. Anhand multimodaler Bildge-
bung wurden die neuralen Korrelate von 1.767 Patienten mit idiopathis-
chem Parkinson und 210 Patienten mit progressiver supranukleärer Blick-
lähmung anaylsiert (Study 1 & 2, Albrecht et al. (2018, 2019a)). Für die
idiopathische Parkinson-Krankheit zeigte die [18F]-Fluorodeoxyglucose-
Positronen-Emissions-Tomographie (FDG-PET) einen Glucosehypometa-
bolismus im bilateralen inferioren parietalen Kortex und linken Nucleus cau-
datus. Nur eine geringfügige Atrophie der grauen Substanz konnte im
mittleren occipitalen Gyrus durch die strukturelle Magnetresonanztomogra-
phie (MRT) festgestellt werden. Die Analyse für die progressive supranuk-
leäre Blicklähmung zeigte eine Atrophie in der grauen Substanz im Mittel-
hirn und der weißen Substanz des Mittelhirns und zerebralen/ zerebellären
Pedunculi. Die Ergebnisse zeigen, dass bei der idiopathischen Parkinson-
Krankheit FDG-PET sensitiver als das MRT ist und somit das erstere Poten-
tial für die Biomarkersuche bietet. Für die progressive supranukleäre Blick-
lähmung validierten wir bekannte pathognomonische Marker. Diese kön-
nen als krankheitsspezifisch gelten, da wir unsere Resultate mit anderen
publizierten Metaanalysen neurodegenerativer Erkrankungen abglichen. An-
hand datengetriebene Metaanalysen entwerfen wir ein neues Konzept zur
Identifikation krankheitsspezifischer Muster für die klinische Applikation.
Investigation krankheitsspezifischer Regionen und Krankheitsklassi-
fikation mittels voxel-basierter Morphometrie und Support Vector Ma-
chine -Analysen: Für individualisierte Diagnostik und Behandlungstrate-
gien untersuchten wir die neuralen Korrelate und prädizierten Erkrankun-
gen und deren Syndrome mittels multi-zentrischer Daten von Patienten
mit kortikobasalem Syndrom und mit zusätzlich einem außergewöhnlichen
Symptom, dem Alien/ anarchische Extremitäten-Phänomen. 3T T1 -ge-
wichtete strukturelle MRT Bilder von 25 Patienten mit kortikobasalem Syn-
drom, 8 Patienten mit kortikobasalem Syndrom plus Alien/ anarchische
Extremitäten Phänomen wurden mit 25 gesunden Kontrollen verglichen.
Zur Identifikation neuraler Korrelate führten wir eine voxel-basierte Morh-
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pometrie -Analyse durch: Eine valide Methode um strukturelle Veränderun-
gen zu untersuchen, z.B. Atrophie bei Patienten. Ein mulitvariates Mus-
tererkennungsverfahren, die Support Vector Machine-Klassifikation, wurde
trainiert für die Prädiktion von (i) kortikobasalem Syndrom und Kontrollen
und um zwischen Patienten mit kortikobasalem Syndrom mit und ohne
Alien/ anarchische Extremitäten-Phänomen zu differenzieren. Die voxel-
basierte Morphometrie-Analyse ergab Differenzen im grauen Substanzvol-
umen zwischen Patienten und Kontrollen in frontotemporalen und occipi-
talen Arealen, motorischen Arealen und der Insel. Spezifisch für Patienten
mit Alien/ anarchische Extremitäten-Phänomen war, kontralateral zur Syn-
dromseite, der frontotemporale Gyrus inklusive des supplementär-motor-
ischen Kortex. Die Prädiktion der Erkrankung erreichte eine Genauigkeit
von 79.0%. Die Prädiktion des Syndromes innerhalb der Erkrankung erzielte
Resultate bis zu 81.3% Genauigkeit. Die zusätzliche Verwendung einer
krankheitsspezifischen Maske aus Metaanalysen führte zu ähnlich stabilen
Resultaten (Appendix, Albrecht et al. (2017)). Aufgrund der Klassifikation
von jeweils zwei Gruppen, liegt das Zufallsniveau bei 50%. Mit dieser
Studie unterschieden wir zuverlässig Patienten von Kontrollen durch ob-
jektive Mustererkennungsverfahren. Weiterhin zeigten wir, dass sogar die
Prädiktion eines Syndromes einer Erkrankung möglich ist.
Diskussion
Durch quantitative Metaanalysen konnten wir die Konvergenz publizierter
Studien für neurodegenerative Erkrankungen statistisch validieren. Für
die idiopatische Parkinson-Krankheit ist eine Reduktion des Gluckosehy-
pometabolismus im inferioren parietalen Kortex und dem linken Nucleus
caudatus spezifischer als die strukturelle Hirnatrophie. Für die progres-
sive supranukleäre Blicklähmung verifizierten wir Atrophie des Mittelhirns
und der zerebralen/ zerebellären Pedunculi als krankheitsspezifisch. Mit-
tels maschinellem Lernens differenzierten wir Patienten von Kontrollen und
prädizierten ein Symptom einer Erkrankung. Die zusätzliche krankheitsspez-
ifische Maske aus den Ergebnissen vorhergehender Metaanalysen führte
zu den gleichen stabilen Resultaten (Appendix, Albrecht et al. (2017)).
Krankheitsdiagnosen stützen sich primär immer noch auf Experten und
die genaue Observation des Krankheitsverlaufes. Ins besondere atypische
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Parkinson-Syndrome werden häufig zu Beginn der Krankheit fehldiagnos-
tiziert. Die Korrekte und frühzeitige Diagnose spielt eine essentielle Rolle
für die Therapieentscheidung und den Krankheitsverlauf. Die Mehrheit der
Diagnosekriterien wurde schon revidiert und bezieht objektive, krankheits-
spezifische Hirnveränderungen ein (Albert et al., 2011; Dubois et al., 2014;
Gorno-Tempini et al., 2011; Rascovsky et al., 2011). Die Diagnostik für die
idiopathische Parkinson-Krankheit, die progressive supranukleäre Blickläh-
mung und die kortikobasale Degeneration wurden revidiert, betrachten die
medizinische Bildgebung jedoch nur als unterstützendes oder Ausschlußkri-
terium. Die Berücksichtigung unserer vorgeschlagenen regionalen Muster
könnte wesentlich zur Validierung der Krankheitsdiagnose beitragen. Stu-
dien zur frontotemporalen lobären Degeneration und der Alzheimer-Krank-
heit zeigen, dass im Vergleich zur rein klinischen Diagnose, die Genauigkeit
seit der Integration der neurologischen Bildgebung anstieg (Rascovsky et al.,
2002; Dubois et al., 2007; Kipps et al., 2009). Folglich wäre die Inklu-
sion der Bildgebung auch in die Diagnostik anderer neurodegenerativer
Erkrankungen in Betracht zu ziehen. Jedoch benötigen unsere vorgeschla-
genen, bildgebenden Marker eine Verifizierung in externen, unabhängigen
Kohorten und Einzelfallanalysen. Ein Exempel für die Validierung bildgeben-
der Diagnostik zeigt die primär progrediente Aphasie: Kriterien wurden
vorgeschlagen von Gorno-Tempini et al. (2011) basierend auf Resultaten
von Bildgebungsstudien und daraufhin statistisch validiert durch objektive
Metaanalysen (Bisenius et al., 2016). Hier stellt die bildgebungsgestützte
Diagnose sogar eine höheres Niveau der Genauigkeit der Klassifikation
dar. Demzufolge erfüllen diagnostizierte Patienten die klinischen Kriterien
und zusätzlich die neurologischen Bildgebungskriterien. Bisenius et al.
(2016) bestätigen, dass die Bildgebungskriterien bezüglich der Hirnverän-
derungen im MRT eine hohe Unterscheidungskraft aufweisen.
Konklusion
Die vorliegende Arbeit hat zum Ziel objektive, krankheitsspezifische Muster
und deren Applikation zur verbesserten Diagnostik beizutragen. Für die
progressive supranukleäre Blicklähmung schlagen wir die regionale Atro-
phie im Mittelhirn und den zerebralen/ zerebellären Pedunculi als krankheit-
srelatierte Veränderung vor, welche die Einbindung in die Diagnosekriterien
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nahelegen. Für die idiopatische Parkinson-Krankheit ergaben die Resul-
tate, dass der regionale Hypometabolismus sensitiver ist als strukturelle
Veränderungen. Dieser Hypometabolisums ist aber nicht spezifisch genug
für die Unterscheidung zu anderen neurodegenerativen Erkrankungen. Weit-
erhin konnten wir mit Masken krankheitsspezifischer Muster und unter Ein-
schluss des gesamten Gehirns stabile Klassifikationsresultate für das kor-
tikobasale Syndrom erzielen. Diese ermöglichen die Differenzierung zwis-
chen Patienten und Kontrollen und sogar die Prädiktion von Syndromen
innerhalb einer Erkrankung.
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The thesis investigated objective neuroimaging biomarkers in parkinsonian
syndromes, which could be applied to increase diagnostic accuracy. To
find convergence of the literature concerning disease-specific patterns in
Parkinson’s disease and progressive supranuclear palsy, we conducted
meta-analyses. In Parkinson’s disease glucose hypometabolism was re-
vealed in bilateral inferior parietal cortex and left caudate nucleus and focal
gray matter atrophy in the middle occipital gyrus. In progressive supranu-
clear palsy we identified gray matter atrophy in the midbrain and white mat-
ter atrophy in the cerebral/cerebellar pedunculi and midbrain. In sum, in
Parkinson’s disease hypometabolism outperforms atrophy and in progres-
sive supranuclear palsy we validated pathognomonic markers as disease-
specific. Our studies create a novel framework to investigate disease-
specific regional alterations for use in clinical routine. Further, we inves-
tigated neural correlates by voxel-based morphometry and discriminated
disease and clinical syndrome by multivariate pattern recognition in sin-
gle patients with corticobasal syndrome and corticobasal syndrome with a
unique syndrome - alien/ anarchic limb phenomenon. We found gray matter
volume differences between patients and controls in asymmetric frontotem-
poral/ occipital regions, motor areas, and insulae. The frontoparietal gyrus
including the supplementary motor area contralateral to the side of the af-
fected limb was specific for alien/ anarchic limb phenomenon. The predic-
tion of the disease among controls was 79.0% accurate. The prediction of
the specific syndrome within a disease reached an accuracy of 81.3%. In
conclusion, we reliably classified patients and controls by objective pattern
recognition. Moreover, we were able to predict a specific clinical syndrome
within a disease, paving the way to individualized disease prediction.
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11 GENERAL INTRODUCTION
Healthy living and aging are one of the major challenges for our soci-
ety. Worldwide demographic changes lead to an increased occurrence of
neurodegenerative diseases (Saba, 2015). Neurodegenerative diseases
- defined as the precipitate loss of specific neurons (Graeber and Moran,
2002) - have in common that incidence and prevalence are rising with age
(Muangpaisan et al., 2011). In particular, Alzheimer’s disease, idiopathic
Parkinson’s disease, and Amyotrophic Lateral Sclerosis are the most fre-
quent occurring neurodegenerative diseases (Graeber and Moran, 2002).
For example, the incidence rate of Parkinson’s disease varies from 10
to 13 per 100,000 persons yearly (Muangpaisan et al., 2011). Of note,
this only includes the typical appearance of parkinsonian syndromes, id-
iopathic Parkinson’s disease, which encompasses 63% of parkinsonism
cases. Hence, idiopathic Parkinson’s disease only represents one entity
of a whole group of parkinsonian syndromes. Parkinsonian syndromes
have in common several clinical features but differ regarding their under-
lying pathologies. Up to now, histopathological examination remains gold
standard for a definite discrimination and diagnosis. Belonging to this net-
work are also scarce entities such as corticobasal degeneration (CBD) and
progressive supranuclear palsy (PSP). CBD and PSP are atypical parkin-
sonian syndromes and neurodegenerative diseases, which can only be
confirmed by histopathological examination. Reported to be associated
with various clinical syndromes, the classical clinical phenotypes are corti-
cobasal syndrome (CBS) and Richardson syndrome (RS) respectively. As
aforementioned there are overlaps with other diseases belonging to the
group of parkinsonian syndromes making it a special interest to separate
CBS and PSP from different syndromes and pathologies. Parkinsonian
syndromes are often misdiagnosed and mixed up in clinical diagnosis, es-
pecially in the early beginning of the disease. In general, diagnosis primar-
ily depends on clinical variables. Thus, generalized, quantifiable image-
based markers to independently and accurately diagnose patients are of
high interest and needed. The following is an introduction to the topic of
parkinsonian syndromes and related research outcomes.
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1.1 Parkinsonian Syndromes
The group of parkinsonian syndromes can be stratified into typical (ido-
pathic Parkinson’s disease), acquired (posttraumatic), hereditary (genetic),
and atypical parkinsonism. The pattern of atypical parkinsonism includes
the rare, fast progressing illnesses of PSP, Lewy-body disease, multiple-
system atrophy, and CBD. All of them show special symptoms but are likely
to be misdiagnosed or confounded as Parkinson’s diseases or even as an-
other atypical parkinsonism. Moreover, the parkinsonian syndromes are
further distinguished by their underlying histopathology. Wrong folding or
accumulation of proteins is the major cause leading to a proteinopathy.
CBD and PSP are tau-based, while Parkinson’s disease, multiple-system
atrophy, and Lewy-body disease are alpha synuclein-based pathologies.
Due to similarities of symptoms to other diseases associated with the de-
position of microtubule-associated tau, it is of special interest to separate
CBD and PSP from different tau-based pathologies (tauopathies).
1.2 Parkinson’s Disease
“An Essay on The Shaking Palsy” (Parkinson, 1987) was the inception
of the disease, which is now named after its discoverer James Parkinson.
Parkinson’s disease (PD) is mainly characterized as a motor disease but
amended diagnostic criteria point out the increasing importance of non-
motor features (Postuma et al., 2015). Nevertheless, the hallmark of PD re-
mains parkinsonism described by bradykinesia and additionally rest tremor
or rigidity. Patients with bradykinesia suffer from slowness of movements
as well as a decrease in speed during performance of movements. Rest
tremor means a shaking that is present when inactive, vanishes when mov-
ing but increases during mental tasks (Williams and Litvan, 2013). The
term rigidity refers to a rise in muscle tone causing a resistance to super-
ficially imposed limb movements. Additionally, non-motor symptoms range
from mild cognitive impairment over fatigue to visual hallucinations and sig-
nificantly increase the burden on the patients quality of life (Poewe et al.,
2017). Non-motor symptoms do not only accompany PD, they antedate the
disease years before as so called prodromal PD stages: rapid eye move-
ment sleep behavior disorder, depression, anxiety, daytime sleepiness, and
smell disturbance.
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Concerning pathology, the neuropathological criteria for PD describe
morphological changes in the substantia nigra pars compacta assessed by
neuronal loss and Lewy pathology identified by alpha-synuclein immuno-
histochemistry (Dickson et al., 2009). On a molecular level, PD is charac-
terized by dopaminergic depletion due to nigrostriatal degeneration. Treat-
ment of the disease connects this fact and mainly relies on pharmacological
dopamine substitution. Here, PD is quite exceptional among the neurode-
generative diseases: symptoms and quality of daily living can be sustained
for a long time of the disease course. Nevertheless, medication can man-
age the symptoms but neither slow down progression nor heal the disease
at all.
1.2.1 Diagnostic Criteria
The recent clinical diagnostic criteria by the Movement Disorder Society
are summarized in Table 1 (Postuma et al., 2015). Note that neuroimaging
is only mentioned as an exclusion criterion.
Table 1. Diagnostic Criteria of Parkinson’s Disease (PD) adapted from Postuma
et al. (2015).
• Essential criterion: Parkinsonism
– Bradykinesia plus either rest tremor or rigidity
• Clinically Established Parkinson’s disease
– None of exclusion criteria: cerebellar abnormalities, supranuclear gaze palsy,
parkinsonian features restricted to the lower limbs, no response to high-dose
dopaminergic therapy, or normal neuroimaging of dopaminergic system
– Two supportive criteria: response to dopaminergic therapy, dopaminergic-
induced dyskinesia, rest tremor of a limb, olfactory loss or cardiac sympathetic
denervation
– No red flags: rapid progression of gait impairment, no progression of motor
symptoms, early bulbar dysfunction, respiratory dysfunction, frequent falls, bi-
lateral symmetric parkinsonism or lack of non-motor features (sleep dysfunc-
tion, psychiatric dysfunction or autonomic dysfunction)
• Clinically Probable Parkinson’s disease
– None of exclusion criteria
– Presence of red flags counterbalanced by supportive criteria: 1 red flag + at
least 1 supportive criterion or 2 red flags + at least 2 supportive criteria
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1.3 Progressive Supranuclear Palsy
Occurring in 5 to 10 per 100,000 persons, progressive supranuclear
palsy (PSP) belongs to the spectrum of rare atypical parkinsonian syn-
dromes (Levin et al., 2016). PSP was firstly reported in a small case series
by Steele, Richardson, and Olszewski in 1964. The authors already iden-
tified vertical supranuclear gaze palsy and neuronal loss in the brain stem
as core signs for this rapidly progressing disease. Interestingly, nearly all
cases were examined histopathologically, which revealed a shrinkage of the
midbrain and cerebellar pedunculi; nowadays still considered as pathog-
nomonic markers of PSP.
Central motor characteristics of PSP include postural instability, early
falls, and eye-movement disturbances; differentiating it from other neurode-
generative diseases (McFarland, 2016). Note that PSP responds poorly to
dopaminergic treatment making it an important difference to PD (Williams
and Litvan, 2013). Another feature discriminating PSP from PD is the ab-
sence of severe autonomic dysfunctions. PSP further affects non-motor do-
mains leading to dementia, emotional lability, depression or slowed speech
(McFarland, 2016).
The underlying pathology, also referred to as PSP, is known for the
accumulation of microtubule-associated protein tau with four microtubule-
binding side repeats, neurofibrillary tangles, astrocytic tufts, and oligoden-
drocytic coils (Hoeglinger et al. 2017). Like other atypical parkinsonian
syndromes, a definite diagnosis of PSP can only be confirmed postmortem.
Among evaluated PSP-tauopathy patients, 10% to 30% do not present
the classic clinical phenotype of Richardson syndrome (PSP-RS) (Williams
and Litvan, 2013). Hence, the amended diagnostic criteria recognize that
the histopathology of PSP is linked to several other clinical phenotypes
(Höglinger et al., 2017). Beside the typical representation of PSP-RS, other
phenotypes mimicking PD (PSP-parkinsonism) or CBS (PSP-CBS) are ac-
knowledged. Even though diagnostic criteria were recently revisited, PSP
diagnosis remains primary dependent on clinical evaluation. Indeed, imag-
ing is only considered as a supportive criterion, i.e. ’predominant midbrain
atrophy or hypometabolism’ (Höglinger et al., 2017).
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1.3.1 Diagnostic Criteria
Table 2 summarizes the recent clinical diagnostic criteria for PSP by
the International Parkinson and Movement Disorder Society-endorsed PSP
Study Group (Höglinger et al., 2017). These criteria consider the core fea-
tures of PSP and rely on different levels of functional domains. For diag-
nosing the clinical phenotypes of PSP, criteria are further stratified.
Table 2. Diagnostic criteria of progressive supranuclear palsy-Richardson
syndrome (PSP-RS) adapted from Höglinger et al. (2017).
• Highest certainty
– Vertical supranuclear gaze palsy
– Repeated unprovoked falls within 3 years
– Progressive gait freezing within 3 years
– Speech/language disorder
• Mid certainty
– Slow velocity of vertical saccades
– Tendency to fall on the pull-test within 3 years
– Parkinsonism, akinetic-rigid, predominantly axial, and dopaminergic resistant
– Frontal cognitive/behavioral presentation
• Lowest certainty
– Frequent macro square wave jerks or “eyelid opening apraxia”
– More than two steps backward on the pull-test within 3 years
– Parkinsonism, with tremor and/or asymmetric and/or dopaminergic responsive
– Corticobasal syndrome
1.4 Corticobasal Degeneration
In 1968, corticobasal degeneration (CBD) was first referred to it as ’cor-
ticonigral degeneration with neuronal achromasia’ in a case study of 3 pa-
tients having a progressive neurologic disorder (Rebeiz et al., 1968). All pa-
tients showed clinical characteristics of a decrease in speed and alienation
during voluntary movements as well as superimposed involuntary move-
ments. Rebeiz et al. presented patients with a lateralization of motor
symptoms at the beginning of the disease; severe cognitive impairments
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were not noticed until death. Subsequently, patients were also histopatho-
logically evaluated showing asymmetrical gray matter loss in frontoparietal
regions. Changes on cellular level such as loss of neurons, gliosis, and
swollen cell bodies were further observed. The study of Rebeiz et al. de-
scribes the clinical and histopathological features of CBD unaware of the
fact that nowadays it is common to distinguish the disorder by the clinical
phenotype (corticobasal syndrome, CBS) and the associated histopathol-
ogy (CBD).
CBS is considered as an orphan disease, only occurring in about 1
per 100,000 individuals, and represents the classical clinical phenotype of
CBD (Levin et al., 2016). In a 2013 review, Armstrong et al. summarized
that over 37% of CBD cases show CBS as clinical syndrome. Nevertheless,
CBD can also be linked to other clinical syndromes: behavioral variant fron-
totemporal dementia, primary progressive aphasia, posterior cortical atro-
phy, a type of dementia with histopathology similar to Alzheimer’s disease,
and Richardson syndrome (Boeve, 2011). On the other hand, also CBS
can be associated with different pathologies such as Alzheimer’s disease,
Creutzfeld-Jakob disease, Pick’s disease, PSP, Lewy-body disease, and
frontotemporal lobar degeneration. CBD, as the typical underlying pathol-
ogy, is defined by widespread deposition of hyperphosphorylated 4-repeat
tau in neurons and glia (Dickson et al., 2002). High variety of symptoms
makes a diagnosis of CBD challenging. In only 25% to 56% of patients,
CBD is predicted ante-mortem (Armstrong et al., 2013). Identifying phe-
notypes and specific features of CBD is an ongoing problem restricting the
ability to develop definitive clinical criteria foreseeing the pathology.
Although CBS/CBD is firstly considered as a motor disease, there are
also major changes in behavior and general cognition. Concerning the
motor symptoms, limb rigidity and bradykinesia are the most frequent fea-
tures seen in later post-mortem proven CBD (Armstrong et al., 2013). 85%
of patients develop limb rigidity and 76% bradykinesia during the disease
course. Other less frequent motor features include postural instability that
often leads to falls, myoclonus (brief muscle twitching), dystonia (continu-
ous muscle contraction leading to abnormal postures), and tremor (rhyth-
mic muscle contraction and relaxation), which are observed in 20% of the
cases. With regard to higher cortical features, symptoms such as apraxia,
speech impairment, behavioral/ cognitive changes, and alien/ anarchic limb
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phenomenon are linked to CBD. 57% of CBD patients are suffering from
apraxia meaning that they are unable to fulfill skillful motor movements
(Armstrong et al., 2013). Interestingly, this deficit cannot be explained by
dysfunctions in motor or sensory system (Zadikoff and Lang, 2005). A re-
ally scarce and peculiar feature is the alien/anarchic limb phenomenon.
About 30% of patients show these signs of a limb, recognized as foreign,
which can perform purposeless movements or interrupt movements. Other
features include speech impairments like aphasia, which are seen in about
52% of cases or cognitive decline, which is shown in 70% of CBD patients.
Although the disease has been known since nearly 50 years, disentangling
the interplay of the clinical syndrome and histopathology is still a matter for
research.
1.4.1 Diagnostic Criteria
Recently, Armstrong et al. (2013) published new consensus criteria for
evaluating CBS and predicting CBD. In her work Armstrong et al. suggested
to use the term CBD only for pathology-proven cases. This leads to the fact
that a clinical diagnosis can only be probable or possible CBD. Diagnostic
criteria to evaluate cases of CBD phenotype CBS are summarized in Table
3.
1.5 Imaging Biomarkers
Since the emergence of neuroimaging during the 1980’s, researcher
took advantage of medical imaging. Medical neuroimaging can be used
as a window into the brain identifying structures with physical alterations,
lesions, and damages. These features yield the potential to be disease-
specific and hence can be transformed into imaging biomarkers. Under-
standing the emergence of diseases started with analyzing neuroimaging
data by single case descriptions of patients or lesion studies. Researchers
and doctors tried to understand the functions of altered brain regions-of-
interest. Later on statistical analysis methods came into play to provide
a mathematical validation to investigate regions-of-interest and the whole
brain by the means of voxels – the smallest unit of an imaging analysis. This
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Table 3. Diagnostic criteria of corticobasal syndrome (CBS) adapted from
Armstrong et al. (2013)
• Probable Corticobasal Syndrome
– Two of:
∗ 1. Limb rigidity or akinesia
∗ 2. Limb dystonia
∗ 3. Limb myoclonus
– Plus two of:
∗ 4. Orobuccal or limb apraxia
∗ 5. Cortical sensory deficit
∗ 6. Alien/ anarchic limb phenomenon
• Possible Corticobasal Syndrome
– At least one of:
∗ 1. - 3.
– Plus one of:
∗ 4. - 6.
further paved the way for methods like voxel-based morphometry analy-
ses to compare groups and derive specific regions of differences. With
this method differences between patients and healthy controls, basically at-
rophy, can be assessed. Regions that were identified as disease-related
can be used in clinical trials as imaging biomarker for disease identifica-
tion or for neuromodulation therapies like treatment prediction (Ballarini
et al., 2019). Indeed, several neurodegenerative diseases already bene-
fit from the incorporation of imaging biomarkers to support clinical diag-
nosis. Magnetic resonance imaging (MRI) and amyloid as well as [18F]-
fluorodeoxyglucose positron emission tomography have been integrated in
the current diagnostic criteria for mild cognitive impairment and Alzheimer’s
disease (Albert et al., 2011; Dubois et al., 2014). Moreover, for primary pro-
gressive aphasia imaging-supported diagnosis has been successfully intro-
duced and subsequently validated by meta-analysis in independent cohorts
(Gorno-Tempini et al., 2011; Bisenius et al., 2016). Multimodal imaging, i.e.
structural and metabolic changes, is considered for diagnosis and iden-
tification of phenotypes. Note that also for behavioral variant frontotem-
poral lobar degeneration disease-characteristic imaging biomarkers have
been successfully applied: frontal and/or anterior temporal alterations can
be detected by MRI, computed tomography, positron emission tomography
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or single-photon emission computed tomography (Rascovsky et al., 2011).
Hence, my aim was to investigate the utility and applicability of objective
neuroimaging biomarkers in parkinsonian syndromes, which could be ap-
plied to support diagnosis. In my thesis I apply three approaches to extract
the neural correlates and disease-specific patterns: (1) meta-analysis to
find convergence among smaller cohort studies, (2) voxel-based morphom-
etry to identify structural differences between patients and controls, and (3)
support-vector machine classification to predict the disease individually.
1.6 Current Thesis
1.6.1 Motivation and Framework
The close cooperation with the Clinic for Cognitive Neurology of the
University Clinic of Leipzig and working with patients has sensitized me
what is needed and necessary in daily clinical assessment. The thesis
aims at contributing objective tools to improve diagnoses and treatment of
neurodegenerative diseases in clinical routine. We took advantage of the
integration of MR imaging into clinical routine and extracted patterns to en-
able an objective image assessment for accurate disease diagnosis. So far,
diagnosis of parkinsonian syndromes remains primarily clinical. Diagnos-
tic criteria for PD, PSP, and CBS have been amended recently but include
the factor of objective medical imaging as supportive or exclusion criteria.
Other neurodegenrative disease are exemplary regarding the application
of neuroimaging as diagnostic criteria, e.g Alzheimer’s disease or primary
progressive aphasia (Gorno-Tempini et al., 2011; Dubois et al., 2014). In
line with that, we investigate the neural correlates of PD, PSP, and CBS as
well as predict such syndromes individually, paving the way to personalized
disease identification.
1.6.2 Research Questions
The current thesis investigates disease-specific markers to classify parkin-
sonian syndromes. Aiming at a powerful, detailed description and disentan-
glement of clinical features as well as neurodegenerative patterns of PD,
CBS, and PSP we perform several different approaches.
Firstly, we conducted quantitative and systematic meta-analyses across
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voxel-based morphometry studies to identify disease-specific patterns to
disentangle parkinsonian syndromes, which are clinically hard to distin-
guish. The resulting patterns contribute to objectify disease identification,
understand these diseases by serving as masks for imaging biomarker or
subsequent machine learning analyses. We investigated convergence of
the literature regarding neural signatures of PD (Study 1, Albrecht et al.
(2018)) and PSP (Study 2, Albrecht et al. (2019a)). For disease-specificity,
we qualitatively and quantitatively compared the results with other pub-
lished meta-analyses on neurodegenerative diseases. We hypothesized
in PSP atrophy is mostly focused on midbrain regions and in PD anterior
cerebral regions.
Secondly, we performed a study on multi-centric data of CBS patients
from the Research Consortium for Frontotemporal Lobar Degeneration Ger-
many (FTLD Consortium) (Study 3, Albrecht et al. (2019b)). Investigating a
rare occurring disease such as CBS, multi-centric data is advantageous for
the analysis. We performed a voxel-based morphometry analysis to detect
regional gray matter volume differences and a machine learning approach
to predict the disease itself and a related syndrome. Further, the ma-
chine learning approach was used to test the application and accuracy of a
disease-specific mask, which was obtained from our recent meta-analysis
(Appendix, Albrecht et al. (2017)). Results pave the way to individualized
disease and syndrome prediction. We hypothesized to find similar results
as in our meta-analysis of CBS: asymmetrical gray matter loss in the left
frontal lobe (Appendix, Albrecht et al. (2017)).
Additionally to my main projects, I was engaged in two other projects
investigating PD, which I have not described in detail in my thesis. One
study predicted the treatment response to dopaminergic medication in a
cohort of patients with PD from our cooperation with the Charles University
in Prague (Study 4, Ballarini et al. (2019)). We investigated how age, dis-
ease duration, and treatment dose/ length influence accuracy as well as re-
sponsiveness. Voxel-based morphometry was applied to assess structural
differences and support-vector machine classification to foresee individual
treatment response. The other study in cooperation with the Charles Uni-
versity in Prague investigated the relationship between memory deficits in
PD and hippocampus alterations by neuroimaging and neuropsychological
assessments (Study 5, Bezdicek et al. (2019)). Two concepts that could
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explain memory impairment in PD were tested and underlying differences
in functional connectivity of different hippocampal subfields were analyzed.
Overall, with this thesis I aim to establish an overview over parkinsonian
syndromes, their prototypical networks, and identify patterns, which may
objectively support diagnosis.
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2 GENERAL MATERIALS AND METHODS
In the following section I will explain general methods, which all of my
studies during my PhD have in common.
2.1 Magnetic Resonance Imaging
Over the past decade rapid developments in imaging the brain have oc-
curred. Especially in neuroscience, neuroimaging has become an impor-
tant method to investigate the brain’s structure and functions non-invasively.
One method has gained special attention, namely the technique of mag-
netic resonance imaging (MRI) since it can be applied in diagnostic/clinical
and basic research settings. MRI uses hydrogen atoms to visualize different
types of brain tissue under changing physiological conditions and provides
high spatial resolution (Bear et al., 2009). In research, MRI has provided
abundant information about the areas of cognitive and sensory processes
in the human brain. Further, MR images can also visualize lesions in the
brain due to the fact that tumors and inflammation increase the amount of
extracellular water (Bear et al., 2009).
The underlying principle is based on quantification of hydrogen atoms in
body water. Physically a hydrogen atom can exist in two states: either high-
energy state or low-energy state. Both states are abundant in the brain. By
applying electromagnetic waves, energy is added to the atoms. These in
turn will absorb this energy and gain a higher state of energy, which is
called resonant frequency. Turning off these electromagnetic fields lead
atoms to return to their lower state and emit a signal of their own special
frequency. Signals are collected by a radio receiver, whereas stronger sig-
nals reflect greater amounts of hydrogen atoms. Further, MRI scanners
use a varying magnetic field to give emitted waves a spatial coding. One
side of the magnet has a stronger field, where high-frequency signals of the
hydrogen protons are located. Hence, low-frequency waves are located on
the weaker side. During the measurement the gradient of the magnet is
arranged to different angles relative to the brain. Altering the magnetic field
causes a relaxation of the spin of the hydrogen atoms and a shift back to
their original states (Cohen and Sweet, 2011).
Due to the fact that the recovering process happens along different spa-
tial dimensions one can distinguish between two options. A spatial distri-
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bution along the longitudinal axis is referred to as T1 relaxation. On the
contrary, the phase coherence loss of the spin at the transverse axis cor-
responds to T2 relaxation. Further, T1 is correlated with the enthalpy of the
atoms spin and T2 with the entropy (Cohen and Sweet, 2011). Both ap-
proaches differ in their resolution and also sensitivity of tissue type. Most
of brain scans assessing atrophy are T1-weighted. The whole procedure
results in an image visualizing tissue, which actually depicts the distribution
of hydrogen atoms.
2.2 Analytical Methods
2.2.1 Meta-Analysis
Meta-analysis were applied to identify disease-specific brain regions for
imaging biomarkers. It is defined as "use of statistical methods in a sys-
tematic review to integrate the results of included studies" (Moher et al.,
2009). This approach creates larger samples, thus leading to higher statis-
tical power to validate convergence of published results. Especially in rare
diseases, it is a powerful technique to investigate consistencies in disease
features.
Assuring validity and quality, meta-analyses are conducted according
to the guidelines of PRISMA (preferred reporting items for systematic re-
views and meta- analyses) (Moher et al., 2009). To ensure a standard to
report different types of results, Moher et al. (2009) provide a flow diagram
and checklist leading to a good scientific practice, transparency, and repro-
ducibility. According to PRISMA statement, literature search and selection
should be performed by two investigators separately and discussed after-
wards. Literature search engines like PubMed from the National Center for
Biotechnology Information (NCBI) are queried by combining different tags.
Additionally, inclusion criteria are set for selection: (1) peer-reviewed, (2)
whole-brain studies, (3) diagnosis according to established diagnostic crite-
ria, (4) original studies, (5) comparison with age-matched healthy controls,
and (6) results normalized to a stereotactic space.
To analyze convergence of literature in the respective diseases, anatomic
likelihood estimate meta-analysis method (ALE) (Fox et al., 2005; Laird
et al., 2011, 2005; Turkeltaub et al., 2002) and seed-based D mapping
(SDM) (Radua and Mataix-Cols, 2009) can be applied. Applying two meth-
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ods enables double-validation and leads to robust results, ready for sug-
gestion of disease-specificity. The methods were firstly invented for meta-
analyses of functional imaging studies with psychological stimulation of
participants. Later, this approach has been extended to imaging studies
investigating atrophy (Sacher et al., 2012; Schroeter and Neumann, 2011;
Schroeter et al., 2007, 2008). With this analysis one is addressing the
question, which brain regions show a higher convergence of atrophy across
studies than it would be the case in a random relationship.
In general the underlying algorithm transforms extracted peaks into prob-
ability distributions around these peaks. The distribution estimation for each
included study is based on empirical estimates of between-subject variabil-
ity and according to the number of subjects of each study. As a result maps
of the single studies are recreated. In an analysis of random-effects, val-
ues in the modeled map are afterward combined across studies and tested
against the null hypothesis of a random spatial distribution between mod-
eled maps. With this step regions are identified where empirical values are
higher than could be expected by chance. The resulting map is thresh-
olded with a customized threshold to reveal statistically significant atrophic
regions. For double-validation results of both methods can be overlaid in a
conjunction analysis; only revealing clusters significant in both approaches.
2.2.2 Voxel-Based Morphometry
To compare different whole-brain MRI scans the method of voxel-based
morphometry (VBM) is widely used. This technique is an unbiased ap-
proach for a comprehensive assessment of structural brain alterations. Ba-
sis of VBM is a voxel-wise contrast of local gray or white matter values
between subjects or also groups (e.g. healthy controls and patients) (Ash-
burner and Friston, 2000).
An important step in processing MRI images is merging to a particular
stereotactic space. Stereotactic space refers to a 3-dimensional coordinate
system of the brain to locate certain areas despite of individual differences
in structure. Nowadays, the stereotactic space of Montreal Neurology Insti-
tute and Hospital (MNI) is the reference standard. In order to define a more
representative brain of the population a large amount of ’normal’ brains
were scanned and averaged here to create a brain template with a respec-
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tive coordinate system. Creating this new template included a two-step
procedure: (1) in 250 normal MRI scans various landmarks were defined
manually and (2) another 55 images were registered to this atlas by an au-
tomatic linear registration technique (Rorden and Brett, 2000). Both, the
manually and computed brain matches were used to create the MNI 305
atlas. It consists of 239 male and 66 female right handed subjects with an
average age of 23.4 (± 4.1) (Rorden and Brett, 2000). To spatially normal-
ize to the same stereotactic space, each image is registered to the same
standardized template brain. However, not all cortical areas are matched
perfectly; there is only a correction for global shape differences. An exact
overlay would diminish all regional concentration differences. Gray matter,
white matter, and cerebrospinal fluid are segmented while normalizing the
images. During normalization it is possible that regional atrophy might dis-
appear. To compensate this, data can be modulated by multiplying the gray
matter value after warping the images to the template with the Jacobian de-
terminant. Hence, modulation spatially compensates for deformation. Gray
matter is then used for further processing and smoothed. This step ensures
a normal distribution of the data and seeds assumptions for subsequent
statistical analyses. Using this data tests performing voxel-wise parametric
statistics can be run to compare different groups. This technique results in
a statistical parametric map displaying regions where concentration of gray
matter is significantly different to contrasted group. Such so called univari-
ate approaches lead to a massive number of tests in these regions and
voxels (50,000–350,000) (Woo et al., 2017).
2.2.3 Support-Vector Machine Classification
Machine learning can identify brain patterns, which discriminate pa-
tients from healthy subjects and establish objective features of underlying
disease pathology (Woo et al., 2017). We applied support-vector machine
classification (SVM), a multivariate method taking into account multiple de-
pendencies across the whole-brain, to find a function separating classes of
data in a multidimensional space (Klöppel et al., 2008; Arbabshirani et al.,
2017).
Basically, SVM has two outcomes: a classification result and a weight
map. The first provides the answer whether groups are distinguishable or
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not. The second provides a map containing the relative contribution of the
individual features (Schrouff and Mourao-Miranda, 2018). Linear machine
learning weight maps have no applicable unit and provide not directly a
surrogate of information about the neural correlates. Thus, in a prediction
model of patients and controls weights do not necessarily symbolize atro-
phy. They rather display the distance from the separating function, meaning
the features that yielded the highest predictive value to distinguish between
the groups. To reach high classification accuracy, cross-validation using the
’leave-one-subject-out’ approach can be implemented into the model. Clas-
sification is done several times and at each iteration a patient and a healthy
subject is left out when building the classifier. Subsequently, it is checked if
both remaining data sets are classified correctly. Specificity and sensitivity
of the classification are calculated by the number of correctly classified pa-
tients and healthy subjects. It has been shown that SVM is robust against
scanner differences, which makes it suitable for multi-centric trials (Klöppel
et al., 2008; Franke et al., 2010).
2.3 Multi-Centric Data
The Max-Planck-Institute for Human Cognitive and Brain Sciences and
the Clinic of Cognitive Neurology at the University of Leipzig are taking part
in the Research Consortium for Frontotemporal Lobar Degeneration Ger-
many (FTLD Consortium) (Otto et al., 2011). This project was sponsored
by the German Federal Ministry of Education and Research as part of the
competence network for neurodegenerative dementias. The FTLD Consor-
tium is a network consisting of several study centers, which includes clinical
centers and centers for translational research. Study sites are spread over
whole Germany and Italy; the consortium’s headquarter is located in Ulm.
Research consortia and multi-center trials have numerous advantages:
fast recruitment of necessary number of patients - especially in rare dis-
eases, higher statistical power due to large sample-sizes, and variance
between study center cohorts reflect the real setting. Each clinical cen-
ter contributes to the project and is allowed to use the comprehensive col-
lected data from all centers. On the other hand, an efficient coordination
is indispensable to ensure a high reliability and quality of data. It is impor-
tant that all study sites follow the same recruitment criteria, study protocols,
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and follow-ups. Hence, standard operating procedure protocols are imple-
mented since data quality is depending on the material, equipment, and
competence of the collaborators of the study center. All in all, advantages
of multi-centric data acquisition are predominant. For Study 3 (Albrecht
et al., 2019b), CBS patients and healthy control subjects’ data were ac-
quired from the database of the FTLD Consortium Germany.
2.4 Clinical Assessment
For grading disease severity of patients, several tests are administered
to assess cognitive deficits and motor impairment. To quantify cognitive im-
pairment, the Mini-Mental State Examination (MMSE) (Folstein et al., 1975)
is widely applied. Main target are patients with Alzheimer’s dementia, since
there are no effects in healthy elderly or patients with personality disorder
(Folstein et al., 1975). The MMSE shows a high validity and retest relia-
bility by multiple test dates and examiners. Hence, there are no practicing
effects, which enables application to serially document cognitive changes.
Patients with cognitive deficits cooperate well only for short time periods,
thus the MMSE requires only five to ten minutes (Folstein et al., 1975). The
test focuses on cognitive aspects of mental functions, excluding questions
depending on mood or mental experiences. First part requires vocal re-
sponses of patients addressing orientation, memory, and attention. In the
second part, patients have to practice naming and follow verbal or written
commands by writing a sentence and copying a geometrical shape.
Clinical features and disease progression of parkinsonian syndromes
are assessed by the Unified Parkinson Disease Rating Scale (UPDRS)
(Fahn, 1987). The UPDRS is consisting of several parts evaluating differ-
ent domains from daily living difficulties to behavior, and motor impairment.
For clinical studies particularly the motor score of the UPDRS is reported
(UPDRS-III) as it points out the severity of motor symptoms. This part of
the test examines several motor domains of a patient: speech, facial ex-
pressions, gait, postural stability, and movements of extremities. Questions
are completed, if possible, by the patient otherwise by the caregiver.
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A B S T R A C T
Recently, revised diagnostic criteria for Parkinson's disease (PD) were introduced (Postuma et al., 2015). Yet,
except for well-established dopaminergic imaging, validated imaging biomarkers for PD are still missing, though
they could improve diagnostic accuracy.
We conducted systematic meta-analyses to identify PD-specific markers in whole-brain structural magnetic
resonance imaging (MRI), [18F]-fluorodeoxyglucose-positron emission tomography (FDG-PET) and diffusion
tensor imaging (DTI) studies. Overall, 74 studies were identified including 2323 patients and 1767 healthy
controls. Studies were first grouped according to imaging modalities (MRI 50; PET 14; DTI 10) and then into
subcohorts based on clinical phenotypes. To ensure reliable results, we combined established meta-analytical
algorithms - anatomical likelihood estimation and seed-based D mapping - and cross-validated them in a con-
junction analysis.
Glucose hypometabolism was found using FDG-PET extensively in bilateral inferior parietal cortex and left
caudate nucleus with both meta-analytic methods. This hypometabolism pattern was confirmed in subcohort
analyses and related to cognitive deficits (inferior parietal cortex) and motor symptoms (caudate nucleus).
Structural MRI showed only small focal gray matter atrophy in the middle occipital gyrus that was not confirmed
in subcohort analyses. DTI revealed fractional anisotropy reductions in the cingulate bundle near the orbital and
anterior cingulate gyri in PD.
Our results suggest that FDG-PET reliably identifies consistent functional brain abnormalities in PD, whereas
structural MRI and DTI show only focal alterations and rather inconsistent results. In conclusion, FDG-PET
hypometabolism outperforms structural MRI in PD, although both imaging methods do not offer disease-specific
imaging biomarkers for PD.
1. Introduction
Among neurodegenerative diseases, Parkinson's disease (PD) is the
second most common disorder with annually 5–35 new cases per
100,000 persons (Poewe et al., 2017). In the last two decades, research
on PD has shed new light on its clinical characterization and patho-
genesis. However, the most often used diagnostic criteria were pub-
lished back in 1992 by the Parkinson's Disease Society Brain Bank
(PDSBB) (Hughes et al., 1992). These are based on the clinical ob-
servation of the parkinsonian syndrome, defined as bradykinesia plus
one of rigidity, tremor at rest or postural instability, combined with
fulfilling both exclusion and supportive positive prospective criteria,
such as levodopa responsiveness and asymmetry of the motor impair-
ment (Hughes et al., 1992). Beyond motor-symptoms, PD may show
also non-motor manifestations, such as sleep disorder, anosmia, con-
stipation, hallucinations, and cognitive impairment possibly leading to
dementia (Poewe et al., 2017; Schapira et al., 2017). This is shifting the
conceptualization of PD from a pure dopaminergic motor syndrome to a
multisystem and multi-neurotransmitter one (Titova et al., 2017). The
recently updated PD diagnostic criteria by the Movement Disorder So-
ciety have already included the current clinical knowledge of PD re-
search, comprising non-motor features, thus increasing diagnostic
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accuracy (Postuma et al., 2015). Nevertheless, the diagnosis is still
predominantly based on clinical symptoms. Indeed, the only brain
biomarker mentioned, i.e. normal presynaptic dopaminergic function as
detected by molecular imaging, is used as an exclusion criterion for PD
(Postuma et al., 2015). A recent meta-analysis has already provided a
synthesis of studies investigating presynaptic dopamine function in PD
(Kaasinen and Vahlberg, 2017). No other imaging biomarkers have
been included so far for the diagnosis of PD, although they could be
crucial to improve the diagnostic accuracy. In this respect, Alzheimer's
disease research is exemplary. Indeed, magnetic resonance imaging
(MRI) and amyloid and [18F]-fluorodeoxyglucose (FDG) positron
emission tomography (PET) have been successfully integrated in the
most recent diagnostic criteria for mild cognitive impairment, as a pre-
stage, and Alzheimer's disease (Albert et al., 2011; Dubois et al., 2014).
Along the same line, disease-specific imaging biomarkers have been
also proposed for other neurodegenerative diseases, such as fronto-
temporal lobar degeneration or primary progressive aphasia (Gorno-
Tempini et al., 2011; Rascovsky et al., 2011). The identification of PD-
specific imaging biomarkers based on MRI or FDG-PET imaging could
provide a useful tool to improve the differential diagnosis, for example
in comparison to atypical parkinsonism.
Up to date, many studies have tried to identify new imaging bio-
markers for PD (Lehericy et al., 2017; Lotankar et al., 2017; Postuma
and Berg, 2016). Recent qualitative reviews about multimodal bio-
markers in PD suggested diffusion tensor imaging (DTI) as preferably
useful for diagnosis and staging of PD (Lehericy et al., 2017; Tuite,
2017). Indeed, a pattern recognition algorithm (support vector machine
classification) using DTI data of the substantia nigra has proved to yield
high accuracy (up to 97.5%) in differentiating PD from healthy subjects
and other parkinsonian syndromes (Haller et al., 2012). Also other MRI-
and FDG-PET-based measures have been investigated by many studies.
However, due to the large variability between study settings and ana-
lysis methods, the reported results are heterogeneous and consequently
they are considered as still developing methods for PD assessment
(Lehericy et al., 2017; Lotankar et al., 2017; Postuma and Berg, 2016).
In order to provide an unbiased overview of the up-to-date literature,
Fig. 1. PRISMA statement flow diagram. Flow of information through different phases of the systematic literature search identifying the neural correlates of
Parkinson's disease. Image modified according to the PRISMA statement (Moher et al., 2009).
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free from a priori hypotheses, we decided to focus our meta-analysis on
whole-brain studies applying structural MRI, FDG-PET or DTI imaging.
For a complete account of the literature, the reader can refer to the
references in the Supplementary material. To further disentangle the
effects of different clinical phenotypes, we stratified our findings into
several clinical subcohorts. Our aim was to identify a robust and re-
plicable neural signature of PD that can be used in the research and
clinical settings. To this end, we systematically applied quantitative
data-driven meta-analyses on multimodal neuroimaging data to iden-
tify prototypical neural networks involved in PD and to extract disease-
specific imaging biomarkers. Moreover, we aimed to compare the dif-
ferent imaging modalities by directly contrasting them. However, given
the limited number of DTI studies performing whole-brain analysis, this
comparison could be performed only between MRI and FDG-PET. Of
note, to cross-validate our results, we used a unique approach in-
tegrating two meta-analytical algorithms.
2. Materials and methods
2.1. Study selection
Literature search and study selection were performed according to
the Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) statement (www.prisma-statement.org), to assure
high quality and reproducibility. First, we searched PubMed for studies
published until November 2016 and matching the following keywords:
(“Parkinson's disease” OR “PD” OR “idiopathic Parkinson's disease”)
AND (“voxel-based morphometry” OR “gray matter” OR “white matter”
OR “VBM” OR “FDG-PET” OR “DTI”). Only studies satisfying the fol-
lowing criteria were further considered: (1) original and peer-reviewed
study, (2) established diagnostic criteria for PD diagnosis2, (3) whole-
brain neuroimaging analysis, (4) comparison with age-matched healthy
controls, and (5) result coordinates reported in stereotactic reference
systems, e.g. Talairach or Montreal Neurological Institute (MNI). To
prevent any a priori assumptions, region-of-interest analyses and case
studies were excluded. The selection is summarized in the PRISMA
flowchart (Fig. 1). Both literature search and study selection were in-
dependently performed by two investigators (FA and TB).
FDG-PET and structural voxel-based morphometry MRI (MRI-VBM)
studies were numerous enough to be stratified into subcohorts.
Specifically, three subcohorts were created according to the PD patients'
clinical characteristics: (1) an inclusive group comprising all PD pa-
tients irrespective of their clinical features (e.g. cognitive impairment or
visual hallucinations) (PD-All), (2) a subgroup including only PD pa-
tients with cognitive impairment, defined as Mild Cognitive Impairment
or dementia (PD-Cog), (3) a subgroup of patients with only PD motor
symptoms without specific cognitive or behavioral deficits (PD-Motor).
Additional subanalyses were run on structural MRI studies reporting
gray matter increases in PD as compared to controls (PD-Inc) and white
matter changes in PD (PD-WM). Furthermore, white matter changes
were also investigated in DTI fractional anisotropy studies.
2.2. Statistical analyses
2.2.1. Demographic and clinical features
The following variables were extracted across studies: age, gender,
Mini-Mental State Examination (MMSE), disease duration, Hoehn&Yahr
stage, and Unified Parkinson's Disease Rating Scale motor score
(UPDRS–III). Summary statistics (i.e. means and standard deviations)
were computed across all the studies (MRI+PET+DTI), as well as
separately for the clinical subgroups (i.e. PD-All, PD-Motor, PD-Cog,
and PD-Inc) and imaging modalities (Table 1). Group comparisons by
means of Kruskal-Wallis tests were conducted to statistically assess
differences in the extracted variables across different imaging cohorts.
Multiple statistical tests were Bonferroni corrected with α=0.01.
2.2.2. Meta-analysis
Statistical analyses were performed with two different software
packages to obtain robust, reliable results and to validate the results of
each individual technique. Anatomical Likelihood Estimation (ALE) and
Seed-based D Mapping (SDM) approaches are implemented in Ginger
ALE (v2.3.6) (Eickhoff et al., 2012) and SDM (v5.141) (Radua and
Mataix-Cols, 2009) (Table-e11 summarizes characteristics of both
methods).
First, we applied the SDM approach (Radua and Mataix-Cols, 2012;
Radua et al., 2014). In brief, the extracted maxima from the literature
are used to build a statistical map for each study. A value is assigned to
each voxel in the map depending on its proximity to the reported co-
ordinates of interest, so that the closer the voxel, the higher its value. In
the case of voxels that lie in the proximity of more than one coordinate,
the values are linearly summed. To avoid the issue of studies reporting
coordinates in close proximity, a multilevel kernel density analysis is
implemented to limit the values to a maximum. Then, pooling the in-
dividual maps together, a mean meta-analytical map is computed, in
which the value of a voxel is defined as the proportion of studies re-
porting a coordinate around that voxel. Finally, the resulting map is
tested against a whole-brain null distribution of the meta-analytical
values (Radua and Mataix-Cols, 2009). Of note, the SDM software does
not provide a built-in function for multiple comparison correction.
Accordingly, we performed false discovery rate (FDR) correction of the
uncorrected p-values using the SDM FDR online calculator.
For SDM analyses, the extracted coordinates of gray matter density,
metabolic or fractional anisotropy changes and the corresponding z-scores
were used. In case of reported t-values, a t-to-z conversion was performed
(www.sdmproject.com/utilities/?show=Statistics). Coordinates were
converted into MNI space by the software. The null distribution was
computed with 100 randomizations and an anisotropic kernel. The first
threshold was set at p < .001 uncorrected. In addition, to test the stability
of the results, a jack-knife approach was applied, i.e. removing one study
at a time and running the analysis again. We thus report only clusters
present in at least 80% of the jack-knife folds for the PD-All analysis and
the full range (1–100%) for the subanalyses on limited number of studies.
Notably, the SDM software takes into account the sample size differences
between the included studies and it allows also the inclusion of studies
with negative findings.
Secondly, the same meta-analysis was run by means of the ALE
method (Eickhoff et al., 2012; Laird et al., 2009). In summary, each
coordinate is set as the center of a Gaussian probability distribution,
whose width is corrected according to the sample size of the corre-
sponding study. Then, all the Gaussian distributions are summed in one
statistical map that is tested voxel-wise against the null hypothesis of an
equal spatial distribution of the foci. Thus, regions with ALE values
higher than expected by chance are identified.
We converted Talairach coordinates into MNI space with Lancaster
transformation as implemented in GingerALE. The statistical threshold
at the voxel-level was set at p < .001 uncorrected as in SDM. Results
were considered significant after Family-Wise Error (FWE) correction at
the cluster level (p < .05). In contrast to SDM, studies reporting ne-
gative findings cannot be included in the ALE meta-analysis and were
thus discarded. Furthermore, to enable direct comparison of FDG-PET
and MRI-VBM results, we run a contrast analysis between the two
modalities on the PD-all cohort. This analysis, which statistically as-
sesses differences between two modalities, is only implemented in
GingerALE and was performed with standard parameters, i.e. un-
corrected voxel-level threshold at p < .001 and 10,000 permutations.
Finally, to facilitate the comparison of results of both meta-analytic
approaches, we created an overlap image combining them (SDM∩ALE).
This conjunction analysis revealed clusters that were significant by both
algorithms. In the following results and discussion sections we focus on
brain changes in PD that were consistently identified by SDM and ALE
meta-analyses. This highlights the most reliable findings that are in-
dependent from the specifics of the applied meta-analytical method.
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Table 1
Summarized subjects' demographics.
Cohort Modality Cohorts Patients Age (years) Disease duration
(years)
MMSE UPDRS-III Hoehn and Yahr
N total (N in studies with null-
findings, %)
N total (N in studies with null-
findings, %)
PD-All FDG-PET 19 (3, 15.8%) 295 (46, 15.6%) 65.9 ± 4.9 8.4 ± 4.6 26.1 ± 5.0 29.8 ± 20.5 2.7 ± 0.9
MRI 65 (18, 27.7%) 1767 (475, 26.9%) 66.0 ± 5.8 7.1 ± 4.5 25.2 ± 7.9 18.6 ± 10.9 1.5 ± 1.0
DTI 11 (3, 27.3%) 212 (74, 34.9%) 62.5 ± 4.6 5.4 ± 2.6 28.1 ± 1.7 32.5 ± 17.0 1.8 ± 0
Combined 95 (21, 22.1%) 2274 (595, 26.2%) 65.6 ± 5.5 7.2 ± 4.4 25.7 ± 7.0 22.4 ± 14.9 1.9 ± 1.1
PD-Motor FDG-PET 13 (3, 23.1%) 240 (46, 19.2%) 64.8 ± 4.6 7.3 ± 4.2 26.1 ± 5.2 30.1 ± 23.0 2.5 ± 0.9
MRI* 42 (13, 31.0%) 1177 (368, 31.3%) 64.5 ± 5.5 6.8 ± 2.8 27.8 ± 1.2 24.0 ± 7.2 2.1 ± 0.4
Combined 55 (16, 29.1%) 1417 (414, 29.2%) 64.6 ± 5.2 7.0 ± 3.3 27.3 ± 3.2 25.7 ± 13.6 2.2 ± 0.6
PD-Cog FDG-PET 5 (0, 0%) 92 (0, 0.0%) 69.0 ± 5.1 10.7 ± 5.7 20.7 ± 7.4 20.9 ± 8.8 3.3 ± 0.4
MRI 11 (1, 9.1%) 256 (36, 14.1%) 71.1 ± 3.1 7.6 ± 3.9 24.0 ± 4.3 29.7 ± 7.3 2.7 ± 0.8
Combined 15 (1, 6.7%) 348 (36, 10.3%) 70.4 ± 3.8 8.7 ± 4.7 23.4 ± 4.7 27.3 ± 8.3 2.9 ± 0.8
PD-WM MRI 4/6 (2, 33.3%) 139 (64, 46.0%) 63.8 ± 2.5 7.0 ± 3.0 28.5 ± 0.8 22.6 ± 6.4 2.2 ± 0.7
PD-Inc MRI 5 (0, 0%) 57 (0, 0.0%) 59.5 ± 7.5 8.1 ± 4.6 26.0 ± NA(1) 22.2 ± 0.8 2.1 ± 0.1
Note: Data shown as mean ± standard deviation. Cohorts reporting null findings were subsequently excluded in our meta-analysis. *The MRI meta-analyses led to
non-significant results for the PD-Motor cohort, hence we do not elaborate on the results. (1)Only one study reported a value.
Abbreviations: DTI diffusion tensor imaging, MMSE Mini-Mental State Examination, MRI magnetic resonance imaging, NA not reported, PD-All all Parkinson's
disease patients, PD-Cog Parkinson's disease patients with cognitive impairment, PD-Motor Parkinson's disease patients with motor impairment, PD-WM white matter
atrophy in Parkinson's disease, FDG-PET [18F]-fluorodeoxyglucose-positron emission tomography, UPDRS-III motor score of Unified Parkinson Disease Rating Scale.
Fig. 2. Hypometabolism and atrophy in Parkinson's disease (PD) patients compared to controls. Upper rows: Meta-analysis of FDG-PET (249 PD/186 controls) and
MRI-VBM (1292 PD/1014 controls) studies. The SDM∩ALE conjunction highlights brain regions consistently found in both analyses. Anatomical regions are
highlighted only for these consistent results. Bottom row: The contrast analysis shows significant regions for the contrast FDG-PET > MRI-VBM. Images shown in
neurological convention in MNI space.
Abbreviations: ALE Anatomical Likelihood Estimation, CdN caudate nucleus, FDG-PET [18F]-fluorodeoxyglucose-positron emission tomography, FWE Family-Wise
Error rate, IPC inferior parietal cortex, mOC middle occipital cortex, MRI-VBM voxel-based morphometry analysis of magnetic resonance imaging, PD-All cohort of
all PD patients, SDM Seed-based D mapping.
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3. Results
3.1. Included studies
The PRISMA (Moher et al., 2009) flowchart, describing the selection
procedure, is displayed in Fig. 1. The overall meta-analysis included
2323 PD patients and 1767 healthy controls. Out of the total 74 studies,
50 implemented structural MRI (VBM), including 1816 PD patients.
Fourteen FDG-PET studies investigated 295 patients and ten whole-
brain DTI studies comprised 212 patients. Only studies reporting sig-
nificant findings are displayed in Table e-1. Notably, negative findings
(i.e. no difference comparing patients and controls) were reported in 14
(28% out of all) MRI studies, 3 (21.4%) FDG-PET, and 3 (30%) DTI
studies (Table e-2). As for the clinical subgroups, Table 1 displays the
number of subjects in each category stratified by imaging modalities.
3.2. Demographic and clinical characteristics
Considering significant studies, Table 1 displays means and stan-
dard deviations of descriptive variables for the entire sample, the
clinical subgroups, and the imaging modalities. Overall, the mean age
of PD patients was 65.6 ± 5.5 years (MRI 66.0 ± 5.8; PET
65.9 ± 4.9; DTI 62.5 ± 4.6) with a good balance between males and
females (m/f) 927/728 (MRI 711/561; PET 107/92; DTI 82/56). Dis-
ease duration was on average 7.2 ± 4.4 years (MRI 7.1 ± 4.5; PET
8.4 ± 4.6; DTI 5.4 ± 2.6).
Kruskal-Wallis tests showed no significant differences across ima-
ging modalities for age (χ2= 3.0), disease duration (χ2= 1.9), and
severity (UPDRS-III χ2= 5.9, MMSE χ2= 1.2), guaranteeing a well-
matched analysis with balanced variables. For disease severity assessed
with the Hoehn & Yahr scale there was a significant difference between
the groups (χ2= 9.0, df= 2, p= .011). The results should be inter-
preted with care, though, as 46% of the included studies did not report
and/or assess Hoehn & Yahr stage, 39% did not report MMSE, and 19%
did not report UPDRS-III. Accordingly, studies' comparability in
UPDRS-III scores seems to be more valid than the difference in Hoehn &
Yahr stages. Note that only two studies (Watanabe et al., 2013; Yarnall
et al., 2014) used the MDS-UPDRS scale (Goetz et al., 2008) instead of
the UPDRS scale (Fahn, 1987).
3.3. Meta-analysis on the PD-All cohort
Overlapping results of SDM and ALE were deemed significant and
are here reported. The PD-All < Controls comparison revealed sig-
nificant glucose hypometabolism in the entire PD cohort in the bilateral
inferior parietal cortex and in the left caudate nucleus, independently of
the meta-analytical approach implemented (Fig. 2, top row, and
Table 2, e-3, e-4). The conjunction analysis of the PD-All < Controls
contrast revealed small focal gray matter atrophy in the middle occi-
pital gyrus (Fig. 2, middle row, and Table 2, e-5, e-6).
3.4. Contrast analyses
The contrast analysis between FDG-PET and MRI-VBM showed only
significant findings in the FDG-PET > MRI-VBM contrast. Namely,
FDG-PET compared to MRI-VBM revealed brain changes in the left
caudate nucleus and right superior parietal cortex/precuneus (Fig. 2,
bottom row Table e-10).
3.5. Meta-analysis on subcohorts
The results of the meta-analysis of the subcohorts are displayed in
Fig. 3.
PD-Cog: Glucose metabolism was reduced in the bilateral inferior
parietal cortex and in the right orbitofrontal cortex with both meta-
analytical algorithms in the PD-Cog < Controls comparison, i.e. in PD
patients with cognitive deficits (Fig. 3 and Table e-3, e-4). Conversely,
the conjunction analysis of SDM and ALE for the structural MRI meta-
analysis showed no overlap. ALE detected atrophy in left hippocampus
only, while using SDM atrophy was seen in left insula, putamen,
claustrum, and right putamen, as well as in the globus pallidus (Fig. 3,
left side, Table e-5, e-6).
PD-Motor: The conjunction analysis on FDG-PET results revealed
consistent glucose hypometabolism in the PD-Motor < Controls com-
parison, i.e. PD patients with solely motor impairment, in the left
caudate nucleus, a motor structure. For structural MRI (Fig. 3, right
side, and Table e-3, e-4), the ALE meta-analyses did not provide sig-
nificant results for the PD-Motor cohort.
PD-Inc: Right side of Fig. 3 and Table e-5 and e-6 display findings of
higher gray matter density in PD compared to controls (PD-Inc >
Controls). An overlap between SDM and ALE was found in basal
ganglia, i.e. caudate nucleus, putamen, globus pallidus, and thalamus.
White matter (DTI): DTI studies revealed lower fractional anisotropy
in PD compared to controls with consistent results for SDM and ALE in
the cingulate bundle close to the orbital and anterior cingulate gyri
(Fig. 3, bottom row, and Table e-7, e-8).
White matter (MRI-VBM): The conjunction analysis revealed white
matter atrophy in superior longitudinal fasciculus, internal capsule, and
extreme/external capsule in the vicinity of the right putamen and
globus pallidus in PD compared to controls. White matter atrophy was
further found in the superior occipitofrontal fasciculus, corpus cal-
losum, corona radiata, external and internal capsule surrounding the
left caudate nucleus (Fig. 3, bottom row, and Table e-5, e-6).
4. Discussion
In summary, our multimodal meta-analysis across whole-brain
imaging studies revealed that FDG-PET glucose hypometabolism is
more consistently associated with PD as compared to brain atrophy as
identified by MRI-VBM. Moreover, the meta-analysis on the subcohorts
provides an interesting initial glimpse into specific neural signatures of
different PD clinical phenotypes and into white matter changes in PD.
4.1. FDG-PET hypometabolism is more specific than MRI-VBM structural
changes in PD
We hypothesize that the reason behind the dissociation between
FDG-PET and MRI-VBM results lies in the different PD-related brain
changes captured by the two techniques. Indeed, structural MRI ana-
lyzed with VBM identifies morphological brain abnormalities
(Ashburner and Friston, 2000), while FDG-PET is a proxy of early
neuronal injury and synaptic dysfunction. Such functional brain al-
terations may antedate morphological changes by several years, as in
the case of Alzheimer's disease or Huntington's disease (Mosconi, 2013;
Tang et al., 2013). Indeed, FDG-PET studies have shown Alzheimer's
disease-related brain hypometabolism in cognitively intact subjects at
genetic risk (i.e. ε4 homozygous carriers) several years before disease
onset (Reiman et al., 1996). Similarly, multimodal imaging studies,
combining FDG-PET and structural MRI to investigate presymptomatic
genetic Alzheimer's disease, have shown that hypometabolism precedes
and exceeds atrophy in the early identification of brain abnormalities
(Gordon et al., 2018; Mosconi et al., 2006). In line with that, metabolic
changes were shown to be more sensitive to progression of the disease
than structural changes in preclinical Huntington's disease mutation
carriers (Tang et al., 2013). Thus, in analogy with Alzheimer's disease
and Huntington's disease, FDG-PET might be a more accurate bio-
marker for subtle brain abnormalities in PD. Of note, cohorts in FDG-
PET and MRI-VBM studies did not differ regarding age, disease dura-
tion, and disease severity, making respective biases unlikely. Although
differences in Hoehn & Yahr stage were evident, this comparison was
less reliable due to multiple missing data.
Since functional brain changes seem to be more relevant for PD
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assessment, also resting-state functional MRI (rs-fMRI) could be em-
ployed to investigate the neural signature of PD. Indeed, recent meta-
analyses on rs-fMRI studies in PD revealed functional alterations in
patients compared to controls in both motor (i.e. supplementary motor
areas, left putamen and premotor cortex) and non-motor (i.e. bilateral
inferior parietal and supramarginal gyri) networks (Pan et al., 2017;
Tahmasian et al., 2017). This result aligns with our FDG-PET findings,
pointing out that functional changes both inside and outside the motor
network, namely in the inferior parietal cortex, might represent a cru-
cial hallmark of PD that has been neglected so far. Indeed, the inferior
parietal cortex is a higher order associative region that plays an im-
portant role in various mechanisms ranging from language (e.g. se-
lecting gestures, verbal integration of complex contexts like sentences)
to spatial orientation (e.g. processing personal space, localization of
objects) as well as motor functions (e.g. tactile reception of complex
movements and interaction with objects) (Culham and Kanwisher,
2001). There is even evidence of mirror neurons in the inferior parietal
cortex, which encode goals of motor acts (Rizzolatti et al., 2009). Im-
pairment in this region can lead to the well-described effect of spatial
hemineglect and further to dysfunction in autobiographical memory, as
in the case of Alzheimer's disease, and visual disorientation or mis-
localization (Berryhill et al., 2007; Culham and Kanwisher, 2001;
Schroeter et al., 2009).
Moreover, we found consistent hypometabolism in the PD-all cohort
in the left caudate nucleus, a core structure in the basal ganglia network
that, together with the putamen, serves as input structure for nigros-
triatal projections (Fallon, 1988). Of note, the conjunction analysis
showed a consistent hypometabolism in the left, but not right, caudate
nucleus. Different reasons may account for this finding. First, majority
of patients with PD present and progress in their parkinsonism uni-
laterally. In the recent diagnostic criteria by Postuma et al. (2015) bi-
lateral motor symptoms at onset are even considered as a red flag to
exclude the diagnosis of PD. Second, SDM additionally identified the
right caudate nucleus as compromised by PD, suggesting that our
unilateral finding may have been due to statistical power effects or the
differences in algorithms.
Moreover, the result of a consistent caudate hypometabolism in the
PD-motor subgroup, but not in the PD-Cog subgroup, is to a certain
extent surprising. On the one hand, several previous studies have drawn
a link between caudate nuclei function and cognitive deficits – mainly
executive functions (Grahn et al., 2008) – in PD with and without de-
mentia (Apostolova et al., 2010; Polito et al., 2012). On the other hand,
motor symptoms, particularly rigidity and bradykinesia, are generally
associated with dysfunctions in the posterior putamen that shows an
earlier and faster decline in dopamine function as compared to the
caudate nucleus (Pavese and Brooks, 2009). However, an interesting
observation comes from a dual-tracer PET study from Holtbernd et al.
(2015) that investigated the relationship between dopaminergic dys-
function and glucose metabolism in a large PD cohort. The study reports
significant correlations between dopamine function in the caudate nu-
cleus and the expression of both motor- and cognition-related metabolic
patterns in PD, while dopaminergic activity in the putamen was related
only to the expression of the motor-related PD pattern. This result
supports the role of the posterior putamen in PD motor impairment,
while the involvement of the caudate nucleus seems to be implicated in
both cognitive and motor symptoms. Of note, many of the studies
showing involvement of the putamen in PD by means of FDG-PET ap-
plied spatial covariance analysis and reported relative increases in
glucose metabolism in the putamen (Eckert et al., 2007). This approach
is intrinsically different from the univariate voxel-based statistics im-
plemented by the FDG-PET studies that were object of the present meta-
analytical work.
Notably, the subcohort analyses on the FDG-PET data revealed that
glucose hypometabolism in cortical associative parietal regions is
mainly related to cognitive impairment in PD, while hypometabolism in
the caudate nucleus is more strongly associated with the motor phe-
notype. This might indicate that functional changes outside the basal
ganglia are more associated with the presence of cognitive deficits in
Table 2
Results for the PD-All cohort.
Cluster # Volume (mm3) ALE Value x y z Region
Local maxima of ALE analyses in FDG-PET
1 1424 0.022737322 −14 12 4 Left caudate body
2 1416 0.015668042 −42 −56 50 Left inferior parietal lobule
0.015623625 −44 −62 36 Left middle temporal gyrus
3 1336 0.023226662 38 −64 48 Right precuneus
4 856 0.017095294 16 12 4 Right caudate body
Local maxima of ALE analyses in MRI
1 976 0.0337 −24 −90 24 Left middle occipital gyrus
Cluster # Voxels SDM-Z x y z Region
Local maxima of SDM analyses in FDG-PET
1 2217 −4.015 −50 −62 38 Left angular gyrus
2 2070 −3.528 34 −72 38 Right middle occipital gyrus
3 568 −2.894 0 46 20 Left superior medial frontal gyrus
4 466 −3.185 −6 14 4 Left caudate nucleus
5 186 −2.804 46 30 −12 Right inferior frontal gyrus
6 45 −2.590 −44 46 −2 Left middle frontal gyrus
7 43 −2.695 14 12 2 Right anterior thalamic projections
8 28 −2.509 46 26 28 Right inferior frontal gyrus
9 27 −2.506 62 −32 −12 Right middle temporal gyrus
10 26 −2.508 14 −94 16 Right cuneus cortex
11 25 −2.537 60 −50 −6 Right middle temporal gyrus
12 22 −2.574 8 −90 2 Right calcarine fissure
Local maxima of SDM analyses in MRI
1 1952 −3.304 −24 −2 −18 Left amygdala
2 1804 −3.345 50 2 2 Right rolandic operculum
3 33 −2.746 −24 −90 24 Left superior occipital gyrus
Clusters below an effect-size estimate (SDM) threshold p < .001 and an anatomical likelihood estimate (ALE) threshold p < .05 FWE are listed. Coordinates are in
MNI space.
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PD, as previously suggested (Huang et al., 2007; Lopes et al., 2017).
Hypometabolism in parietal associative areas is also a hallmark of
Alzheimer's disease, thus limiting the specificity of our finding as PD
biomarker (Schroeter et al., 2009). Also the caudate nucleus, due to its
connectivity with prefrontal regions, may play a role in the emergence
of cognitive dysfunction in PD beside motor deficits (Brück et al.,
2000). Disease specificity of glucose hypometabolism in this brain re-
gion for PD is not guaranteed as it has also been reported in behavioral
variant frontotemporal dementia and nonfluent/agrammatic variant of
primary progressive aphasia (synonymous with progressive non-fluent
aphasia) (Bisenius et al., 2016; Schroeter et al., 2014).
Remarkably, five out of the 14 FDG-PET studies reported hy-
permetabolism in PD as compared to controls, but no significant result
was found applying the meta-analytical procedure. Relative metabolic
increases in the putamen, globus pallidus, pons and cerebellum have
been consistently reported as a crucial feature of the PD-related spatial
covariance pattern (Eckert et al., 2007). However, the identification of
real FDG-PET hypermetabolism in PD has been questioned, as increased
glucose metabolism could be the result of the intensity normalization
procedure applied in PET analysis. For example, Borghammer et al.
(2009) showed that regional (i.e. mainly subcortical) metabolic in-
creases in PD as compared to controls might artifactually emerge as a
consequence of global mean normalization when lower global values
characterize the patient group. A comparable finding has been reported
for Alzheimer's disease and frontotemporal lobar degeneration (Dukart
et al., 2011). However, (Ma et al., 2009) reported that global values in
early PD stages are identical to those of healthy controls and that
subcortical metabolic increases also correlate with clinical measures. In
our meta-analysis, studies reporting hypermetabolism in PD, especially
in subcortical structures, applied global mean normalization, while
none of the studies that used either normalization to white matter,
cerebellum, pons or absolute FDG-PET measures found increased me-
tabolism. This fact might support the assumption of artefactual in-
creases in metabolism due to normalization to the global mean, al-
though other reasons are still possible. Table e-9 reports different
intensity normalization procedures for FDG-PET studies.
Finally, our meta-analysis considered whole-brain FDG-PET studies
generally applying univariate statistics to compare patients and con-
trols. A consistent body of literature on multivariate network analysis
has also demonstrated the usefulness of FDG-PET (Eidelberg, 2009).
Several studies identified the so-called PD-related covariance pattern
(PDRP) that distinguishes PD patients from healthy controls
(Niethammer and Eidelberg, 2012). This metabolic pattern has high
accuracy (sensitivity 84%, specificity 97%) in differentiating PD from
atypical parkinsonism, is modulated by treatment and is predictive for
disease progression (Niethammer and Eidelberg, 2012; Tang et al.,
2010). This supports the relevance of functional brain changes as PD
biomarkers, which in future might be improved by focusing analyses on
the prototypical networks identified in our meta-analyses.
4.2. MRI-VBM changes in PD are heterogeneous and unspecific
In contrast with FDG-PET, we did not find a specific consistent
pattern of structural brain changes in PD as detected by whole-brain
MRI-VBM analysis. This was also apparent in the contrast analyses
where we obtained significant differences only for the FDG-
Fig. 3. Hypometabolism and atrophy across Parkinson's disease (PD) clinical subgroups and white matter changes comparing PD to controls. The SDM∩ALE con-
junction highlights brain regions consistently found in both analysis algorithms. Anatomical regions are highlighted only for these consistent results. Images shown in
neurological convention in the MNI space.
Abbreviations: ALE Anatomical Likelihood Estimation, CdN projections surrounding caudate nucleus, DTI diffusion tensor imaging, FDG-PET [18F]-fluorodeox-
yglucose-positron emission tomography, FWE Family-Wise Error rate, GP projections surrounding globus pallidus, IPC inferior parietal cortex, MRI-VBM voxel-based
morphometry analysis of magnetic resonance imaging, OFC orbitofrontal cortex, PD-Cog PD with cognitive impairment, PD-Inc gray matter increases in PD, PD-
Motor idiopathic PD with only motor symptoms, PU putamen/projections surrounding putamen, SDM Seed-based D mapping.
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PET > MRI-VBM contrast. The PD-all < controls comparison revealed
only minor atrophy in the middle occipital gyrus. Similarly to our study,
also previous meta-analyses investigating structural changes in PD
showed only minor and heterogeneous changes (Pan et al., 2012; Shao
et al., 2014; Shao et al., 2015; Yu et al., 2015). Furthermore, the high
number of MRI-VBM studies reporting null findings for the patients vs.
controls comparison indicates that gray matter changes in PD are un-
specific and heterogeneous. Additionally, the neuropathological criteria
for PD only describe morphological changes in the substantia nigra pars
compacta and Lewy pathology as specific pathological signatures of PD
even in late phases of the disease (Dickson et al., 2009). Concerning the
subcohort analyses, both the meta-analyses in PD with solely motor
(PD-Motor) and additional cognitive symptoms (PD-Cog) did not reveal
consistent results between the two meta-analytical approaches. This
further confirms the inadequacy of atrophy and structural MRI in PD.
Notwithstanding, implementing structural MRI could be more useful in
the diagnostic workout when guided by a priori hypothesis (e.g. fo-
cusing on the substantia nigra) and applying recent technical MRI im-
provements, such as relaxometry, magnetization transfer, and neuro-
melanin-sensitive imaging (Lehericy et al., 2012). In addition, more
sophisticated machine learning approaches have been proposed for the
detection of morphometric PD imaging biomarker, providing high ac-
curacy in differentiating PD patients and controls (Peng et al., 2017).
Surprisingly, we found higher gray matter volume in the right len-
tiform nucleus and thalamus in PD compared to controls. According to
Braak's staging model of disease spreading, the degeneration of the
thalamic nuclei is a PD hallmark (Braak et al., 2003). The higher gray
matter volume might be a compensatory mechanism to counteract the
reduction of inhibitory input to the thalamus (Lin et al., 2013). Indeed,
it has been proposed that PD leads to a reduction of the inhibitory input
from the globus pallidus and the substantia nigra to the thalamus and a
consequent derangement of the thalamic excitatory output to the
cortex.
4.3. White matter changes: preliminary evidence
Voxel-wise white matter changes were investigated with both MRI-
VBM and DTI. The former revealed widespread white matter changes,
while the latter indicated the cingulate bundle near the orbital and
anterior cingulate gyri as more affected. These findings are in line with
the non-motor symptoms of PD. Orbitofrontal gyri are involved in
sniffing and smelling (Sobel et al., 1998). Notably, olfactory dysfunc-
tion is one of the earliest features of prodromal PD, preceding disease
onset by years to decades (Postuma et al., 2015). The anterior cingulate
cortex has been associated with behavioral symptoms in PD (Tekin and
Cummings, 2002). However, generalizability of these findings is un-
dermined by the small number of studies in the analysis. As afore-
mentioned, combining the knowledge from histopathological findings
and in vivo brain imaging could provide a more accurate PD biomarker.
Indeed, DTI studies that focused on the substantia nigra have shown
high accuracy in discriminating PD patients from healthy controls
(Cochrane and Ebmeier, 2013).
4.4. Limitations of the study
This is, to our knowledge, the largest whole-brain meta-analysis
comparing PD patients and controls and the only multimodal study
combining MRI, FDG-PET, and DTI. The replicability of our findings is
assured by the combination of independent meta-analytic algorithms.
Nevertheless, we recognize some limits. First, all included studies lack
PD histopathological confirmation, as studies on autopsy-proven cases
are extremely rare. Second, methodological and technical differences
exist among the included studies, e.g. in field-strength of MR scanners,
processing protocols, or data modulation. However, the impact of these
differences on our results is limited since the meta-analytical algorithms
only take maxima into account and not the cluster size that is more
affected by this heterogeneity. Additionally, our study could not dis-
entangle the influence of pharmacological treatment on PD and the
disease process itself, because almost all studies investigated medicated
subjects. The aim of our meta-analysis was to identify PD-specific
imaging biomarkers to support the diagnosis in the earliest disease
stages. However, most of the included studies were performed with
patients who have had the disease for several years (mostly in inter-
mediate disease phase), making sub-meta-analyses for early PD un-
feasible. We believe that defining biomarkers on subjects in moderate
disease stages and applying them at earlier time points, i.e. in de-novo
patients or even in pre-symptomatic subjects, is a valid approach. This
research strategy has been successfully applied in the case of
Alzheimer's disease (see for example Bateman et al., 2012; Mosconi
et al., 2004; Whitwell et al., 2007). Finally, we remark once again the
exploratory nature of the subcohort analysis given the limited number
of included studies. Accordingly, future validation of the meta-analysis
in independent cohorts is necessary. Specificity and sensitivity of the
suggested PD-specific brain regions for differential diagnosis should be
validated in large, preferably multicenter, and independent patient
cohorts. This approach has already been successfully applied to other
neurodegenerative diseases such as Alzheimer's disease and fronto-
temporal lobar degeneration (Dukart et al., 2013; Dukart et al., 2011).
As for the DTI studies, we recognize that the choice of focusing on
whole-brain investigations reduced the number of included studies and
penalized the results of its diagnostic accuracy. Indeed, as aforemen-
tioned, the in vivo tractography of the projections of the substantia
nigra provided promising results in classifying patients with PD (Haller
et al., 2012).
5. Conclusion
This multimodal and cross-validation meta-analysis aimed at ex-
ploring potential imaging biomarkers for PD beyond dopaminergic
imaging. The novelty of the meta-analysis is to statistically validate
convergence of published results and hence draw solid conclusions with
a higher statistical power than single studies. Consistent glucose hy-
pometabolism was found in bilateral inferior parietal cortex and left
caudate nucleus combining both meta-analytic methods. Glucose hy-
pometabolism in PD was confirmed in subcohort analyses and related to
cognitive deficits (inferior parietal cortex) and motor symptoms (cau-
date nucleus). Structural MRI showed only small focal gray matter
atrophy in the middle occipital gyrus that could not be confirmed in
subcohort analyses. DTI revealed fractional anisotropy reduction in the
cingulate bundle in the vicinity of the orbital and anterior cingulate gyri
in PD. Our meta-analysis suggests that, when applying data-driven
whole-brain analysis to neuroimaging data, functional changes as as-
sessed by FDG-PET better characterize PD as compared to structural
alterations investigated by MRI-VBM and DTI. Results suggest focusing
the search of PD imaging biomarkers on functional rather than struc-
tural brain abnormalities. To date neither atrophy nor glucose hypo-
metabolism offer disease-specific imaging biomarkers for PD as the
latter regionally overlaps with other neurodegenerative diseases.
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A B S T R A C T
Objective: Progressive supranuclear palsy (PSP) is an atypical parkinsonian syndrome characterized by vertical
gaze palsy and postural instability. Midbrain atrophy is suggested as a hallmark, but it has not been validated
systematically in whole-brain imaging.
Methods: We conducted whole-brain meta-analyses identifying disease-related atrophy in structural MRI.
Eighteen studies were identiﬁed (N=315 PSP, 393 controls) and separated into gray or white matter analyses
(15/12). All patients were diagnosed according to the National Institute of Neurological Disorders and Stroke
and the Society for PSP (NINDS-SPSP criteria, Litvan et al. (1996a)), which are now considered as PSP-
Richardson syndrome (Höglinger et al., 2017). With overlay analyses, we double-validated two meta-analytical
algorithms: anatomical likelihood estimation and seed-based D mapping. Additionally, we conducted region-of-
interest eﬀect size meta-analyses on radiological biomarkers and subtraction analyses diﬀerentiating PSP from
Parkinson's disease.
Results: Whole brain meta-analyses revealed consistent gray matter atrophy in bilateral thalamus, anterior in-
sulae, midbrain, and left caudate nucleus. White matter alterations were consistently detected in bilateral su-
perior/middle cerebellar pedunculi, cerebral pedunculi, and midbrain atrophy. Region-of-interest meta-analyses
demonstrated that midbrain metrics generally perform very well in distinguishing PSP from other parkinsonian
syndromes with strong eﬀect sizes. Subtraction analyses identiﬁed the midbrain as diﬀerentiating between PSP
and Parkinson's disease.
Conclusions: Our meta-analyses identify gray matter atrophy of the midbrain and white matter atrophy of the
cerebral/cerebellar pedunculi and midbrain as characteristic for PSP. Results support the incorporation of
structural MRI data, and particularly these structures, into the revised PSP diagnostic criteria.
1. Introduction
Progressive supranuclear palsy (PSP) is a gradually progressive,
atypical parkinsonian syndrome characterized by vertical gaze palsy
and prominent postural instability with backward falls from disease
onset on (Litvan et al., 1996a). Commonly applied diagnostic criteria
were proposed by the National Institute of Neurological Disorders and
Stroke and the Society for PSP (NINDS-SPSP criteria) in 1996 (Litvan
et al., 1996a, 1996b). To fulﬁll the diagnostic criteria for possible PSP,
patients' age of onset should be>40 years. Additionally, postural in-
stability leading to falls, accompanied by slower vertical saccades, or
vertical gaze palsy alone is required for diagnosis. Probable PSP is di-
agnosed, when a patient shows all of the aforementioned features.
Certainty of the underlying tauopathy can only be conﬁrmed by his-
topathology - the remaining gold standard for diagnosis (Litvan et al.,
1996b). Despite advances in research, the evaluation of atypical
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parkinsonian syndromes has remained primarily dependent on clinical
diagnostics. Disease-speciﬁc, brain imaging, biomarkers have been in-
troduced to increase diagnostic validity of neurodegenerative diseases,
for example, in frontotemporal lobar degeneration and primary pro-
gressive aphasia (Bisenius et al., 2016; Gorno-Tempini et al., 2011;
Rascovsky et al., 2011; Schroeter et al., 2014). In terms of potential
biomarkers, previous PSP studies have focused on the local boundary
shift integral, longitudinal diﬀusion changes, or measurements of the
midbrain/cerebellum (Kato et al., 2003; Longoni et al., 2011; Oba et al.,
2005; Paviour et al., 2006; Slowinski et al., 2008; Zhang et al., 2016).
The aforementioned metrics of midbrain and cerebellum were mainly
investigated in small cohorts. During the analysis phase of the present
study, the diagnostic criteria for PSP were updated in an attempt to
increase diagnostic conﬁdence by including neuroimaging measures as
supportive and exclusion criteria, highlighting the timeliness of our
report. Clinical diagnostic criteria were further improved by including
more detailed diagnosis and acknowledging the several phenotypes of
PSP. The amended criteria propose that former diagnosis according to
Litvan et al. (1996a) relates to the phenotype of PSP-Richardson syn-
drome. Indeed, diagnostic criteria by Litvan et al. (1996a) have been
shown to be 95–100% speciﬁc, validated by pathological examination
(Höglinger et al., 2017). In the new criteria, in particular the use of
midbrain atrophy or hypometabolism and/or postsynaptic, striatal,
dopaminergic degeneration (Höglinger et al., 2017) has been suggested.
Whitwell et al. (2017) published a qualitative review of radiological
biomarkers, supporting midbrain and cerebellar pedunculi as speciﬁc to
PSP even in the early phases of disease. However, it is important to
prove the reliability of those disease patterns in quantitative whole-
brain analyses.
We investigated the neural correlates of PSP to validate pathogno-
monic signs and further identify possible imaging biomarkers with
systematic and quantitative meta-analyses; a thorough and powerful
data-driven approach (Bisenius et al., 2016; Schroeter et al., 2014). The
meta-analysis focused on whole-brain voxel-based morphometry (VBM)
studies that applied structural magnetic resonance imaging (MRI) in
PSP. By including only whole-brain studies, we prevented possible vi-
cious circles if only expected brain regions are examined. We in-
vestigated disease-associated atrophy separately in gray and white
matter in PSP compared with controls. Two widely acknowledged
meta-analytical approaches, anatomical likelihood estimation (ALE)
(Eickhoﬀ et al., 2012) and anisotropic eﬀect size seed-based D mapping
(SDM) (Radua and Mataix-Cols, 2009; Radua et al., 2014), were applied
and double-validated against each other. Overlay analyses were used to
conﬁrm the ﬁndings of the individual approaches, by assessing the
degree of overlap. This provided reliable results and enabled us to
identify a robust, disease-characteristic imaging biomarker. To in-
vestigate disease-speciﬁcity we run subtraction analyses to compare
PSP with related diseases, i.e. Parkinson's disease (Albrecht et al.,
2018). We hypothesized atrophy in PSP of white matter in the midbrain
and gray matter in the midbrain, thalamus, and insulae (Shao et al.,
2014; Shi et al., 2013; Yu et al., 2015). Additionally we performed a
supportive region-of-interest eﬀect size meta-analysis on the disease-
speciﬁc imaging marker studies identiﬁed by (Whitwell et al., 2017).
2. Materials and methods
2.1. General study selection
The meta-analysis was conducted according to the PRISMA guide-
lines (www.prisma-statement.org) and Müller et al. (2018). Two au-
thors (FA, SB) independently searched the PubMed database with the
following search strategy: (“progressive supranuclear palsy” OR
“Steele-Richardson-Olszewski syndrome”) AND (voxel* OR gray matter
OR VBM). Studies were included if they: (1) were peer-reviewed, (2)
used established diagnostic criteria, (3) were original work, (4) made
comparisons with age-matched healthy controls, (5) reported results
normalized to a stereotactic space (Talairach or the Montreal Neuro-
logical Institute's (MNI)), and (6) took a whole-brain approach. Region-
of-interest analyses, small volume corrected peaks, and case studies
were discarded to prevent any regional a priori assumptions. As we did
not ﬁnd enough [18F]-ﬂuorodeoxyglucose positron emission tomo-
graphy (FDG-PET) or diﬀusion tensor imaging (DTI) studies fulﬁlling
our criteria, we limited analysis to structural MRI, investigating gray
and/or white matter atrophy. The literature search was performed be-
tween February and May 2016, reviewing all studies regardless of their
publication date. We contacted corresponding authors to request local
maxima not reported in their original publications and obtained data
(Burciu et al., Premi et al., and Hughes et al.). The corresponding author
of Burciu et al. conﬁrmed by email that they used the NINDS-SPS cri-
teria for diagnosis.
2.2. Statistical analyses
2.2.1. Whole-brain ALE & SDM meta-analyses
To obtain robust and reliable neural correlates of PSP, we applied
two separate meta-analysis methods, enabling conﬁrmation of the re-
sults of each individual technique. Our methods included the widely
used approaches of ALE and SDM (Eickhoﬀ et al., 2012; Radua and
Mataix-Cols, 2009). For in depth details and diﬀerences between the
methods see Table e-1. In brief, we ﬁrst applied SDM (v4.31) (Radua
and Mataix-Cols, 2009; Radua et al., 2014). SDM involves rebuilding
eﬀect size and variance maps for each study using t-scores and the
extracted local maxima (i.e. points of diﬀerence between patients and
controls). Each map consists of voxels with assigned values depending
on their proximity to reported maxima coordinates. Voxels close to
reported coordinates have higher values. If voxels lie in the proximity of
more than one coordinate, the values are summed. Eﬀect sizes from
peaks close to each other are calculated by a weighted average. From
these study-speciﬁc eﬀect size and variance maps, SDM calculates a
mean meta-analytical map, taking between study variability into ac-
count. The between study variability is deﬁned as the weighted inverse
of the variance of the diﬀerence of the studies. The resulting map is
tested, voxel-wise, against a null distribution of the meta-analytical
values. Analyses were performed on 500 permutations with an aniso-
tropic kernel of 1.0. Results are reported and displayed at p < 0.001,
uncorrected for multiple comparisons, because SDM does not correct
the brain mask for the number of statistical tests by default. However,
to correct the resulting values for multiple comparisons, probabilities
were put into the web-converter of SDM (false discovery rate (FDR)
correction) (Hochberg and Benjamini, 1990) and are reported in the
Supplement (Table e-3). Note that this only provides a peak-based FDR
correction for multiple comparisons. To examine the robustness of the
main meta-analytical output, jack-knife analyses were carried out by
removing one study at a time and repeating the analysis. Clusters pre-
sent in> 90% of iterations are marked as such in Table e-3.
Secondly, we ran meta-analyses using ALE (GingerALE 2.3.6)
(2012). This technique transforms the study-speciﬁc extracted peaks, of
diﬀerence between patients and controls, into Gaussian probability
distributions surrounding the coordinates. Coordinates reported in the
Talairach stereotactic space were transformed into the stereotactic MNI
space using the Lancaster transform implemented in GingerALE
(Lancaster et al., 2007). The estimation of the width of these Gaussian
probability distributions is adapted for each study using the number of
included subjects based on empirical estimates of between-subject and
between-template variability. The resulting ALE maps are then com-
bined, across studies, and tested against the null hypothesis of a random
spatial distribution between the modeled maps. We ﬁrst analyzed the
data at p < 0.001, uncorrected for multiple comparisons, to ensure
comparability with SDM. Thereafter, we corrected the ALE results with
FDR, as was done with SDM (Figure e-2) (Laird et al., 2005). FDR is the
only method implemented in ALE and SDM, but they use diﬀerent al-
gorithms.
F. Albrecht, et al. NeuroImage: Clinical 22 (2019) 101722
2
Thirdly, separate conjunction analyses were performed for gray and
white matter by superimposing the results of SDM and ALE, revealing
the most consistent atrophic regions. To overcome the potential bias the
diﬀerent FDR algorithms may introduce, we used the results at
p < 0.001 uncorrected.
Finally, to investigate disease-speciﬁcity of the results, we ran
subtraction analyses comparing the present results with the ﬁndings of
our recently published meta-analysis on Parkinson's disease (For further
information please refer to Albrecht et al., 2018). We used the results at
p < 0.001 uncorrected from the present analysis and the white and
gray matter MRI cohort of the Parkinson's disease meta-analysis (cohort
with Parkinson's disease only). Data were analyzed in GingerALE with
10.000 randomizations at p < 0.001 uncorrected. Again, we corrected
the ALE results applying FDR afterwards. Results are shown for the
contrasts of PSP - Parkinson's disease for gray and white matter.
To reveal diﬀerences in age, gender, disease duration, Mini-Mental-
State Examination (MMSE), and the motor score of the Uniﬁed
Parkinson's Disease Rating Scale (UPDRS-III) between the gray and
white matter cohorts, we performed Pearson's χ2 and unpaired
Student's t-tests in R with a signiﬁcance threshold at p < 0.05.
2.2.2. Region-of-interest eﬀect size meta-analyses
As supportive analyses, we performed an eﬀect size meta-analysis
on the biomarker studies provided by the systematic review of
(Whitwell et al., 2017). To include recently published studies, two
authors searched the Pubmed database applying the same search tags as
Whitwell and colleagues (October 2017–March 2018). Analyses were
performed on studies reporting three metrics: midbrain area, midbrain-
pons area ratio, and the MR Parkinsonism Index (MRPI), a midbrain to
pons and middle to superior cerebellar pedunculus ratio. Data were
analyzed with metafor in R (Viechtbauer, 2010) and normalized by
calculating the standardized mean diﬀerence (Hedges' g), with 95%
conﬁdence intervals as an eﬀect size estimate. A random-eﬀects model
was applied to account for both within- and between-study variance.
Between-study heterogeneity was assessed using Q-statistics and I2 es-
timate.
2.3. Potential sources of bias and error
To avoid biasing the results toward speciﬁc brain areas, only
quantitative and automated whole-brain studies were included for the
whole-brain meta-analyses; region-of-interest studies were excluded. To
eliminate age as a confounding variable, we only included comparisons
with age-matched controls. Studies comparing PSP with other neuro-
degenerative diseases were further excluded. In line with the PRISMA
recommendations, two investigators performed the literature search
independently and discussed discrepancies (FA, SB). SDM and ALE al-
gorithms are able to balance analyses by taking the sample size of each
included study into account, thereby equalizing the contributions of
each study. It may be the case that only studies ﬁnding atrophy in PSP
patients were published and others ﬁnding null results were not,
leading to a publication bias. While we cannot rule this out completely
it does seem unlikely as the eﬀect sizes in the published studies tend to
be large and the proportion of patients showing quite severe atrophy
has been extremely high.
Table 1
Studies included in the whole-brain meta-analyses identifying the neural correlates of progressive supranuclear palsy with structural magnetic resonance imaging.
Study PSP (N) HC (N) Age (years) Gender (male/ female) Disease Duration (years) MMSE UPDRS-III Notes Criteria
Gray matter studies
Boxer et al., 2006 15 80 70.9 ± 6.9 9/6 4.8 ± 1.7 24.0 ± 3.2 NR a,b Litvan
Brenneis et al., 2004 12 12 67.5 ± 6.6 NR 2.7 ± 0.9 NR 38.9 ± 10.9 a,b Litvan
Burciu et al., 2015 20 20 67.8 ± 7.1 10/10 2.6 ± NR NR 39.0 ± 14.5 a,b,* Litvan
Cordato et al., 2005 21 23 70.3 ± 6.4 14/7 4.0 ± 2.8 25.4 ± 3.2 23.1 ± 10.1 a,b Litvan
Ghosh et al., 2012 23 22 71.1 ± 8.6 14/9 2.5 NR 33.8 ± 15.7 a,b,* Litvan
Giordano et al., 2013 15 15 68.9 ± 1.2 8/7 3.2 ± 1.3 21.2 ± 1.2 38.3 ± 4.0 a,b,* Litvan
Kamiya et al., 2013 16 21 71.4 ± 6.0 10/6 NR NR NR b Litvan
Lagarde, 2015 21 18 65.5 ± 6.5 8/13 4.4 ± 1.7 25.8 ± 2.7 NR a,b* Litvan
Lehericy et al., 2010 10 9 66.9 ± 6.4 6/4 4.3 ± 1.0 27.0 30.0 a,b Litvan
Padovani et al., 2006 14 14 73.0 ± 5.6 7/7 3.1 ± 1.0 25.8 ± 2.7 22.1 ± 8.9 a,b Litvan
Piattella et al., 2015 16 16 68.1 ± 5.9 9/7 3.1 ± NR 24.3 ± 3.9 27.0 ± 3.9 a,b,* Litvan
Premi et al., 2016 32 32 73.5 ± 6.9 17/15 6.9 ± 3.5 24.9 ± 3.9 NR b Litvan
Sandhya et al., 2014 10 8 NR 9/1 NR NR NR a,b,* Litvan
Takahashi et al., 2011 16 20 64.6 ± 6.4 11/5 NR 21.0 ± 4.4 NR b Litvan
Whitwell et al., 2013 16 20 72.1 ± 4.6 8/8 4.1 ± NR 25.8 ± 2.7 52.9 ± 12.6 b,* Litvan
Total GM ∑257 ∑334 69.4 ± 2.8 140/105 3.9 ± 1.2 24.5 ± 2.0 33.9 ± 9.7
White matter studies
Boxer et al., 2006 15 80 70.9 ± 6.9 9/6 4.8 ± 1.7 24.0 ± 3.2 NR a,b Litvan
Brenneis et al., 2004 12 12 67.5 ± 6.6 NR 2.7 ± 0.9 NR 38.9 ± 10.9 a,b Litvan
Burciu et al., 2015 20 20 67.8 ± 7.1 10/10 2.6 ± NR NR 39.0 ± 14.5 a,b,* Litvan
Cordato et al., 2005 21 23 70.3 ± 6.4 14/7 4.0 ± 2.8 25.4 ± 3.2 23.1 ± 10.1 a,b Litvan
Ghosh et al., 2012 23 22 71.1 ± 8.6 14/9 2.5 NR 38.3 ± 4.0 a,b,* Litvan
Hughes et al., 2014 13 15 68.0 ± 6.8 9/4 4.3 ± 3.1 26.9 ± 2.9 29.2 ± 14.3 b,* Litvan
Lagarde, 2013 19 18 65.9 ± 6.5 7/12 4.5 ± 1.8 25.5 ± 2.7 NR a,b,* Litvan
Lehericy et al., 2010 10 9 66.9 ± 6.4 6/4 4.3 ± 1.0 27.0 30,0 a,b Litvan
Price, 2004 12 12 65.3 ± 5.8 7/5 4.8 ± 1.7 27.0 ± 3.3 20.4 ± 8.7 a,b Litvan
Sakurai et al., 2015 33 32 78.0 ± 6.0 20/13 4.8 ± 2.6 NR NR Litvan
Takahashi et al., 2011 16 20 64.6 ± 6.4 11/5 NR 21.0 ± 4.4 NR b Litvan
Whitwell et al., 2017 16 20 72.1 ± 4.6 8/8 4.1 ± NR 25.8 ± 2.7 52.9 ± 12.6 b,* Litvan
Total WM ∑210 ∑265 69.0 ± 3.7 115/99 4.1 ± 0.8 25.3 ± 2.0 34.0 ± 10.5
Total GM+WM ∑315 ∑393 69.2 ± 3.2 176/127 4.0 ± 1.0 24.9 ± 2.0 33.9 ± 9.7
Gender, age, disease duration, MMSE and UPDRS scores are speciﬁed for patients (mean ± standard deviation). All MRI studies used 1.5 T (except for *=3 T).
Disease duration mean scores were calculated without Gosh et al. because they reported data as median. Abbreviations: GM gray matter, HC healthy controls, MMSE
mini-mental state examination, N number of subjects, NR not reported, PSP progressive supranuclear palsy, UDPRS-III motor score of uniﬁed Parkinson's disease
rating scale, WM white matter. a corrected for multiple comparisons, b modulated
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2.4. Data availability statement
Data and analysis methods are shared at request for purposes of
replicating procedures and results.
3. Results
3.1. Whole-brain meta-analyses
3.1.1. Study characteristics
A total of 18, gray and white matter, MRI studies, with 315 patients
and 393 healthy controls, were included (Table 1, Figure e-1). Some
studies reported both measures, leading to the inclusion of 12 white
matter and 15 gray matter patient cohorts consisting of 257 and 210
patients respectively. Unpaired Student's t-tests indicated no signiﬁcant
diﬀerence between the mean values of the white and gray matter
samples concerning age (t=0.28,p= 0.78), disease duration
(t=−0.04,p=0.97), and severity of clinical symptoms using MMSE
scores (t=−0.84,p= 0.41), and UPDRS-III scores
(t=−0.02,p=0.99). Furthermore, Pearson's χ2 test showed no sig-
niﬁcant diﬀerences in gender distribution (χ2= 0.41,p=0.52). There
were also no signiﬁcant diﬀerences in standard deviations between the
samples regarding age (t=−0.83,p=0.42), disease duration
(t=−0.44,p=0.67), and severity of clinical symptoms using MMSE
scores (t=−0.26,p= 0.80), and UPDRS-III scores
(t=−0.35,p=0.74).
All included studies reported decreased gray/white matter volume
or density. There were no reports of gray/white increases found in the
literature. Moreover, all studies used exactly the same clinical diag-
nostic criteria (Litvan et al., 1996a), avoiding a potential vicious circle
as no imaging biomarker was included. Out of 315 patients, the ma-
jority was diagnosed with PSP-Richardson syndrome according to the
new criteria by Höglinger et al. (2017). Note that a maximum of 19
patients (Burciu et al., 2015) may have been diagnosed with PSP-par-
kinsonism additionally, although they fulﬁll the Litvan criteria for PSP.
Hence, in the following, we refer the naming of our cohort to PSP as
proposed by the Litvan criteria.
3.1.2. Seed-based D mapping analysis
The upper part of Fig. 1 and Table e-2 illustrate the consolidated
neural correlates of PSP identiﬁed by SDM meta-analysis. The analysis
across structural MRI studies revealed regional gray matter atrophy
convergence bilaterally in the inferior and middle frontal and superior
temporal gyri, adjacent to the insulae, in the putamen, caudate nuclei,
midcingulate cortex, thalamus, and midbrain. White matter con-
vergence occurred bilaterally in the corpus callosum, thalamus, cere-
bral and superior cerebellar pedunculi, and right middle cerebellar
pedunculus.
3.1.3. Anatomical likelihood analysis
The bottom part of Fig. 1 and Table e-3 display the results of the
ALE meta-analysis in PSP. The analysis revealed gray matter atrophy
convergence in the paracingulate and anterior cingulate gyri, insulae,
inferior frontal gyrus, superior parietal lobule, thalamus, caudate nu-
clei, and cerebellum. White matter regions consistently found were the
midbrain, pyramid, pons, thalamus, and cerebral and superior cere-
bellar pedunculi. FDR correction of the ALE meta-analysis conﬁrmed
involvement of the anterior insula and thalamus for gray matter and
midbrain for white matter (see Supplement, Figure e-2).
3.1.4. Overlap analysis
Finally, we performed an overlap analysis by superimposing the
results of the two separate approaches meta-analyzing PSP (Fig. 2). The
results for gray matter revealed that clusters in the bilateral thalamus,
bilateral anterior insulae, midbrain, and left caudate nucleus were
consistently identiﬁed as aﬀected by PSP. The results for white matter
analysis revealed consistent converged atrophy bilaterally in the su-
perior and middle cerebellar pedunculi, cerebral pedunculi, midbrain,
and right thalamus.
3.1.5. Subtraction analysis
We performed a subtraction analysis to directly compare disease-
speciﬁcity of the aforementioned results by integrating white and gray
matter atrophy of PSP and Parkinson's disease patients. The Parkinson's
disease cohort consist of 809 patients from 29 gray matter studies and
75 patients from four white matter studies (Fig. 3, Table e-5). Gray
matter atrophy diﬀered between PSP and Parkinson's disease in the
thalamus bilaterally as well as the left insula and claustrum, both sur-
viving multiple comparisons correction. Concerning white matter,
subtracting Parkinson's disease from PSP revealed the midbrain. Note
that the white matter analysis did not survive FDR correction, which
may have been due to underpowered analysis.
Fig. 1. Brain regions consistently associated with progressive supranuclear palsy. Analysis of gray matter (GM, dark blue) included 257 patients contrasted to 334
healthy subjects. White matter analysis (WM, light blue) included 210 patients contrasted to 265 healthy subjects. Upper image shows eﬀect size estimates (seed-
based D mapping, SDM) and bottom image anatomical likelihood estimate (ALE) meta-analyses. Abbreviation: L left. (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the web version of this article.)
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3.2. Region-of-interest eﬀect size meta-analyses
3.2.1. Study characteristics
Our literature search identiﬁed one study (Kim et al., 2017) that we
included additionally to the studies already summarized by (Whitwell
et al., 2017) in their systematic review. Study details and demographics
are speciﬁed in Table-e6 in the Supplement. In total, 15 studies, in-
cluding 246 patients and 173 healthy controls reported midbrain me-
trics in three neurodegenerative diseases: PSP (15 cohorts,
age= 69.8 ± 3.6 years, disease duration=3.3 ± 0.8 years), Parkin-
son's disease (14 cohorts, age=66.6 ± 6.7, disease dura-
tion=6.3 ± 2.4), and multiple system atrophy (5 cohorts,
age= 64.7 ± 4.3, disease duration=5.6 ± 1.6). The cohort of PSP
patients in the region-of-interest eﬀect size meta-analyses did not diﬀer
in age (t=0.50, p= 0.62) or gender distribution (χ2= 0.77, p=0.38)
compared to the PSP cohort of the whole-brain meta-analyses. Note that
disease duration (t=−2.10, p=0.04) was slightly higher in the PSP
cohort of the whole-brain meta-analyses.
3.2.2. Eﬀect size meta-analyses
All random-eﬀects models revealed signiﬁcant results, highlighting
that midbrain metrics generally perform very well in distinguishing PSP
from multiple system atrophy and Parkinson's disease with strong eﬀect
sizes (Fig. 4). Note that inter-study heterogeneity was overall quite
large. Midbrain area measurements yielded smallest between-study
heterogeneity in our study as well as largest eﬀect size
(I2= 73.8%,Hedges' g=−2.79). The highest between-study hetero-
geneity but still high eﬀect size was observed in midbrain-pons area
ratio studies (I2= 90.7%,Hedges' g=−1.64). Notably, even multiple
system atrophy and PSP were distinguished by using midbrain-pons
ratio with a high eﬀect size (Hedges' g=−2.37). MRPI also yielded a
large eﬀect size but a high between-study heterogeneity
(I2= 89.9%,Hedges' g= 2.10) in distinguishing PSP from Parkinson's
disease. These results emphasize the importance of our work in vali-
dating and replicating these patterns in whole brain with quantitative
statistical methods.
Fig. 2. Overlap analysis. Overlay analysis for impaired brain regions in progressive supranuclear palsy as revealed by anatomical likelihood estimate (ALE) and eﬀect
size estimates (seed-based D mapping, SDM) meta-analyses. Results of ALE are shown in red. Results of SDM are shown in green. Yellow clusters indicate overlap of
both analyses (ALE and SDM). Upper image displays gray matter (GM) atrophy, bottom image displays white matter (WM) atrophy. Abbreviation: L left. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 3. Brain regions consistently associated with progressive supranuclear palsy in comparison to Parkinson's disease. Analysis of gray matter (GM, dark blue)
included 257 patients with PSP contrasted to 809 patients with PD. White matter analysis (WM, light blue) included 210 patients with PSP contrasted to 75 patients
with PD. Image shows subtraction anatomical likelihood estimate (ALE) meta-analyses. Abbreviation: L left, PD Parkinson's disease, PSP progressive supranuclear
palsy. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
F. Albrecht, et al. NeuroImage: Clinical 22 (2019) 101722
5
Fi
g.
4.
Eﬀ
ec
t
si
ze
(H
ed
ge
s'
g)
m
et
a-
an
al
ys
es
of
ra
di
ol
og
ic
al
bi
om
ar
ke
rs
of
pr
og
re
ss
iv
e
su
pr
an
uc
le
ar
pa
ls
y
(P
SP
)
ba
se
d
on
W
hi
tw
el
l
et
al
.
(2
01
7)
an
d
ad
di
ti
on
al
lit
er
at
ur
e
se
ar
ch
.
(1
)
M
ea
su
re
m
en
t
us
in
g
1.
5
Te
sl
a,
(2
)
m
ea
su
re
m
en
tu
si
ng
3
Te
sl
a,
(3
)
pa
th
ol
og
ic
al
ly
co
nﬁ
rm
ed
,a
nd
(4
)
cl
in
ic
al
ly
di
ag
no
se
d
gr
ou
ps
.A
bb
re
vi
at
io
n:
C
Ic
on
ﬁ
de
nc
e
in
te
rv
al
,d
fd
eg
re
es
of
fr
ee
do
m
,R
E
ra
nd
om
eﬀ
ec
ts
,P
D
Pa
rk
in
so
n'
s
di
se
as
e,
M
SA
m
ul
ti
pl
e
sy
st
em
at
ro
ph
y,
M
R
PI
M
ag
ne
ti
c
R
es
on
an
ce
Pa
rk
in
so
ni
sm
In
de
x.
F. Albrecht, et al. NeuroImage: Clinical 22 (2019) 101722
6
4. Discussion
To our knowledge, we report the largest most powerful data-driven
whole-brain meta-analyses of the neural correlates of PSP to date. The
analyses included 315 patients and 393 healthy controls. To help ensure
high validity and speciﬁcity, all included patients were diagnosed by
the same clinical diagnostic criteria, by Litvan et al. (1996a). In the
aforementioned criteria imaging biomarkers are not implemented,
which avoids a biased and circular design. According to the new PSP
criteria (Höglinger et al., 2017), these patients would be referred to as
PSP-Richardson syndrome. Note, however, that time criteria are dif-
ferent between both diagnostic systems, that our cohort might have
included a minority of subjects with PSP-Parkinsonism additionally to
PSP-Richardson syndrome (see Results, 3.1.1), and that one has to be
generally very careful in translating old into new clinical criteria see
Bisenius et al. (2016 for a related discussion on primary progressive
aphasia).
Including only whole-brain studies in our meta-analysis guaranteed
a data-driven approach. Notably, the overlap analysis between the two
meta-analytical methods revealed gray matter atrophy in four regions
in PSP: the bilateral thalamus, bilateral anterior insulae, midbrain, and
left caudate nucleus. Concerning white matter atrophy, an overlap of
the two methods was observed in the bilateral superior/middle cerebral
and cerebellar pedunculi, midbrain, and right thalamus in PSP.
Subtraction analysis diﬀerentiating PSP from Parkinson's disease con-
ﬁrmed the midbrain as speciﬁc for PSP.
Although previous meta-analyses of gray and white matter atrophy
have been conducted for PSP, studies investigated either gray or white
matter alterations alone and relied on a single meta-analytical algo-
rithm (Shao et al., 2014; Shi et al., 2013; Yang et al., 2014; Yu et al.,
2015). Remarkably, these meta-analyses may have been biased by
systematic errors introduced by ﬂawed multiple comparison correction
analysis tools, as has been stated recently by (Eickhoﬀ et al., 2016) for
former GingerALE software versions. Despite using distributions that
contained errors in the FDR calculation, the results are still quite con-
sistent with our own (Yang et al., 2014; Yu et al., 2015).
The present meta-analysis improves on previous studies in several
ways. First, we used a novel approach, combining and double-vali-
dating two independent meta-analytical techniques to increase validity
of our biomarker ﬁndings. Second, we included the largest cohort of
PSP patients studied to date. Third, we investigated changes in gray and
white matter with exactly the same methods to enable comparability of
results. Finally, our meta-analyses support region-speciﬁc atrophy as an
imaging biomarker for PSP – a move toward the inclusion of MRI in the
diagnostic workﬂow for PSP.
4.1. Validating pathognomonic imaging markers for PSP with meta-
analyses
Thinning of regions of the midbrain has been suggested as a pa-
thognomonic marker of PSP; previously identiﬁed in small cohorts by
precisely measuring the diameters of the pons, midbrain, and superior/
middle cerebellar pedunculi (Kato et al., 2003; Longoni et al., 2011;
Oba et al., 2005; Slowinski et al., 2008). A recent multi-centric volu-
metric and manual morphometry study has endorsed this view, de-
monstrating that the midsagittal area and the anterior-posterior dia-
meter of the midbrain distinguishes between PSP and other
parkinsonian syndromes (Moller et al., 2017). Previous ﬁndings de-
scribe three diﬀerent pathognomonic signs, typically found in PSP pa-
tients. First, the ‘hummingbird sign’ reﬂects a thinning of the anterior
part of the midbrain tegmentum (Kato et al., 2003). The second char-
acteristic feature called the ‘penguin silhouette sign’ relates to an
Fig. 5. Meta-analyses conﬁrm proposed pathogno-
monic imaging markers of progressive supranuclear
palsy (PSP). Left column shows meta-analytic results
(green seed-based D mapping – SDM – analysis, red
anatomical likelihood estimation analysis – ALE –,
and yellow overlay). Right column depicts individual
examples of corresponding structural magnetic re-
sonance images of individual PSP patients with
midbrain atrophy. Images in the middle are the sil-
houettes of a penguin, a hummingbird, and Mickey
Mouse projected onto these patients' brain images.
(For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web ver-
sion of this article.)
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atrophy in the shapes of midbrain tegmentum and pons (Oba et al.,
2005). The hummingbird and the penguin silhouette signs are apparent
in mid-sagittal MRI scans. Another feature, the ‘Mickey Mouse sign’,
describes selective atrophy of the midbrain tegmentum, with relative
preservation of the tectum and cerebral pedunculi (Schott, 2007). Axial
MRI scans of PSP patients reveal this sign. We were able to lend support
to these pathognomonic markers with a large cohort (Fig. 5) by re-
vealing white matter loss in the midbrain (speciﬁcally the tectum and
parts of the tegmentum such as cerebellar pedunculi, red nucleus, and
substantia nigra). The Mickey Mouse sign seems less speciﬁc, according
to our data, because atrophy spread to the cerebral pedunculi (Fig. 5).
Due to the algorithm, assumptions concerning the exact neuroanato-
mical substrates of meta-analyses should be interpreted with caution.
Nevertheless, our conﬁdence is increased by the fact that both meta-
analytical algorithms across whole-bran studies revealed midbrain
atrophy. By replicating previously observed atrophy patterns in a large
meta-analytical study, using multiple approaches, we provide further
evidence supporting the use of these signs as a diagnostic tool for PSP.
4.2. Atrophy in the midbrain and cerebral/cerebellar pedunculi is disease-
characteristic for PSP as compared to other neurodegenerative diseases
Through the conjunctive overlay of the two meta-analytic ap-
proaches, we identiﬁed gray matter atrophy in PSP patients in the
midbrain, thalamus, insulae, and caudate nuclei compared to controls.
White matter atrophy was found in the midbrain, thalamus, cerebral
pedunculus and superior/middle cerebellar pedunculi. To assess the
potential disease-speciﬁcity of these patterns we compared our ﬁndings
to other whole-brain meta-analyses of neurodegenerative diseases
qualitatively (Table 2) and quantitatively (Table e-5, Fig. 4). A direct
statistical comparison of PSP with another neurodegenerative disease,
i.e. Parkinson's disease (Albrecht et al., 2018), revealed that PSP diﬀers
in white matter midbrain atrophy. This highlights again the importance
of the midbrain in PSP, especially in distinguishing closely related
diseases. Gray matter was signiﬁcantly impaired in PSP compared to
Parkinson's disease in the thalamus and insula. Note that in qualitative
comparisons, gray matter loss in the insulae, caudate nuclei, and tha-
lamus has been recently reported in several other neurodegenerative
diseases. Hence, these patterns are neither speciﬁc to PSP nor other
neurodegenerative diseases.
As also illustrated in Table 2 white matter atrophy in the midbrain
has not been observed in other neurodegenerative diseases and thus is
suggested as a pathognomonic signature of PSP. PSP shows also severe
gray matter atrophy distributed over the whole midbrain indicating
disease-relatedness in this comparison. Although gray matter atrophy
was detected in ALE meta-analyses in the red nucleus in multiple
system atrophy (Shao et al., 2015), it was restricted to this brain region.
Moreover, white matter atrophy in the cerebral or superior/middle
cerebellar pedunculi seems to be characteristic for PSP as we did not
ﬁnd any other evidence in the literature. Missing eﬀects in the cerebral
and cerebellar pedunculi in our meta-analytical subtraction analysis
might be related to the small number of white matter studies in-
vestigating Parkinson's disease. Although, one might assume cerebral
pedunculi atrophy in amyotrophic lateral sclerosis/motor neuron dis-
ease, a recent meta-analysis of DTI data rejects such an assumption (Li
et al., 2012b). White matter atrophy in the thalamus/adjacent white
matter structures seem to be characteristic for PSP as compared to other
meta-analyses of Parkinson's disease and Alzheimer's disease (Albrecht
et al., 2018; Li et al., 2012a; Yin et al., 2015). As studies on white
matter are rare, greatly limiting meta-analytical assessment, disease-
speciﬁcity should be interpreted with care. Nonetheless, our meta-
analyses suggest that gray matter loss in the midbrain and white matter
atrophy in the midbrain, cerebral pedunculus, superior/middle cere-
bellar pedunculi, and thalamus may serve as a disease-characteristic
signature for PSP, quantitatively and qualitatively compared to related
diagnoses. Further meta-analyses might apply the same methods and
Table 2
Meta-analytical evidence for biomarker speciﬁcity of regional atrophy in progressive supranuclear palsy as measured with structural magnetic resonance imaging.
Anatomical region
Neurodegenerative disease Study Thalamus Midbrain Insula Cerebellar & cerebral
pedunculi
Caudate
nucleus
Gray matter
Parkinson's disease (Shao et al., 2014; Shao et al., 2015, Albrecht et al.,
2018)
− − − − −
Atypical Parkinson's syndromes
Corticobasal degeneration & syndrome (Yu et al., 2015; Albrecht et al., 2017) + − − − +
Progressive supranuclear palsy (Present study, Shao et al., 2014; Yu et al., 2015; Shi
et al., 2013)
+ + + − +
Multiple system atrophy (Shao et al., 2015) + + (Red nucleus) + − −
Lewy body dementia (Zhong et al., 2014) − − + − −
Alzheimer's disease (Schroeter and Neumann, 2011; Schroeter et al., 2009;
Yang et al., 2012a)
+ − + − −
Behavioral variant frontotemporal
dementia
(Schroeter et al., 2014; Schroeter and Neumann, 2011;
Schroeter et al., 2008; Schroeter et al., 2007; Pan
et al., 2012)
− − + − +
Primary progressive aphasias
Nonﬂuent/ agrammatic variant
(progressive non-ﬂuent aphasia)
(Bisenius et al., 2016; Schroeter and Neumann, 2011;
Schroeter et al., 2007)
− − + − −
Semantic variant (semantic dementia) (Bisenius et al., 2016; Schroeter and Neumann, 2011;
Schroeter et al., 2007; Yang et al., 2012b)
− − − − −
Logopenic variant (logopenic aphasia) (Bisenius et al., 2016) − − − − −
White matter
Parkinson's disease (Albrecht et al., 2018) − − − − +
Atypical Parkinson's syndromes
Progressive supranuclear palsy (Present study, Yang et al., 2014) + + − + −
Alzheimer's disease (Yin et al., 2015; Li et al., 2012a) − − − − −
Meta-analyses were conducted by calculating either anatomical likelihood estimates (ALE) or eﬀect-size signed diﬀerential mapping (SDM) in the gray or white
matter.
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parameters to compare several diseases and assess disease-speciﬁcity
quantitatively by comparing disease patterns with subtraction analyses.
During the course of the present investigation the diagnostic criteria
were revised by the Movement Disorder Society-endorsed, P.S.P. Study
Group (Höglinger et al., 2017). In this context, (Whitwell et al., 2017)
reviewed radiological biomarkers. Our argumentation is in line with
their qualitative review. The researchers identiﬁed the MRPI, a mid-
brain to pons and middle to superior cerebellar pedunculus ratio,
measured from structural MRI scans, as a supportive criterion even for
early clinical diagnosis. Our region-of-interest eﬀect size analyses based
on Whitwell et al.'s review demonstrate large eﬀect sizes for distin-
guishing PSP from Parkinson's disease and multiple system atrophy.
Our dual-approach meta-analytic assessment with a large PSP sample is
consistent with these recent developments, supporting the use of these
particular regions in diagnosing PSP.
It is clearly necessary to validate the applicability of these disease-
related MRI biomarkers for individual diagnosis in single patients be-
fore being transferable to clinical routine, for example by support
vector machine classiﬁcation for single-patient neurodegenerative dis-
ease discrimination (Bisenius et al., 2017; Dukart et al., 2013; Meyer
et al., 2017). In an atlas-based MRI volumetry study, high classiﬁcation
accuracy for PSP versus other parkinsonian syndromes (86%) was in-
deed driven by atrophy in the midbrain and cerebellar pedunculi
(Huppertz et al., 2016). Another MRI study suggests that disease-
characteristic regions extracted from meta-analyses can outperform
whole-brain approaches in identifying PSP by increasing classiﬁcation
accuracy from 80% to 85% (Mueller et al., 2017). Furthermore, com-
bining structural MRI with DTI in support vector machine classiﬁcation
can increase classiﬁcation results to 100% accurate (Cherubini et al.,
2014). One may conclude that our meta-analytically extracted disease-
speciﬁc atrophy pattern is ready for application as an imaging bio-
marker for PSP.
4.3. Study limitations
Our study identiﬁed consistent ﬁndings of atrophy in PSP, but we
recognize some limitations. MRI studies on autopsy-proven cases of PSP
are extremely rare (Table 1), hence, we could not validate clinical
syndromes with histopathology (Albrecht et al., 2017). Furthermore,
we could not disentangle the clinical syndromes seen in PSP as too few
studies reported those data. Our meta-analyses had to be limited to MRI
studies, because insuﬃcient number of studies applied FDG-PET or DTI.
We recommend including other imaging modalities and longitudinal
data in the future (Bisenius et al., 2016; Schroeter et al., 2014;
Schroeter and Neumann, 2011). The accuracy of the disease-speciﬁc
patterns needs further validation in multi-centric, independent patient
cohorts, which provide clinical imaging data, surrogate markers for
histopathology from serum/cerebrospinal ﬂuid or post-mortem ex-
amination. Researchers have already applied this successfully in Alz-
heimer's disease (Klöppel et al., 2008). Due to the lack of combined
white matter and gray matter meta-analyses, direct statistical in-
vestigation of the results was only possible between PSP and Parkin-
son's disease. Note that SDM results are only peak-based FDR corrected
for multiple comparisons, which should be preferably replaced by
cluster- or voxel-based corrections in the future like it is already
available for GingerALE.
4.4. Conclusion
We conducted a comprehensive, systematic, and quantitative meta-
analysis investigating the neural correlates of PSP. Patients were all
diagnosed applying the same diagnostic criteria of Litvan et al. (1996a),
which is now referred to as PSP-Richardson syndrome according to
Höglinger et al. (2017). By combining two commonly used meta-ana-
lytical algorithms, we identiﬁed consistent results validating well-
known pathognomonic signs in whole-brain imaging to support the
diagnosis of PSP. Results suggest gray matter atrophy in the midbrain
and white matter atrophy in the cerebral pedunculus, superior/middle
cerebellar pedunculi, and midbrain as imaging biomarkers for diagnosis
of PSP ante-mortem. Further, subtraction analyses of meta-analyses of
related neurodegenerative diseases could strengthen the disease-speci-
ﬁcity of midbrain atrophy by quantitatively comparing atrophy pat-
terns. Taken together, our results are completely consistent with the
recent move toward the inclusion of MRI data in the diagnostic work-
ﬂow for PSP.
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Alien limb phenomenon is a rare syndrome associated with a feeling of non-belonging and
disowning toward one's limb. In contrast, anarchic limb phenomenon leads to involuntary
but goal-directed movements. Alien/anarchic limb phenomena are frequent in corticobasal
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syndrome (CBS), an atypical parkinsonian syndrome characterized by rigidity, akinesia,
dystonia, cortical sensory deficit, and apraxia.
The structureefunction relationship of alien/anarchic limb was investigated in multi-
centric structural magnetic resonance imaging (MRI) data. Whole-group and single-
subject comparisons were made in 25 CBS and eight CBS-alien/anarchic limb patients
versus controls. Support vector machine was used to see if CBS with and without alien/
anarchic limb could be distinguished by structural MRI patterns.
Whole-group comparison of CBS versus controls revealed asymmetric frontotemporal
atrophy. CBS with alien/anarchic limb syndrome versus controls showed frontoparietal
atrophy including the supplementary motor area contralateral to the side of the affected
limb. Exploratory analysis identified frontotemporal regions encompassing the pre-/and
postcentral gyrus as compromised in CBS with alien limb syndrome. Classification of CBS
patients yielded accuracies of 79%. CBS-alien/anarchic limb syndrome was differentiated
from CBS patients with an accuracy of 81%. Predictive differences were found in the
cingulate gyrus spreading to frontomedian cortex, postcentral gyrus, and temporopar-
ietoocipital regions.
We present the first MRI-based group analysis on CBS-alien/anarchic limb. Results pave
the way for individual clinical syndrome prediction and allow understanding the under-
lying neurocognitive architecture.
© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Alien and anarchic limb syndromes (AL) are peculiar phe-
nomena that encompass patients struggling with an extrem-
ity experienced as rogue. In 1972, this syndrome was first
acknowledged by Brion and his colleagues as ‘main etrangere’
(Brion, 1972). Only in 1991, Della Sala et al. published a first
attempt to disentangle alien and anarchic limb syndrome
cases, introduced an English terminology and description for
the scientific community (Della Sala, Marchetti, & Spinnler,
1991). Alien limb syndrome is characterized by a feeling that
the limb is unfamiliar or does not belong, whereas anarchic
limb syndrome additionally involves the extremity perform-
ing targeted but unintended movements that are recognized
as one's own (Della Sala et al., 1991; Marchetti & Della Sala,
1998; Synofzik, Vosgerau, & Newen, 2008). Alien limb, or
posterior variant, seems related to the postcentral gyrus and
somatosensory cortex, while anarchic limb, or frontal variant,
seems related to the supplementary motor area and medial
prefrontal cortex (Hassan & Josephs, 2016; Marchetti & Della
Sala, 1998). In the following we generally use the term AL as
an umbrella term for both alien and anarchic limb phenom-
ena e in the literature both syndromes are often confounded
e but apply the exact terms if referring to the peculiar phe-
nomena. AL can be caused by various diseases, amongst
which corticobasal syndrome (CBS) is the most frequent
(Graff-Radford et al., 2013). CBS is a rare, atypical parkinsonian
syndrome characterized by rigidity, akinesia, dystonia,
cortical sensory deficit, and apraxia (Armstrong et al., 2013).
Revised diagnostic criteria of CBS consider AL an important
diagnostic criterion, seen in 30% of CBS patients. However, the
exact anatomical correlates of AL are still a matter of debate.
This multi-center study assessed structural differences in
the brains of CBS patients with and without AL. Our sample
consisted of 25 CBS patients, of which eight were diagnosed
with AL. In the main analyses we did not distinguish between
the subtypes of AL, as it would lead to insufficiently powered
analysis. In an additional exploratory pilot analysis, we
divided the CBS-AL cohort into four alien and three anarchic
limb syndrome patients and compared them to the whole-
group of controls to unmask the specific anatomical coun-
terpart. Whole-group analyses were performed using voxel-
based morphometry. We investigated whether multivariate
pattern recognition (support vector machine) could distin-
guish between CBS patients and controls and also predict AL
in CBS. We hypothesized atrophy in CBS with AL in the sup-
plementary motor area, medial prefrontal cortex, posterior
postcentral gyrus, and somatosensory cortex. For the CBS
versus healthy controls contrast, we hypothesized atrophy in
frontal, parietal, and temporal lobes.
2. Material and methods
2.1. Participants
Multi-centric patients' data were included from the German
Consortiumof Frontotemporal Lobar Degeneration (Otto et al.,
2011). Detailed information on patients'/controls' de-
mographic data and summarized AL symptoms are listed in
Table e1ee3. Specialists of the respective clinics (i.e., neurol-
ogists and/or psychiatrists) examined the patients thoroughly
according to a standard operating procedure protocol and
evaluated diagnosis (here CBS) as well as the occurrence of AL
(i.e., ‘alien feeling’ or ‘unintended movements’) among
several other clinical symptoms/syndromes to assesswhether
they fit the inclusion criteria for the FTLD Consortium (Otto
et al., 2011). Twenty-five CBS patients were compared with
25 age- and gender-matched healthy controls. The patient
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group was subdivided into a cohort of 17 CBS patients without
AL (CBS-O) and a cohort of eight CBS patients with AL (CBS-
AL). Four patients were diagnosed with alien limb, three with
anarchic limb syndrome, and one showed signs of both.
Pearson's Chi Squared test (c2) and unpaired Student's T-tests
indicated no significant differences between the cohorts
concerning gender, age, disease duration, and severity of
clinical symptoms (Table 1). The study was approved by the
local ethics committees (Leipzig:ID137-11-18042011). Partici-
pants were fully informed and gave written consent in
accordance with the Declaration of Helsinki.
2.2. Data acquisition
T1-weighted structural brain images were acquired at each
center using the magnetization-prepared rapid gradient-echo
(MP-RAGE) sequence implemented on 3T scanners (Table e-2).
Although scanner parameters slightly differ, an F-test in
SPM12 (UCL, UK) revealed no significant influence.
2.3. Asymmetry correction in alien/anarchic limb
syndrome patients
AL is seen in left and/or right limbs. The most severely
affected limb for each subject was designated by clinical fea-
tures at the time of scanning, but without considering the
image. If necessary, images were flipped in the left-right
dimension (Whitwell et al., 2010) such that the presumably
affected hemisphere, contralateral to syndrome location, was
positioned on the right side of the image in all AL patients.
This allowed investigation of AL in the same hemisphere
across subjects.
2.4. Voxel-based morphometry
Voxel-based morphometry was performed applying the
CAT12 toolbox (University of Jena, Germany)with SPM12 (UCL,
UK). Images were spatially normalized, segmented, modu-
lated by the amount of non-linear deformation, and smoothed
with a Gaussian kernel of 8-mm full-width at half-maximum.
Voxel-wise Student's T-tests were performed to compare,
separately, the groups of patients with controls. Covariates
were used to control for age, gender, and total intracranial
volume. For the main comparison, clusters were detected
using a voxel-threshold of p < .001 and a family-wise error
(FWE) corrected cluster-threshold of p < .05. For exploratory
analyses, clusters were detected applying an uncorrected
voxel-threshold of p < .001.
The three patient cohorts (CBS, CBS-O, CBS-AL) were
compared with healthy controls in whole-group comparisons.
For exploratory pilot analyses, we split the CBS-AL cohort
according to either alien (N ¼ 4) or anarchic limb (N ¼ 3)
syndrome. Note that one patient was omitted given that he
showed both syndromes (AL-16).
2.5. Support vector machine classification
Support vector machine classification allows the separation of
data, by class, in a multidimensional space. We ran a support
vector machine attempting to distinguish between CBS pa-
tients and controls aswell as between CBS-AL and CBS-O using
libSVM 3.18 (Chang & Lin, 2011). Classification accuracy was
obtained by cross-validation using the “leave-one-subject-out”
approach. Specificity and sensitivity were calculated by the
number of correctly classified cases in each group. To inves-
tigate the reliability of the results the influence of several
analysis parameters was inspected (e.g., linear/polynomial
kernels). First, feature selection was based on SPM's gray
matter tissue probability map, using different minimum gray
matter probabilities ranging from 0 to 60% (Table e-5). The SPM
map was also interpolated and smoothed with a Gaussian
kernel of 8-mm full-width at half-maximum. Second, we used
disease-specific regions-of-interest for feature selection.
Regions-of-interest were selected according to our recent
meta-analysis of CBS (Albrecht, Bisenius, Morales Schaack,
Neumann, & Schroeter, 2017) as suggested previously
(Bisenius et al., 2017; Meyer et al., 2017; Mueller et al., 2017) and
generated using the WFU PickAtlas 3.0 (Lancaster, 1997).
Table 1 e Summarized subjects' demographic and clinical characteristics.
Cohort Number Female Age (years) Disease duration
(years)
Clinical dementia
rating score
Clinical dementia
rating score-FTLD
Healthy controls 25 11 66.2 ± 10.1
CBS 25 13 66.7 ± 10.1 3.7 ± 2.8 7.0 ± 4.2 8.4 ± 5.1
CBS-O 17 10 68.2 ± 5.4 4.1 ± 3.2 5.8 ± 3.9 7.1 ± 4.6
CBS-AL 8 3 63.4 ± 7.2 2.8 ± 1.6 9.0 ± 4.1 10.8 ± 5.4
Statistical differences
Healthy controls
versus CBS
c2 ¼ .08, p ¼ .8 t ¼ .20, p ¼ .84
Healthy controls
versus CBS-O
c2 ¼ .40, p ¼ .5 t ¼ .84, p ¼ .41
Healthy controls
versus CBS-AL
c2 ¼ .25, p ¼ .6 t ¼ .85, p ¼ .40
CBS-O versus CBS-AL c2 ¼ 8.8e32, p ¼ 1.0 t ¼ 1.67, p ¼ .12 t ¼ 1.4, p ¼ .18 t ¼ 1.8, p ¼ .09 t ¼ 1.5, p ¼ .15
Mean ± standard deviation. Student's T-test was applied to compare numerical variables and c2 test to compare categorical variables across
groups. CBS corticobasal syndrome, CBS-AL corticobasal syndrome with alien/anarchic limb syndrome, CBS-O corticobasal syndrome without
alien limb syndrome, Clinical Dementia Rating Score-FTLD score modified for frontotemporal lobar degeneration.
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2.6. Data availability statement
Study protocol and statistical analysis plan will be shared at
request. Data of participants are stored at the FTLD-
Consortium. Patients' data are bound to maintain confidenti-
ality and, accordingly, are only shared at reasonable request to
replicate procedures and analysis of the study.
3. Results
3.1. Whole-group voxel-based morphometry
Fig. 1 and Table e-4 display gray matter volume differences
between patients with CBS and healthy controls. In the left
hemisphere reduced gray matter volume, for patients, was
observed in inferior and middle occipital gyrus, medial tem-
poral gyrus and temporoparietal junction, inferior/middle/
superior frontal gyri, insula, and premotor and supplementary
motor areas. On the right side, less gray matter was revealed
in postcentral gyrus, supramarginal gyrus, inferior frontal
gyrus, posterior and anterior insula, and supplementary
motor area. Furthermore, right posterior cingulate gyrus,
cuneus, and precuneus were affected.
Comparing CBS-O to controls revealed lower gray matter
volume in superior temporal gyrus, medial temporal gyrus
and temporoparietal junction, middle/inferior frontal gyrus,
claustrum and putamen, posterior superior frontal sulcus and
middle frontal gyrus/precentral gyrus; all on the left side. Less
gray matter volume was also found bilaterally in the insula
spreading to the superior temporal gyrus.
Contrasting CBS-AL and controls showed reduced gray
matter volume in the posterior insula, superior temporal
gyrus, and middle/superior frontal gyrus; all in the left
hemisphere. Lower gray matter volume was observed in the
right precuneus, and cingulate gyrus spreading to fronto-
median cortex. Importantly, this included the supplementary
motor area contralateral to the AL symptoms.
A direct comparison of CBS-AL and CBS-O did not reveal
significant results, but may not have been a sufficiently
powered analysis.
Contrasting CBS with alien limb syndrome to controls,
lower gray matter volume was found in occipital pole, cal-
carine cortex, and inferior occipital gyrus; all on the left side
(Figure e-1 and Table e-6). On the right side, superior/middle
temporal gyrus including temporal pole, precentral/post-
central/supramarginal gyrus, and middle cingulate gyrus
were implicated. Note that clusters in left occipital gyrus, right
precentral/postcentral/supramarginal gyrus, and right supe-
rior/middle temporal gyrus were even apparent when cor-
recting for multiple comparisons (see copper clusters in
Figure e-1). The comparison of CBS with anarchic limb and
controls showed less gray matter volume in superior parietal
lobule/precuneus and parietal operculum/transverse tempo-
ral gyrus; all in the left hemisphere. In the right hemisphere,
superior/middle/inferior occipital gyrus and posterior insula/
putamen were compromised.
3.2. Support vector machine classification
The support vector machine classification could reliably
identify CBS versus controls as well as CBS-AL versus CBS-O
(Fig. 2 and Table e-5). Classification accuracies for the linear
kernel were stable around 70e80%, independent of the gray
matter mask. The highest accuracy of the classification of CBS
patients and controls was 78.9% using a linear kernel and gray
mattermask of .4. Regions contributing to correct classification
mirrored areas identified in the univariate group comparison
Fig. 1 e Reduced gray matter volume in each corticobasal syndrome (CBS) cohort compared with controls (HC). Clusters are
corrected for multiple comparisons, p < .05 family-wise error rate (FWE). CBS whole patient cohort, CBS-AL CBS with alien/
anarchic limb syndrome, CBS-O CBS without alien limb syndrome, L left.
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of the entire CBS group versus controls, as discussed above.
Classifying CBS-AL versus CBS-O, resulted in an accuracy of
81.3%when applying a linear kernel and a graymattermask of
.5. Regions predictive of AL included, among others, the
cingulate gyrus spreading to frontomedial cortex, postcentral
gyrus, and temporoparietooccipital regions, at least partially
overlapping with regions of thinner gray matter observed in
the univariate comparison CBS-AL versus controls. Using the
meta-analytically generated regions-of-interest masks did not
improve the results.
4. Discussion
The complete group of CBS patients was characterized by
apparent atrophy in frontotemporal and occipital regions,
motor areas, and the insulae, in agreement with previous
studies (Lee et al., 2011; Whitwell et al., 2010). To our knowl-
edge, no prior study has systematically evaluated syndrome-
specific atrophy in CBS with AL. Patients with AL showed
apparent atrophy in the insula and frontotemporal gyri
compared with healthy controls, and remarkably, also in the
supplementary motor area and cingulate cortex contralateral
to the symptomatic body side. This patternwas also evident in
the entire CBS group although not when the CBS-O was
compared with controls. This suggests the difference was
driven by the CBS-AL patients.
4.1. Supplementary motor area is a neural correlate for
alien/anarchic limb
Although CBS is mainly asymmetric it affects both body sides.
Interestingly, AL is reportedly more often seen with left limbs,
which would be consistent with neural correlates in the right
hemisphere (Graff-Radford et al., 2013). It is speculated that
the asymmetry of the functions of the hemispheres explains
why certain variants of AL affect only left or right hand.
For example Bartolo et al. (2011) report that the right
supplementary motor area is inhibiting both, right and left
cortex, while the left supplementary motor area is not domi-
nant and inhibits only contralateral, hence leading to right-
sided AL. In Graff-Radford's large cohort, the left extremity
was affected in 69% of AL cases. In our sample the prevalence
was 50%. One should consider that Graff-Radford's review
included caseswith various diseases, not only CBS and did not
differentiate between alien and anarchic limb phenomena.
Their study identified the parietal lobe and its disconnection
from other cortical areas as a common correlate for AL, which
is in line with our CBS-AL comparison.
Interpreting neural correlates of alien and anarchic limb
phenomena is often masked by the fact that in the literature
both syndromes are confounded. Disentangling the
anatomical counterparts of anarchic limb, studies have
identified the supplementary motor area as a crucial brain
structure (Frith, Blakemore, & Wolpert, 2000; Hassan &
Josephs, 2016; Marchetti & Della Sala, 1998; Schaefer,
Heinze, & Galazky, 2013). In line with those findings, our
cohort suggests atrophy in the supplementary motor area.
Thus, it is hypothesized that an impaired supplementary
motor area is necessary for anarchic limb syndrome. The
anterior region of the supplementary motor area is internally
triggered and activated when movements are imagined and
selected (Frith et al., 2000). To initiate the movement the
supplementary motor area needs to be inhibited. The inhi-
bition subsequently leads to activation of the primary motor
cortex and initiates movement. Damage to this network by
atrophy could lead to externally triggered, unintended,
movements and disturbed selection of appropriate motor
programs, as experienced by anarchic limb syndrome pa-
tients. Even visual stimuli of surroundings activate this cir-
cuit and motor programs (Sumner & Husain, 2008). Thus, the
brain needs to weight several competing motor plans acti-
vated by objects in our proximity. Sumner and Husain (2008)
summarized in their review that a network of medial frontal
areas (including supplementary motor area) and parietal re-
gions inhibit reflexive behavior and mediate competing
Fig. 2 eWeights of voxels most relevant for individual support vector machine classification between corticobasal
syndrome (CBS) versus healthy controls (HC) and CBS with alien limb (CBS-AL) versus CBS without alien/anarchic limb (CBS-
O). Note that these weights are relative and have no applicable units. Support vector machine classification was performed
with a linear kernel on all voxels within the SPM's gray matter mask (tissue probability >.4, top row, tissue probability >.5,
bottom row).
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motor programs. Indeed, in patients with focal lesions in the
supplementary motor area and supplementary eye field,
automatic inhibition of subconscious motor activation is
impaired, which correlated with the extent of the lesions
(Sumner et al., 2007). Hence, automatic inhibition is crucial
for flexible and volitional motor control in conditioneaction
associations. Importantly for our results, a case study by
McBride, Sumner, Jackson, Bajaj, and Husain (2013) observed
disturbed automatic inhibition of primed reactions in the
anarchic limb of a CBS patient. In the non-effected limb
automatic inhibition remained preserved. This underlines
that the hypothesis of automatic inhibition processes facili-
tating flexible and volitional behavior due to inhibiting un-
wanted motor plans, primed by surrounding objects, may
account for the well-executed and purposeful anarchic limb
movements. In the exploratory analyses however, we could
not confirm atrophy in the supplementary motor area in
anarchic limb syndrome, which may have been an insuffi-
ciently powered analysis since it only involved three patients.
Why the affected limb would be experienced as foreign in
alien limb syndrome is not clear. One hypothesis is that
disruption of parietal circuits leads to dysfunction in self-
attribution (Sarva, Deik, & Severt, 2014). Thus, alien limb
seems to arise due to a disturbed sense of ownership, but not
disturbed sense of agency (Synofzik et al., 2008). Overall, the
neural network processing body-ownership comprises the
right temporo-parietal junction, right insula, inferior parietal
cortex, and premotor cortex (Tsakiris, Longo, & Haggard,
2010). In line with that, Hassan and Josephs (2016) stated in
their review that lesions in parietal lobe, i.e., posterior post-
central gyrus, posterior primary sensory cortex, and tertiary
somatosensory cortex, lead to alien limb syndrome. Notably,
we also found these networks involved in the univariate group
comparison of CBS-AL and controls as well as in the CBS-AL
versus CBS-O classification results. Further, exploratory pilot
analyses of the alien limb syndrome cohort confirmed puta-
tive atrophy in parietal cortex and postcentral gyrus.
4.2. The role of the cingulate cortex in alien/anarchic
limb syndrome
In general, the cingulate cortex and especially its anterior part
translates motor intentions into actions and mediates willed
control, underlining the important role in motor actions and
their cognitive control (Paus, 2001). Further, the anterior
cingulate cortex is known for its dense projections from the
motor cortex and spinal cord. In healthy conditions, the
cingulate cortex implements the selection of actions aswell as
fights competing motor programs, a crucial part of volitional
control.
Contrasting CBS-AL to controls, putative atrophy was also
found in the right cingulate cortex, contralateral to the
symptoms shown by the patients. In exploratory analyses, we
could confirm volume loss in the cingulate cortex in the alien
limb syndrome cohort but not in the anarchic limb syndrome
cohort. Already, Goldberg, Mayer, and Toglia (1981) hypothe-
sized that the two functional zones of the medial frontal
gyrus, i.e., supplementary motor area and cingulate cortex,
could be the reason for AL when implicated due to a lesion.
Even at this time it was known that both regions are
connected reciprocally as Goldberg further reported. In an
early study, Talairach et al. (1973) observed, when stimulating
continuously the anterior cingulate cortex in epileptic pa-
tients, that they exhibited highly complex motor behavior
even adapted to the environmental conditions. This finding
already supports the hypothesis that the cingulate cortex
plays an important role in high motor integration. Brugger,
Galovic, Weder, and K€agi (2015) confirmed involvement of
the cingulate cortex in disturbed self-initiated movements in
anterior cerebral artery stroke patients with anarchic limb
syndrome. The researchers underlined that the medial motor
system is essential for volitional motor actions. In their study,
they linked especially the pre-supplementary motor area to
the signs of anarchic limb syndrome. Another case report of a
patient with an ischemic lesion within the right cingulate
motor area showed that this leads to anarchic limb-like
involuntary movements of the left arm (Brazdil, Kuba, &
Rektor, 2006). This provides a further hint that the cingulate
cortex is involved in goal-directed motor behavior, their
preparation as well as execution of those action programs.
4.3. Machine learning identifies corticobasal syndrome
patients with and without alien/anarchic limb syndrome
The support vector machine analysis was able to distinguish
between CBS and controls as well as CBS patients with and
without AL, on a single-subject level. Remarkably, multivar-
iate pattern recognition demonstratedmuch higher predictive
power than the univariate group comparison (CBS-AL vs. CBS-
O), which did not reveal any significant effects. Although, the
putative atrophy in CBS/CBS-AL might be the main contrib-
utor to correct classification (if one compares Figs. 1 and 2).
This suggests that support vector machine analysis might be
applied in the future to support individual diagnosis and
perhaps syndrome prediction. This discrepancy might be
related to mathematics of the analyses. In voxel-based
morphometry univariate relationships are detected voxel-
wise across all participants. In support vector machine anal-
ysis, multivariate relationships are identified over the whole
brain. A previous support vector machine analysis showed
that progressive supranuclear palsy, another atypical
parkinsonian syndrome, can be distinguished from controls
achieving accuracies above 80% (Mueller et al., 2017).
4.4. Study's limitations
Our study identified consistent atrophy and enabled individ-
ual classification in CBS with and without AL, but there are
also limitations. As our sample is not completely histopatho-
logically validated one cannot draw conclusions concerning
the pathology of CBS. It is possible that not all patients had
underlying corticobasal degeneration (Armstrong et al., 2013).
Our sample of AL patients is also rather small, thus the
exploratory analyses to disentangle the neural correlates of AL
subtypes should be interpreted with caution. However, as CBS
and AL are regarded as orphan diseases, our multi-centric
design allowed a reasonable number. Possible biases intro-
duced by the multi-centric approach, including different
scanner types/protocols, were minimized by applying strict
standard operating procedures and including only 3T MRI. We
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did not investigate white matter alterations in CBS patients,
thus we cannot account for callosal lesions, which may have
led to AL too.
5. Conclusion
This study presents the first MRI-based group analysis of alien
and anarchic limb syndrome in CBS. Results may pave the
way for individual clinical syndrome prediction, while allow-
ing a better understanding of the underlying brain substrates
and neurocognitive architecture.
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A B S T R A C T
We aimed at testing the potential of biomarkers in predicting individual patient response to dopaminergic
therapy for Parkinson's disease. Treatment eﬃcacy was assessed in 30 Parkinson's disease patients as motor
symptoms improvement from unmedicated to medicated state as assessed by the Uniﬁed Parkinson's Disease
Rating Scale score III. Patients were stratiﬁed into weak and strong responders according to the individual
treatment response. A multiple regression was implemented to test the prediction accuracy of age, disease
duration and treatment dose and length. Univariate voxel-based morphometry was applied to investigate dif-
ferences between the two groups on age-corrected T1-weighted magnetic resonance images. Multivariate sup-
port vector machine classiﬁcation was used to predict individual treatment response based on neuroimaging
data. Among clinical data, increasing age predicted a weaker treatment response. Additionally, weak responders
presented greater brain atrophy in the left temporoparietal operculum. Support vector machine classiﬁcation
revealed that gray matter density in this brain region, including additionally the supplementary and primary
motor areas and the cerebellum, was able to diﬀerentiate weak and strong responders with 74% accuracy.
Remarkably, age and regional gray matter density of the left temporoparietal operculum predicted both and
independently treatment response as shown in a combined regression analysis. In conclusion, both increasing
age and reduced gray matter density are valid and independent predictors of dopaminergic therapy response in
Parkinson's disease.
1. Introduction
Dopaminergic therapy (DT) has been the foundation of Parkinson's
disease therapy for decades. DT is based on two main pharmacological
compounds: levodopa (L-3,4-dihydroxyphenylalanine) and dopamine
receptor agonists. Despite its extensive application in clinical practice,
DT eﬃcacy is inﬂuenced by several factors. For example, DT response
deteriorates after years of treatment, becoming more intermittent and
leading to severe motor and non-motor complications (Connolly and
Lang, 2014). Notably, a high individual variability in treatment re-
sponse is a common ﬁnding in clinical practice and it has been often
reported in the literature (Constantinescu et al., 2007). In particular,
two studies investigated levodopa responsiveness in large series of
autopsy-proven Parkinson's disease cases, showing a suboptimal treat-
ment response in several patients (Hughes et al., 1993; Wenning et al.,
2000). However, the sources of heterogeneous DT responses across
subjects are still unclear. The aim of the study is to shed light on the
potential of clinical and neuroimaging data in predicting clinical re-
sponse to DT in Parkinson's disease.
2. Materials and methods
2.1. Participants
Thirty patients with Parkinson's disease participated in the study
(Hughes et al., 1992) (age= 65.37 ± 7.05 years mean ± SD; Hoehn&
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Yahr stages I-III; 13 females, disease onset after 45 years of age). Stable
DT comprised levodopa either in monotherapy (N=5) or combined
with dopamine agonists (pramipexole and ropinirole, respectively
N=8 and N=17). Diﬀerences in treatment response across DT types
were tested with a one-way ANOVA. The assessment of motor symp-
toms, implemented with the Uniﬁed Parkinson's Disease Rating Scale
(UPDRS) score III, was performed during medicated (DT-on) and un-
medicated states (DT-oﬀ) in a randomized order (DT-on ﬁrst in 16 and
DT-oﬀ ﬁrst in 14 patients). For DT-oﬀ state, dopamine agonists and
levodopa were withdrawn, respectively, at least 72 and 12 h before
examination. We considered the diﬀerence between the UPDRS-III
scores in DT-on and DT-oﬀ conditions (i.e. UPDRS-III-change) as a proxy
for treatment eﬃcacy. The study was authorized by the Ethics Com-
mittee of the General University Hospital in Prague, Czech Republic, in
line with the Declaration of Helsinki.
2.2. Clinical variables
Correlations between UPDRS-III-change and, in turn, age, disease
duration, levodopa treatment duration and levodopa equivalent dose
were assessed. Note that, for each pair, Pearson's partial correlations
(α=0.05) were computed controlling for the remaining variables.
Additionally, multivariate regression (enter mode) was conducted in-
cluding these variables and setting UPDRS-III-change as dependent
factor.
For MRI analyses, patients were stratiﬁed into weak and strong
responders, using as cut-oﬀ the median UPDRS-III-change in our sample
(15.50 points). Table 1 displays demographic and clinical character-
istics of the groups, and their statistical comparison. Notably, age was
signiﬁcantly higher in the weak responders. Hence, age diﬀerences
were controlled for in these and the following dichotomous analyses. In
addition, to deﬁne the clinical signiﬁcance of the treatment-induced
UPDRS-III changes, we compared our results with the cut-oﬀ values
provided by Shulman et al. (2010) deﬁning minimal, moderate and
large clinically important diﬀerences (i.e. diﬀerences that can be ap-
preciated by the patients themselves). Accordingly, the majority of the
patients (n=24) reported large diﬀerences, ﬁve intermediate and only
one minimal. At clinical evaluation, most patients presented with both
akinesia/rigidity involvement and tremor. PD phenotypes were further
deﬁned according to Jankovic's classiﬁcation to allow a better com-
parison with other studies (Jankovic et al., 1990). Three outcomes are
possible here: postural instability and gait diﬃculty (PIGD), tremor
dominant (TD) and intermediate. Namely, a ratio score, computed
based on the UPDRS-III items in the DT-oﬀ state, was used for the
classiﬁcation: ratio=mean(TD items)/mean(PIGD items). For a list of
the items used for computing the mean values for TD and PIGD refer to
Table 1 in Stebbins et al. (2013). In our PD cohort, 22 patients had
predominant PIGD, 5 TD and 3 intermediate phenotypes. Diﬀerences in
the distribution of the clinical phenotypes between strong and weak
responders were assessed by means of chi-squared test.
2.3. Neuroimaging analysis
T1-weighted MR images (3D-MPRAGE, Magnetization Prepared
Rapid Gradient Echo, TR 2.2 s, TE:2.43ms, inversion time 900ms, ﬂip
angle 8°, matrix 224×224) were acquired on a 3 T MAGNETOM Skyra
(Siemens, Erlangen, Germany) at the Radiology Department, Na
Homolce Hospital in Prague.
Images were preprocessed with the Computational Anatomy
Toolbox (CAT-12). After spatial normalization, gray matter compart-
ment was isolated and 8mm smoothing was applied. Then, to take into
account the eﬀect of age, an age-correction procedure was applied
based on data from 30 elderly healthy controls (age=63.57 ±
8.09 years; 15 females) as previously described (Dukart et al., 2011).
Thus, imaging data were normalized for age before all subsequent
structural analyses. The eﬃcacy of the procedure was further tested
performing a whole-brain correlation analysis between age and gray
matter density (GMD) before and after age correction and comparing
the z-maps of the two analyses. Individual gray and white matter vo-
lumes were entered in the models as covariates.
2.3.1. Univariate analysis
Voxel-based morphometry (Ashburner and Friston, 2000) was run
in CAT-12 and SPM (rev.12.6685). Age-corrected GMD images entered
a univariate statistical model to compare GMD between weak and
strong responders using gray and white matter volumes as covariates.
Only clusters surviving p < .05 family-wise error (FWE) correction
were deemed signiﬁcant (uncorrected threshold, p < .005).
2.3.2. Multivariate analysis
Support vector machine (SVM) classiﬁcation was applied on age-
corrected GMD images using libsvm (release 3.18) in Matlab. This
machine learning approach based on multivariate pattern analysis al-
lows testing the prediction accuracy of GMD images for the classiﬁca-
tion of weak and strong DT responders. The classiﬁer was based on a
polynomial kernel and was validated using a leave-one-out cross-vali-
dation procedure. Diﬀerent gray matter probability masks were tested
to assure the stability of results. The relative weights, indicating the
Table 1
Demographic and clinical characteristics of Parkinson's disease patients stratiﬁed according to dopaminergic treatment response.
Total Weak responders Strong responders F (df) p
N 30 15 15 – –
Age (years) 65.37 ± 7.05 68.27 ± 7.56 62.47 ± 5.28 5.93 (28) 0.021⁎
Gender (male/female) 17/13 8/7 9/6 – χ2= 0.14, p= .71
Education (years) 14.1 ± 2.95 13.4 ± 2.82 14.8 ± 3 1.10 (27) 0.34
Disease duration (years) 11.4 ± 3.43 10.87 ± 3.81 11.93 ± 3.03 0.78 (27) 0.386
Levodopa duration (years) 8.529 ± 4.055 8.64 ± 4.2 8.42 ± 4.05 0.86 (27) 0.363
Levodopa equivalent dose (mg) 1385.98 ± 664.75 1155.65 ± 680.28 1600.97 ± 582.85 1.84 (27) 0.186
UPDRS-III DT-oﬀ 31.03 ± 10.31 28.27 ± 10.05 33.80 ± 10.13 1.48 (27) 0.235
UPDRS-III DT-on 14.77 ± 7.58 17.20 ± 8.12 12.33 ± 6.37 1.73 (27) 0.199
UPDRS-III-change 16.27 ± 7.06 11.07 ± 3.73 21.47 ± 5.59 23.93 (27) < 0.0001⁎⁎
UPDRS-IV 4.60 ± 3.65 3.33 ± 3.0 5.87 ± 3.871 2.61 (27) 0.118
NMSS total score 15.10 ± 19.18 13.53 ± 20.79 16.67 ± 18.015 0.50 (27) 0.485
MoCA 25.77 ± 2.34 25.53 ± 2.47 26.00 ± 2.27 0.073 (27) 0.789
Note: Mean ± SD are shown.
Abbreviations: DT -onmedicated state; DT-oﬀ unmedicated state; NMSS non-motor symptoms scale; MoCA Montreal Cognitive Assessment; UPDRS Uniﬁed
Parkinson's Disease Rating Scale (-III motor symptoms; -IV motor complications).
⁎ Signiﬁcant p-value from ANOVA analysis.
⁎⁎ Signiﬁcant p-value from ANCOVA analysis controlling for age diﬀerences.
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contribution to the classiﬁcation of each voxel, were then plotted in the
original 3D brain space.
2.4. Disentangling impact of age and imaging parameters on treatment
To disentangle the inﬂuence of age and gray matter changes, the
SVM model was run on the patients' images also before the age cor-
rection procedure. The rationale is that diﬀerences in SVM accuracy
between pre and post age correction procedure would be attributable to
the detrimental aging eﬀect on GMD.
Moreover, to further address the inﬂuence of clinical and imaging
data on the treatment response, a multivariate linear regression model
was run including as predictors age, levodopa dose/duration, disease
duration and the average GMD values from the consistent (i.e. over-
laying) cluster from the univariate and multivariate analyses, centered
on the x y z MNI coordinates −33 -32 18 (represented in orange in
Fig. 3).
3. Results
3.1. Clinical variables
The distribution of clinical phenotypes (PIGD, TD and intermediate)
was comparable between strong and weak responders (χ2=0.715,
p= .699). No diﬀerence in treatment response was found between
diﬀerent DT types (one-way ANOVA: F(29)= 0.33, p= .723).
A signiﬁcant correlation was found between UPDRS-III-change and
age (r=−0.539,p < .005). All the other tested correlations did not
provide signiﬁcant results: disease duration (r=0.231,p < .256), le-
vodopa treatment duration (r=0.168,p < .412) and levodopa
equivalent dose (r=0.01,p < .96) (Fig. 1).
A multivariate regression model was applied to predict treatment
eﬃcacy from age, disease duration, levodopa equivalent dose and le-
vodopa duration. The overall model was signiﬁcant, F(4,24)= 4.408,
p < .008, with an r2 of 0.424. However, age was the only signiﬁcant
Fig. 1. Partial correlations between clinical variables and UPDRS-III-change as proxy for treatment eﬃcacy. Age is the only variable showing a statistically signiﬁcant
negative correlation (i.e. increasing age was associated with weaker treatment response). Pearson correlation coeﬃcients (r) and p-values are displayed. Note that, for
each correlation, x and y axes represent the two sets of unstandardized residuals from regressing the variables of interest on the confounding variables. Strong and
weak responders, as selected for the neuroimaging analysis, are presented with diﬀerent symbols.
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Fig. 2. Eﬃcacy of the age correction procedure fol-
lowing Dukart et al. (2011). Z-maps showing the
results of correlation analyses in the patient cohort
between age and gray matter density maps before
(upper row) and after (bottom row) the applied age-
correction procedure. The pattern of negative cor-
relations between age and gray matter density,
mainly seen in medial temporal and medial frontal
structures, is suppressed after age correction. Images
shown in neurological orientation: left of the brain
corresponds to the left of the image.
Fig. 3. Results of the univariate and multivariate
analyses contrasting weak and strong responders.
The 3D rendering shows, respectively, the un-
thresholded SPM-t map for the weak responders <
strong responders univariate SPM comparison
(warmer colors indicate lower gray matter density)
and the voxel-wise weights obtained from the mul-
tivariate support vector machine classiﬁcation
(warmer colors regions contributing to weak re-
sponders' classiﬁcation, arbitrary units). The slice
views for the univariate analysis report in red the
results surviving the cluster-level correction for
multiple comparisons (p < .05 FWE), while for the
multivariate analyses, the regions showing higher
weights for the classiﬁcation of the weak vs. strong
responders are shown. On the right, the overlay be-
tween the two thresholded maps is shown in orange.
Images shown in neurological orientation: left of the
brain corresponds to the left of the image. 3D ren-
dering plotted with BrainNet Viewer 1.61 (https://
www.nitrc.org/projects/bnv/).
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predictor in the model (p= .005). Namely, UPDRS-III-change decreased
of −0.604 points for each additional year of age.
3.2. Neuroimaging analysis
The correlation analysis between age and GMD before the age-cor-
rection procedure shows a pattern of negative correlations mainly in
medial temporal and medial frontal structures, as expected from a
consistent body of literature (Giorgio et al., 2010; Tisserand et al.,
2004). After the age correction, this prototypical correlation pattern
was mostly suppressed as shown in Fig. 2.
3.2.1. Univariate analysis
Signiﬁcant lower GMD was found in weak compared to strong re-
sponders in the left temporoparietal operculum after age correction
(Fig. 3). Observing the unthresholded t-map for the weak< strong re-
sponders comparison, a trend towards lower GMD was detected in the
right temporoparietal operculum, in supplementary motor area, su-
perior frontal gyrus and cerebellum. The opposite contrast did not re-
veal signiﬁcant ﬁndings.
3.2.2. Multivariate analysis
The SVM approach, based on whole brain data after age correction,
was able to correctly classify 77.33% weak responders and 70.67%
strong responders, thus with a total accuracy of 74.0%. Positive and
negative predictive values were, respectively, 0.725 and 0.757
(Table 2). The regions that mostly contributed to the classiﬁcation of
weak responders included the supplementary motor and primary motor
areas, superior frontal gyrus, the bilateral parietal opercula, and ex-
tensively the cerebellum (Fig. 3).
3.3. Disentangling impact of clinical and imaging parameters on treatment
The SVM model applied to the patients' images before the age cor-
rection procedure showed a total accuracy of 75.77%, correctly clas-
sifying 78.22% weak and 73.33% strong responders. An additional
multivariate regression model was calculated to predict treatment ef-
ﬁcacy from age and GMD in the left temporoparietal operculum to
disentangle the contributions of both relevant factors. This analysis
revealed signiﬁcant eﬀects, F(5,23)= 6.56, p < .001, with an in-
creased r2 of 0.588. Signiﬁcant predictors in the model were both age
(standardized β=−0.496; p= .009) and GMD in the left tempor-
oparietal operculum (standardized β =0.456; p= .006).
4. Discussion
The present ﬁndings represent an initial insight into clinical and
neuroimaging features that can predict individual DT response in
Parkinson's disease. We showed that both increasing age and lower
GMD predict a weaker DT response. Of note, weak and strong DT
responders were similarly impaired in the DT-oﬀ state, suggesting that
treatment response does not depend on motor symptom severity. The
relationship between aging and Parkinson's disease has been subject of
previous investigations (Levy, 2007). Levy (2007) reported that age,
more than disease duration, is associated with a more severe clinical
progression. In addition, a previous study showed a negative associa-
tion between age and the magnitude of DT response in Parkinson's
disease (Durso et al., 1993). Taken together, these pieces of evidence
are in line with our ﬁnding of a poorer treatment response in older
Parkinson's disease patients.
Concerning neuroimaging results, structural between-group diﬀer-
ences were identiﬁed with univariate and multivariate analyses after
applying a stringent age-correction procedure. A good agreement was
found between the two analytical approaches as exempliﬁed in Fig. 3.
Indeed, both revealed pronounced regional gray matter alterations in
weak DT responders in the left temporoparietal operculum, compared
to strong responders. The parietal operculum is a complex brain
structure where diﬀerent sensorimotor processes take place and, in-
terestingly, it has been previously associated with sensorimotor re-
covery after moderate to severe strokes within the territory of the in-
ternal carotid artery (Hannanu et al., 2017). In addition, the SVM
analysis showed also the involvement of the supplementary motor area,
primary motor cortex and cerebellum in deﬁning the weak responder
group, all crucial regions in the motor pathway. In particular, an im-
paired activity of the supplementary motor area in Parkinson's disease
has been previously associated with motor impairment and, accord-
ingly, attempts to restore its function via transcranial magnetic stimu-
lation showed modest but signiﬁcant symptoms improvement (Hamada
et al., 2008). It is thus reasonable that patients with more severe
structural impairment in this area, as suggested by the univariate un-
thresholded results, present a weaker treatment response.
As for the relationship between age and GMD alterations, the linear
regression model including both as predictors of UPDRS-III change ex-
plained 59% of the variance, as compared to the 42% of the model
without imaging metrics. The comparison of standardized beta coeﬃ-
cients showed a similar eﬀect of aging and GMD alterations in pre-
dicting the treatment response. This suggests that age and GMD are
both signiﬁcantly and independently contributing to the prediction of
treatment response in PD. Additionally, in order to test the modulatory
impact of age on GMD-based predictions, the SVM classiﬁcation was
run on the imaging data before and after applying the age correction
procedure. This analysis revealed that the performance of the classiﬁer
was only minimally improved when images were uncorrected for age
diﬀerences (overall accuracy pre and post age correction were respec-
tively 75.77% and 74.0%). This again suggests a modest modulatory
eﬀect of age on the GMD-based classiﬁcation, thus indicating that age
and GMD are mostly independent predictors of DT treatment response
in PD. Consequently, further research would be needed for the identi-
ﬁcation of mediators of the aging eﬀect on treatment response. For
example, it has been proposed that aging might inﬂuence neurode-
generation (and possibly treatment response) through the complex in-
teraction between iron and neuromelanine accumulation and loss of
dopamine neurons (Zucca et al., 2017).
In conclusion, we provide a new perspective into the issue of het-
erogeneous individual treatment response in Parkinson's disease. The
implementation of SVM classiﬁcation provides a new approach to the
topic and might pave the way to further investigations including larger
Parkinson's disease cohorts, atypical parkinsonian syndromes and dif-
ferent neuroimaging data.
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Objective: Our study explored the retrieval deficit and the associative deficit hypotheses of memory
impairments in Parkinson’s disease (PD). The former supports a memory deficit mediated by attention/
executive dysfunctions, whereas the latter hypothesizes a hippocampal memory impairment in PD.
Method: We studied 31 controls and 34 PD patients classified as PD with normal cognition (PD-NC; n
18) and PD with mild cognitive impairment (PD-MCI; n 16). To test the retrieval deficit hypothesis,
we measured the performance in encoding, retention, and recognition in verbal and visual domains; to
test the associative deficit hypothesis, we used a specific associative binding measure. Using resting-state
functional-MRI, we compared the functional connectivity of different hippocampal subfields between PD
patients and controls, and we related it to memory performance. Results: Consistently with the retrieval
deficit hypothesis, PD-MCI, and PD-NC, were impaired in free recall encoding and retention in
comparison to controls, especially in the visual domain. However, as predicted by the associative deficit
hypothesis, PD-MCI and, to a lesser extent, PD-NC, showed also significant associative and binding
deficits in cued recall. Notably, PD patients compared to controls did not show structural differences,
although they had lower connectivity between the anterior hippocampi and the precuneus/superior
parietal cortex. Worse performance in memory was associated with a more severe disruption of the
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hippocampal connectivity. Conclusions: The pervasive pattern of memory impairment in PD supports
both hypotheses. The interplay between the hippocampus, related to associative memory deficits, and the
precuneus, related to attentional control, provides a neural signature that reconciles them.
General Scientific Summary
Our study contributes significant new findings of memory disorder in patients that suffer from both
Parkinson’s disease and mild cognitive impairment. We tried to coherently reconcile the basic
hypotheses for the interpretation of memory impairment in Parkinson’s disease: the retrieval deficit
and associative deficit hypotheses. Using resting-state functional-MRI, our study reveals the brain
mechanisms that enable the development of memory retrieval deficit and associative memory deficit
in Parkinson’s disease and mild cognitive impairment.
Keywords: memory impairment, mild cognitive impairment, Parkinson’s disease, resting-state functional
MRI
Supplemental materials: http://dx.doi.org/10.1037/neu0000503.supp
Parkinson’s disease (PD) is a neurodegenerative disease asso-
ciated with a heightened risk of cognitive impairment (Aarsland et
al., 2017; Muslimovic´, Post, Speelman, & Schmand, 2005; Pigott
et al., 2015; Schrag, Siddiqui, Anastasiou, Weintraub, & Schott,
2017; Williams-Gray, Foltynie, Brayne, Robbins, & Barker,
2007). The underlying pathophysiological changes include com-
promised dopaminergic neurotransmission in nigro-striatal and
fronto-striatal circuitries, and pathological accumulations of
-synuclein in Lewy bodies and -amyloid plaques in later disease
stages (Del Tredici & Braak, 2016; Petrou et al., 2015; Spillantini
et al., 1997; Zgaljardic, Borod, Foldi, & Mattis, 2003). To describe
and assess cognitive changes, the concept of mild cognitive im-
pairment in PD (PD-MCI) was introduced (Geurtsen et al., 2014;
Litvan et al., 2011; Litvan et al., 2012). PD-MCI is defined as a
deterioration in cognitive functioning, which is more pronounced
than a normal age-associated decline but does not reach the sever-
ity of a dementia syndrome (Emre et al., 2007; Litvan et al., 2012).
MCI affects 24–35% of patients with PD (Broeders et al., 2013;
Janvin, Larsen, Aarsland, & Hugdahl, 2006; Litvan et al., 2011;
Pigott et al., 2015). Higher age, longer disease duration with higher
disease severity as measured with the Unified Parkinson’s disease
rating scale motor score (UPDRS-III) are associated with higher
probability of MCI (Hoogland et al., 2017). In turn, MCI status
increases the hazard of dementia (Hoogland et al., 2017; Musli-
movic´, Schmand, Speelman, & de Haan, 2007; Pagonabarraga &
Kulisevsky, 2012; Reid, Hely, Morris, Loy, & Halliday, 2011;
Williams-Gray et al., 2013).
An evolving episodic memory impairment in PD is frequent
since the early stages of the disease, even though its origin is still
under scrutiny and not well understood (Brønnick, Alves,
Aarsland, Tysnes, & Larsen, 2011; Cohn, Moscovitch, & David-
son, 2010; Whittington, Podd, & Kan, 2000). Up to now, two main
hypotheses were formulated to explain the cause of memory def-
icits in PD: (a) the retrieval deficit hypothesis and (b) the associa-
tive dysfunction hypothesis (Cohn, Giannoylis, De Belder, Saint-
Cyr, & McAndrews, 2016; Cohn et al., 2010; Higginson,
Wheelock, Carroll, & Sigvardt, 2005; Naveh-Benjamin, 2000).
According to the retrieval deficit hypothesis, the typical PD mem-
ory profile is due to impaired attention and executive dysfunction
that lead to derailed encoding strategies and, as a result, to deficits
in learning and retrieval of items from memory (Costa et al., 2014;
Tröster & Fields, 1995; Whittington et al., 2000). This is also
mirrored at the brain level by pathophysiological changes in the
fronto-striatal networks that are associated with strategic aspects of
memory retrieval. The learning/encoding deficit is manifested in
flatter learning curves in memory tests and the retrieval deficit in
the impaired free recall of single items, especially when the ma-
terial is poorly organized. On the other hand, recognition memory
would be relatively spared (Algarabel et al., 2010; Brønnick et al.,
2011; Chiaravalloti et al., 2014; Flowers, Pearce, & Pearce, 1984;
Saka & Elibol, 2009). The associative dysfunction hypothesis
instead supports the presence of a hippocampal memory disorder
in PD that is manifested as impaired recollection when encoding
strategies (acquisition of the material) are equated across groups,
limiting the load on attention and executive functions (Cohn et al.,
2016; Cohn et al., 2010). Indeed, many studies have shown that PD
patients perform worse than controls not only in free recall, but
also in cued recall, recognition, familiarity, and semantic cluster-
ing strategy (Beatty et al., 2003; Brønnick et al., 2011; Buytenhuijs
et al., 1994; Chiaravalloti et al., 2014; Edelstyn et al., 2015;
Pirogovsky-Turk, Filoteo, Litvan, & Harrington, 2015; Whitting-
ton et al., 2000; Whittington, Podd, & Stewart-Williams, 2006). To
isolate this specific memory deficit, learning and cued recall meth-
ods were introduced to mitigate normal age-related problems in
attention, strategic aspects of encoding, and retrieval (Cohn et al.,
2016; Grober & Buschke, 1987). Of note, it has been shown that
the controlled learning and cued recall verbal memory techniques
are especially apt for the differentiation of hippocampal and me-
dial temporal lobe (MTL) involvement in learning and recall
(Sarazin et al., 2007; Vyhnalek et al., 2014; Zimmerman et al.,
2008).
Concerning the neuroimaging correlates of memory deficit in
PD, many studies focused on the MTL areas that are known to be
implicated in memory encoding and retrieval (Kircher et al., 2008;
Miller & D’Esposito, 2012), and especially in recollection
(Schacter, Alpert, Savage, Rauch, & Albert, 1996). Morphological
changes were documented in the entorhinal cortex, hippocampus,
and surrounding MTL areas even in the early PD stages (Biundo et
al., 2013; Junqué et al., 2005; Pirogovsky-Turk et al., 2015; Tanner
et al., 2015). MTL atrophy in PD and PD with dementia (PD-D) is
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milder than in Alzheimer’s disease (Laakso et al., 1996; Tam,
Burton, McKeith, Burn, & O’Brien, 2005) but correlates with
memory performance (Beyer et al., 2013; Brück, Kurki, Kaasinen,
Vahlberg, & Rinne, 2004; Pirogovsky-Turk et al., 2015).
Functional architecture changes as measured by resting-state
functional MRI (rs-fMRI) provide a novel perspective into the
brain and are ideal to investigate neurodegenerative disorders
conceptualized as brain disconnection syndromes (Warren,
Rohrer, & Hardy, 2012). We, therefore, investigated also the
neural substrate of memory in PD-MCI using rs-fMRI to deter-
mine whether hippocampal engagement is reduced in PD and
whether it correlates with this associative memory measure. To our
best knowledge, no previous rs-fMRI study has specifically ad-
dressed declarative memory disorders in PD. Conversely, similar
investigations in Alzheimer’s disease have elucidated memory-
related brain network changes, especially focusing on the hip-
pocampal and default mode network connectivity (Chhatwal &
Sperling, 2012).
In this article, we evaluate both the retrieval deficit hypothesis,
that is, the deficit is due to the impaired free recall of items from
memory, and the associative dysfunction hypothesis in PD pa-
tients, that is, the deficit is due to the impaired association between
items. Therefore, we performed an in-depth assessment of memory
function in a group of PD patients (including PD-MCI) and age-
matched controls to determine differences in encoding, retrieval,
recollection, error scores, and recognition. Specifically, the re-
trieval deficit hypothesis would predict impaired learning and free
recall in PD-MCI as compared to controls and relatively spared
performance in paired cued recall and recognition, due to equal
attentional/executive demands. On the other hand, the associative
dysfunction hypothesis would also predict a worsening of the
performance in PD-MCI compared to controls in the cued paired
recall condition, indicating an associative memory deficit in the
recollection and relational binding. We investigated both, struc-
tural brain images and resting state functional connectivity of
medial temporal lobe structures, focusing on the hippocampus, a
key region for memory (Koen & Yonelinas, 2014; Squire, 2004).
Here we hypothesized significant structural differences between
PD patients and controls in the hippocampus and functional con-
nectivity differences associated with the impaired memory perfor-
mance.
Method
Procedure
Neuropsychological assessment. Both PD patients and con-
trols underwent neuropsychological assessment according to the
standard International Parkinson Movement Disorder Society
Level II criteria for PD-MCI (Bezdicek, Nikolai, et al., 2017;
Bezdicek, Sulc, et al., 2017; Litvan et al., 2012). In addition, an
in-depth memory assessment was performed for the present study.
The PD-MCI battery consisted of 10 tests in five cognitive do-
mains measuring attention and working memory, executive func-
tion, language, visuospatial function, and memory. A complete list
of the tests can be found in Supplemental Table S3. Significant
group differences in analysis of variance (ANOVA) were found in
all the five cognitive domains. PD-MCI was defined when the
patient performed at least two tests below 1.5 SD in comparison
to normative data (Bezdicek, Sulc, et al., 2017; Goldman et al.,
2013).
Memory assessment (retrieval deficit hypothesis). Rey Au-
ditory Verbal Learning Test (RAVLT). It is a classical and stan-
dardized measure that assesses the learning of new material (learn-
ing curve represented by Trials 1 to 5 and a total amount of learned
material; RAVLT-IRS), retention (delayed recall after 20 min;
RAVLT-DR), and recognition memory (a list of 50 words con-
taining all items from Lists A and B and 20 words that are
phonemically or semantically similar to those in Lists A and B;
RAVLT-Rec; Bezdicek et al., 2014; Ivnik et al., 1990). Brief
Visuospatial Memory Test—Revised (BVMT-R). A 2  3 matrix
containing six simple geometric visual designs is shown to the
subjects. The standardized measure is a visuospatial analog of
RAVLT consisting of three consecutive trials that yield measures
of learning curve a total amount of learned material (BVMT-R-
IRS), retention/delayed recall (BVMT-DR), and recognition
(BVMT-R-Rec; Benedict, 1997).
Associative dysfunction hypothesis. The Experimental Mem-
ory Binding Test (MBT) uses controlled learning and cued recall to
elicit encoding specificity and maximum retrieval (Buschke, 2014;
Papp et al., 2015; Rentz et al., 2013; Tulving & Thomson, 1973). A
detailed description of the MBT can be found elsewhere (Buschke,
2014; Buschke et al., 2017). In short, the MBT during cued paired
recall requires the subjects to recollect and associatively bind two-
word items (e.g., brown and yellow) that are interconnected by a
single shared semantic category (i.e., color; associative retrieval and
binding measure). In the present study, we used the MBT measures:
TIP (total number of items cued recalled in the paired condition, range
0–32) as encoding specificity measure and PIP (the number of pairs
cued recalled in the paired condition, range 0–16) as a binding
measure for their ability to detect hippocampal episodic memory
impairment, which is not compromised by the ubiquity of attention/
executive dysfunction in PD (Buschke et al., 2017; Cohn et al., 2016).
Participants
Thirty-four patients diagnosed with sporadic PD (Hughes, Dan-
iel, Kilford, & Lees, 1992) in intermediate or advanced stages and
31 age-matched healthy controls were included in the present
study (see Table 1). Other inclusion criteria were age at onset after
45 years of age and stable pharmacological treatment with
levodopa in monotherapy or combination with dopamine agonists.
The daily levodopa equivalent dose was computed for each patient
(Tomlinson et al., 2010). The Unified Parkinson’s disease Rating
Scale (UPDRS I, II, III and IV) were administered to the patient
group. Exclusion criteria were previous or current psychotic symp-
toms, treatment with antipsychotics, severe cognitive impairment
(i.e., MoCA below 1.5 SD according to the Czech normative
data; Kopecek et al., 2017), treatment with deep brain stimulation
or jejunal infusion of levodopa, and/or presence of any comorbid-
ity potentially interfering with motor or cognitive performance. PD
patients and controls did not differ on any of the measured demo-
graphic variables (see Table 1). Antidepressants were also admin-
istered to eight patients (selective serotonin reuptake inhibitors
only in five patients, in combination with serotonin-norepinephrine
reuptake inhibitors in two cases and tricyclic antidepressants only
in one patient) and three controls (selective serotonin reuptake
inhibitors). All subjects gave their informed consent to participate
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in the study. The study was approved by the Ethics Committee of
the General University Hospital in Prague, Czech Republic, and
therefore performed in accordance with the ethical standards es-
tablished in the 1964 Declaration of Helsinki.
Statistical Analyses
The analyses were performed using IBM SPSS 20.0. Consider-
ing the nonnormal distribution of MBT scores (after checking the
Q-Q plot and Shapiro-Wilk test), we used nonparametric statistics.
The association between test scores and age and years of education
was evaluated by a Spearman’s rho and by a point-biserial corre-
lation for gender. To analyze between-groups differences in the
test performance between controls, PD-MCI and PD-NC, we ran
Mann–Whitney U tests with Bonferroni corrected post hoc com-
parisons. Specifically, we investigated group differences in
RAVLT and BVMT-R for retention (delayed recall), and recog-
nition and in MBT for associative retrieval/binding (cued recall).
Differences in the slope of the learning curve in BVMT-R and
RAVLT were investigated with a mixed between-within subjects
ANOVA. The error patterns were also compared for all the tests
(Thomas et al., 2018). In case of between-groups differences in
sex, we used 
2 test for independence with Yates continuity
correction.   .05 was adopted for statistical significance and
effect size was determined using Cohen’s (r)—.1, small; .3, me-
dium; .5, large (Cohen, 1988)—or partial eta squared (2)—.02,
small, .13, medium, .26, large. In addition, we used Spearman’s
correlations to check the relationship between the different mem-
ory scores (Supplemental Table S1) and between them and the
performance in other cognitive domains (Supplemental Table S2).
To assess the differential impact of attention/working memory and
visuospatial abilities on the memory tests (since these domains are
frequently impaired in PD and might influence the memory per-
formance), linear regression was implemented using as indepen-
dent variables, Trail Making Test, Part A, Digit Span backward
(attention/working memory domain), and a Clock Drawing Test
(visuospatial domain) and setting the different memory measures
as dependent variables.
Neuroimaging
Data acquisition and preprocessing: Magnetic resonance images
were acquired on a 3T MR scanner (Magnetom Skyra, Siemens,
Germany). To investigate brain structure, a whole-brain T1-
weighted MRI dataset was acquired using a sagittal 3D-MPRAGE
(Magnetization Prepared Rapid Gradient Echo) sequence with
voxel resolution 1 mm3, TR  2.2 sec, TE  2.43 ms, inversion
time  900 ms, matrix  224  224, and flip angle  8°. To
assess functional brain connectivity, resting-state functional MRI
(rs-fMRI) was also performed, using T2-weighted gradient-echo-
planar imaging (EPI), flip angle  90 deg, TR  2sec, TE 
30ms, voxel size 333.45 mm, 300 volumes. A T2-weighted
sequence (TR  3.2 sec, TE  9 ms, resolution  0.9x0.9x3 mm)
was also implemented to exclude confounding pathological brain
changes. Because of MRI incompatibility or severe artifacts in
MRI images, six patients and six controls had to be discarded from
the neuroimaging analysis that included, accordingly, 28 PD pa-
tients and 25 controls. The time between MRI and neuropsycho-
logical assessments was on average 11 days. Both cognitive mea-
sures and MRI acquisition were performed when the patients were
taking their usual dopaminergic medication (i.e., in ON state).
Images taken in the ON state were chosen to minimize a possible
influence of the motor impairment on neuropsychological perfor-
mance and head movement during the MRI acquisition.
T1 MRI data were preprocessed in CAT12 toolbox (www.neuro
.uni-jena.de/cat12) and SPM12 (www.fil.ion.ucl.ac.uk/spm) within
Matlab™ environment (MathWorks, Nattick, MA). First, the images
were normalized to MNI space, segmented into white matter, gray
matter, and cerebrospinal fluid. After that, gray matter density (GMD)
images were obtained using modulation that encodes spatial transfor-
mations in the actual voxel gray values. Finally, GMD images were
further smoothed using a Gaussian kernel of 8 mm full-width at
half-maximum. A quality check was performed using quality reports
provided in CAT12.
For rs-fMRI data, the functional images were first realigned and
slice-time corrected. Then, the unified segmentation approach
(Ashburner & Friston, 2005) was implemented to achieve segmen-
tation, bias correction, and normalization through nonlinear warp-
ing. As for T1 data, 8 mm smoothing was applied to comply with
the requirements of the Gaussian random field theory to correct the
statistical analysis for multiple comparisons. We show statistics on
the motion parameters of our patients and healthy controls groups.
To check for differences in head motion during the MRI acquisi-
tion, we computed the mean and maximum frame-wise displace-
ment for each study participant based on the frame-by-frame
translation and rotation values (Power, Barnes, Snyder, Schlaggar,
& Petersen, 2012). Of note, patients and controls did not differ in
head motion as indicated by Student’s t test (mean FD:
t(df)  1.173 (51), p  .246; max FD: t(df)  1.638 (51), p 
.108). Information on mean and maximum frame-wise displace-
ment values are shown in the Supplementary Figure S1 in the
online supplemental material. Next, to increase the signal to noise
ratio and to reduce possible motion-related artifacts, a nuisance
regression was performed at the end of the preprocessing using
signals from WM and CSF, as well as the head motion parameters.
Statistical Analyses
To identify structural changes in the medial temporal lobe and
hippocampus, we applied voxel-based morphometry (VBM; Ash-
burner & Friston, 2000). The preprocessed GMD images were
compared between patients and controls in a two-sample t test
restricting the analysis within a mask including the hippocampus,
the parahippocampal gyrus, and the entorhinal cortex. The statis-
tical design included nuisance covariates to consider the variability
in total intracranial volume and age in the statistical analysis.
To investigate the differences in hippocampal resting-state func-
tional connectivity between patients and controls, we applied seed-
based connectivity analyses. Namely, three seeds for each hip-
pocampus were defined according to previous research (Chen et
al., 2016), anterior (MNI: 24, 14, 20), middle (MNI:
26, 26, 12) and posterior subfields (MNI: 26, 34, 4) of
the hippocampus (see Figure 3). Anterior, middle, and posterior
subfields correspond, respectively, to the hippocampal head, body,
and tail (Chen et al., 2016). Single voxels were used as seeds to
maintain specificity for the hippocampal subregions. Here we
consider that the smoothing step during the preprocessing had
already merged into the seed voxels part of the surrounding signal
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intensity. The time-courses were extracted from the preprocessed
functional images for patients and controls. Whole-brain correla-
tions were performed in Matlab between the time-courses in the
seed voxels and that of all the other voxels in the brain. This
produced a correlation map for each subject, in which each voxel
contains a value corresponding to its correlation in time with the
seed region. After that, individual correlation maps were compared
in SPM12 between patients and controls using a two-sample t test
and entering age as a nuisance covariate. Significant clusters were
obtained with p  .05 using family wise error correction at
cluster-level. When significant results were obtained in the group
comparison, a seed-based connectivity analysis from the selected
seed was also computed independently for patients and controls, to
identify the complete pattern of functional connections with the
seed in each group.
When significant differences in hippocampal seed-based con-
nectivity between patients and controls were identified, we inves-
tigated their relationship with memory performance. Specifically,
we selected the clusters showing a significant difference and tested
if the connectivity change between those regions and the corre-
sponding hippocampal seeds was associated with memory scores
(i.e., MBT, RAVLT, and BVMT). We extracted the correlation
values from the significant clusters using the marsbar toolbox
(http://marsbar.sourceforge.net/) and correlated them with memory
scores using two-tailed nonparametric Spearman’s rho.
Results
Memory Assessment
Retrieval deficit hypothesis: Learning (learning curve) and
encoding. The between groups differences and learning curves
are shown in Figures 1 (top, verbal domain; bottom, visual do-
main) and 2 and Table 1. Overall, based on a mixed between-
within subjects ANOVA, the linear slope was significantly steeper
during RAVLT Trials 1 to 5 across groups, thus indicating a
significant effect for trial (p .001). On the contrary, there was no
effect neither for the group factor (p .124) nor the Trial Group
interaction (p  .212), suggesting no difference in the learning
curves between groups (Figure 1 top). Regarding BVMT-R Trial 1
to 3, there was a significant effect for trial (p .001) and for group
(PD-MCI  PD-NC  controls; p  .001) with no significant
Trial  Group interaction (p  .405). (Figure 1 bottom).
Retention (delayed recall). We found significant differences
with a medium effect size in retention in verbal domain
RAVLT-DR in PD-MCI  controls (r  .38) and medium effect
size in PD-NC  controls (r  .34), whereas the PD-MCI versus
PD-NC comparison was not significant. Differences in retention in
the visual domain were highly significant for all the comparisons,
with the large effect size in PD-MCI  controls (r  .62) and
medium effect size in PD-MCI  PD-NC and PD-NC  controls
(Table 1 and Figure 2 C/2 D).
Recognition. We found significant differences with the me-
dium effect size in recognition in the verbal domain in PD-MCI 
controls (r  .47) and low and medium effect size in PD-MCI 
controls and PD-MCI  PD-NC, respectively (r  .28 and .40).
However, in recognition in the visual domain, there were no
significant between-groups differences (Table 1 and Figure 2
E/2F).
Associative dysfunction hypothesis: Retrieval and relational
binding (cued recall). There were significant differences with
the large effect size in MBT-PIP (binding measure) in PD-MCI 
controls (r  .50) and with the medium effect size in PD-NC 
controls (r  .30). We also found a medium effect size in MBT-
TIP (encoding specificity measure) in PD-MCI  controls (r 
.49) and with the medium effect size in PD-NC  controls (r 
.34) and again no difference between PD-MCI versus PD-NC
(Figure 1G/1H and Table 1).
Memory error patterns. PD-MCI made significantly more
intrusions with the medium effect size in RAVLT Trial 6 to 8
compared to controls and, also, significantly more intrusions with
the medium effect size in the MBT second interference list (MBT
CR-L2; Supplemental Table S4 in the online supplemental mate-
rial). Furthermore, PD-MCI and PD-NC, compared to controls, did
also more false positive errors during recognition with large and
medium effect size, respectively (Supplemental Table S4). The
linear regression analysis showed that performance in attention,
working memory and visuospatial functions predicted BVMT-R-
IRS and BVMT-R-DR, whereas only working memory was a
significant predictor of RAVLT-IRS and only visuospatial func-
tions showed an influence on MBT-TIP (see Table 2).
Neuroimaging Results
Comparing structural brain images between PD patients and
healthy controls using the VBM technique, we did not obtain any
significant GMD differences in the medial temporal lobe and
hippocampus.
Using seed-based connectivity analysis, we obtained significant
group differences between PD patients and controls in the func-
tional connectivity of the bilateral anterior hippocampi. Namely,
both the left and right anterior hippocampi showed reduced con-
nectivity with the precuneus and the adjacent superior parietal
cortex in patients as compared to controls (see Figure 3). The
functional connectivity maps between the bilateral anterior hip-
pocampi and the rest of the brain are additionally shown separately
for patients and controls in Supplementary Figure S2 in the online
supplemental material. No significant results were found neither
for the reverse comparison (i.e., controls PD) nor the middle and
posterior hippocampi. Notably, significant nonparametric correla-
tions were found between memory scores and the connectivity of
the anterior hippocampus and precuneus/superior parietal cortex.
Both the connectivity patterns between the right and left anterior
hippocampi and the precuneus/superior parietal cortex correlated
significantly with associative retrieval and binding (TIP, PIP) and
with retention and learning in visuospatial domain (i.e., BVMT-
R-DR and BVMT-R sum of 1–3 trials). Also, the connectivity
between the left hippocampus and the superior parietal cortex
positively correlated with the performance in the RAVLT-DR
(Figure 4 and Table 3).
Discussion
In the present study, we aimed at clearly distinguishing between
retrieval versus associative models of declarative memory impair-
ment in nondemented PD to explore the associative dysfunction
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versus retrieval deficit hypotheses (Brønnick et al., 2011; Cohn et
al., 2016; Cohn et al., 2010; Costa et al., 2014; Edelstyn et al.,
2015; Chiaravalloti et al., 2014; Tröster & Fields, 1995; Whitting-
ton et al., 2000). Our results, combining neuropsychological and
neuroimaging data, support to a certain degree both models. In-
deed, at the behavioral level, the test performance of PD patients
indicates that memory deficit in PD can be both associative (with
an impairment in binding of two words) and, concurrently, a
Figure 1. Verbal learning curve (top) and visual learning curve (bottom) in Parkinson’ disease patients and
controls. RAVLT  Rey Auditory Verbal Learning Test Learning Curve over five trials. The whiskers of the
lines graph are 	 1 and 1 SD’s; a mixed between-within subjects analysis of variance (ANOVA) in RAVLT
Trial 1 to 5 showed no significant interaction between Trial  Group status, Wilks’   .84, F  (8, 118) 
1.01, p  .212, partial 2  .086. There was a substantial main effect for trial, Wilks’   .12, F  (4, 59) 
110.38, p .001, partial 2  .882, with all groups showing an increment in verbal learning. However, the main
effect of group status was nonsignificant, F  (2, 62)  2.16, p  .124, partial 2  .065. BVMT-R  Brief
Visuospatial Memory Test, revised, learning curve over three trials. The whiskers of the lines graph are 	 1
and 1 SD’s; a mixed between-within subjects ANOVA in BVMT-R Trial 1 to 3 showed no significant
interaction between Trial  Group status, Wilks’   .94, F  (4, 122)  1.01, p  .405, partial 2  .032.
There was a substantial main effect for trial, Wilks’   .21, F  (2, 61)  116.83, p  .001, partial 2  .793,
with all groups showing an increment in visual learning. The main effect of group status was significant, F 
(2, 62)  17.60, p  .001, partial 2  .362. See the online article for the color version of this figure.
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A: Encoding (verbal)
RAVLT-IRS
B: Encoding (visual)
BVMT-R-IRS
C: Retention (verbal)
RAVLT-DR
D: Retention (visual)
BVMT-R-DR
E: Recognition (verbal)
RAVLT-Rec
F: Recognition (visual)
BVMT-R-Rec
  
G: Associative binding measure 
MBT PIP 
H: Encoding specificity measure 
MBT TIP 
  
Figure 2. In-depth analysis of memory profiles in Parkinson’s disease (PD-NC, n  18; PD-MCI, n  16;
controls, n  31). BVMT-R-IRS  Brief Visuospatial Memory Test, revised, immediate recall score; BVMT-
R-DR  delayed recall; BVMT-R-Rec  Recognition; RAVLT-IRS  Rey Auditory Verbal Learning Test
immediate recall score; RAVLT-DR  Rey Auditory Verbal Learning Test delayed recall; RAVLT-Rec  Rey
Auditory Verbal Learning Test recognition; MBTMemory Binding Test; PIP number of pairs cued recalled
in the paired condition; TIP  total number of items cued recalled in the paired condition. The length of the box
is the interquartile range, the whiskers go out to highest and smallest values and the red line across the inside
of the box is median. See the online article for the color version of this figure.
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398 BEZDICEK ET AL.
deficit in retrieval (in free recall, retention and recognition) medi-
ated by attention and encoding strategies (preponderantly in the
visual domain). At the brain level, this complex framework is
mirrored in the functional interplay between the hippocampus and
the precuneus.
In contrast to previous studies, we used rigorously determined
cognitive phenotypes (PD-MCI and PD-NC) by applying the stan-
dard International Parkinson Movement Disorder Society criteria
Level II for PD-MCI (Bezdicek, Sulc, et al., 2017; Litvan et al.,
2012; Williams-Gray et al., 2007). To disentangle the two hypoth-
eses, we implemented both standardized tools with established
psychometric properties in verbal (RAVLT) and visual (BVMT-R)
domains and an experimental cued recall technique (MBT) sensi-
tive to hippocampal dysfunction in MCI and PD-MCI (Balthazar,
Yasuda, Cendes, & Damasceno, 2010; Bezdicek, Sulc, et al., 2017;
Buschke, 2014; Buschke et al., 2017; Cohn et al., 2016; Chang et
al., 2010; Edelstyn et al., 2015; Lee et al., 2010). The behavioral
test results show a specific, declarative memory impairment profile
in basic memory mechanisms in PD-MCI and, to a lesser extent, in
PD-NC. Of note, premorbid intelligence levels and demographic
variables were comparable between patients and controls and even
between PD-NC versus PD-MCI and controls (see Table 1).
Learning/encoding strategies were significantly impaired in the
visual domain, with a gradient PD-MCI  PD-NC  controls,
whereas, surprisingly, the between-groups differences were not
significant in the verbal domain. Moreover, for both tests investi-
gating visual and verbal domains, we found no interaction between
trial and group. This lack of learning slope difference may indicate
that encoding strategies are not a major difference between groups.
If attention/strategic impairments were contributing to encoding
errors, one would predict a flatter slope for at least PD-MCI group.
Nevertheless, PD-MCI showed a trend toward a lower, though not
significant, learning slope in comparison to other groups, which is
consistent with previous research (Brønnick et al., 2011; Chiara-
valloti et al., 2014). This differential affliction of learning in visual
and verbal domains is interesting because it might indicate that the
presentation of visual material to PD patients influence their over-
all memory performance. Indeed, deficits in visuospatial and
Figure 3. Decreased anterior hippocampal functional connectivity in Parkinson’s disease (PD) patients (n 
28) compared to controls (n  25). From top to bottom: graphical visualization of seeds in the anterior, middle
and posterior hippocampus. Single voxels were used as seeds in the analysis. Significant results were found for
the anterior hippocampus (highlighted in yellow). Group comparisons (PD patients  controls) showing
diminished connectivity between the right/left anterior hippocampi and the precuneus and superior parietal
cortex. Red blobs represent clusters surviving the p .05 FWE correction for multiple comparisons at the cluster
level. See the online article for the color version of this figure.
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visuo-constructive abilities have frequently been reported in PD-
MCI with posterior-cortical defects (Martinez-Horta & Ku-
lisevsky, 2011) and might thus significantly contribute to degrad-
ing their performance in the BVMT-R in comparison to RAVLT
learning curve. In retention in the verbal domain we found a
significant difference between PD-MCI versus controls and
PD-NC versus controls, but not between PD-MCI versus PD-NC.
The finding is further corroborated by significantly higher verbal
intrusion rate between PD-MCI and controls (Brønnick et al.,
2011). We found a similar pattern in retention in a visual domain
where, additionally, the difference between PD-MCI versus
PD-NC was significant. This finding is consistent with a higher
affliction of visual than a verbal declarative memory in PD encod-
ing and retention (Lee et al., 2010). In recognition, there was a
striking pattern of significant impairment between all groups in
verbal but not visual domain (Rodríguez, Algarabel, & Escudero,
2014). However, we believe this is not reflecting a real absence of
between-groups differences in visual memory recognition rather a
floor effect in BVMT-R Recognition (see the trend in Figure 2 F).
PD-MCI compared to controls also indicated more false positive
errors with a nonsignificant difference in false negative rate and a
trend toward significance in PD-NC versus controls (Higginson et
al., 2005). Overall, we see a pattern of declarative memory im-
pairment in learning, retention, with a higher level of intrusions
errors, a pattern similar to that observed in the progression of MCI
due to Alzheimer’s disease (Thomas et al., 2018), and recognition
in PD-MCI again with higher intrusion and false positive rates
which is accompanied by a similar but milder memory deficit in
PD-NC (especially in recognition) consistent with previous re-
search (Brønnick et al., 2011). These results would thus indicate a
memory profile to a large degree (especially in the visual domain)
consistent with the retrieval deficit hypothesis (Tröster & Fields,
1995). Moreover, the BVMT-R test revealed larger group differ-
ences as compared to the RAVLT. The linear regression analysis
helps in further understanding the source of this discrepancy.
Indeed, the BVMT-R requires a heavier load not only on visu-
ospatial functions as previously argued but also on attention/
working memory functions that were impaired in our sample
which is in accordance to the previous literature on PD with
cognitive deficits (Martinez-Horta & Kulisevsky, 2011).
Furthermore, we observe a significant difference in the associa-
tive binding (MBT-PIP) and in encoding specificity measure
(MBT-TIP) between PD-MCI and controls. A similar trend is
apparent in PD-NC. Of note, the linear regression analysis did not
reveal a significant contribution of attention/working memory to
the memory performance in TIP and PIP scores. These results
support the associative deficit hypothesis and are consistent with
studies showing memory impairment in recollection and relational
binding in PD-MCI (Brønnick et al., 2011; Cohn et al., 2010, 2016;
Chiaravalloti et al., 2014; Edelstyn et al., 2015; Edelstyn, Mayes,
Condon, Tunnicliffe, & Ellis, 2007; Edelstyn, Shepherd, Mayes,
Sherman, & Ellis, 2010; Higginson et al., 2005), however, discor-
dant findings that PD patients benefit substantially from cueing
also can be found (Costa et al., 2014).
Notably, the neuroimaging results did not show any morpho-
logical change in the Schelten’s MTL scale of PD patients as
compared to controls. This is in contrast with a part of the previous
literature that has reported atrophy in the MTL in PD with cogni-
tive deficit and related it to memory performance (Biundo et al.,
2013; Junque et al., 2005; Pan et al., 2013; Pirogovsky-Turk et al.,
2015; Tanner et al., 2015). However, it has to be mentioned that
the identification of consistent atrophy pattern in PD has been
challenging so far, often leading to heterogeneous and inconsistent
results (Saeed et al., 2017). As for the rs-fMRI analysis, we believe
that our findings may reconcile both the associative and the re-
trieval deficit hypothesis and provide a more coherent account of
memory deficits in PD. Lower performance in memory scores was
significantly associated with disrupted connectivity between the
anterior hippocampi, the precuneus, and superior parietal cortex.
The precuneus and the superior parietal cortex have been related to
Table 2
Multiple Regression Analysis of All Memory Measures and Visual Attention (TMT-A) and Auditory Attention (DS Backwards) and
Visuospatial Measure (CLOX-I) as Predictors
Predictors
ANOVA TMT-A DS backwards CLOX-I
Adjusted R2 F p-value  t p  t p  t p
RAVLT-IRS .122 3.975 .012 .05 .36 .723 .35 2.86 .006 .16 1.26 .210
RAVLT-DR .060 2.368 .079 .20 1.49 .139 .24 1.87 .066 .76 .57 .571
RAVLT-Rec .014 1.298 .283 .05 .38 .704 .18 1.42 .160 .15 1.07 .288
BVMT-R-IRS .466 19.611 .001 .42 4.11 .001 .32 3.30 .002 .22 2.22 .030
BVMT-R-DR .509 23.147 .001 .52 5.33 .001 .19 2.04 .045 .25 2.58 .012
BVMT-R-Rec .002 .048 .986 .05 .37 .716 .01 .03 .978 .03 .23 .816
MBT PIP .127 4.101 .010 .17 1.29 .201 .19 1.52 .132 .21 1.64 .106
MBT TIP .224 7.164 .001 .20 1.63 .107 .21 1.83 .072 .29 2.38 .021
Note. ANOVA  analysis of variance; TMT-A  Trail Making Test, Part A; DS  Digit Span; CLOX-I  an unprompted executive clock drawing task;
BVMT-R-IRS  Brief Visuospatial Memory Test, revised, immediate recall score the sum of all correct responses given over the three consecutive trials
(T1 	 T2 	 T3; min.–max. 0–36); BVMT-R-DR  the total number of correct words recalled on the delayed recall trial (min.–max. 0–12);
BVMT-R-Rec  number of all correctly recognized items in Recognition (min.–max. 0–12); RAVLT-IRS  Rey Auditory Verbal Learning Test
immediate recall score, the sum of all correct responses given over the five consecutive trials (T1 	 T2 	 T3 	 T4 	 T5; min.–max. 0–50); RAVLT-DR,
the total number of correct words recalled on the delayed recall trial (T7; min.–max. 0–15); RAVLT-Rec  number of all correctly recognized items in
recognition (min.–max. 0–50); MBT  Memory Binding Test; CR-L1  number of items cued recalled from List 1 on the MBT; CR-L2  number of
items cued recalled from List 2 on the MBT; PIP  number of pairs cued recalled in the paired condition on the MBT (0–16 pairs); TIP, Total number
of Items cued recalled in the Paired condition on the MBT (0–32).
 p  .05.  p  .01.  p  .001.
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both attentional control and visuospatial imagery (Cavanna &
Trimble, 2006), whereas the hippocampus and, in particular, its
anterior subfield, is pivotal in the memory network, by supporting
relational memory (Giovanello, Schnyer, & Verfaellie, 2004) and
encoding (Lepage, Habib, & Tulving, 1998). The fact that differ-
ences between PD patients and controls were found only in the
anterior hippocampus might be associated with the functional
specialization of the hippocampus along the longitudinal axis
(Poppenk, Evensmoen, Moscovitch, & Nadel, 2013).
Based on our findings, we propose that the reduced connectivity
in precuneus/superior parietal cortex mainly supports the retrieval
deficit hypotheses, where attention plays a crucial role in the
encoding and retention phase (Tröster & Fields, 1995). These tasks
are particularly challenging in PD patients when combined with a
visual attentional or visuospatial component in the material (cf.
BVMT-R-IRS vs. RAVLT-IRS in the encoding and BVMT-R-DR
and RAVLT-DR in the retention when retrieving the information).
We hypothesize that these primarily attention and orienting to
stimuli deficits are leading to bottom-up detrimental effects on
memory encoding and might arise as a consequence of cholinergic
dysfunction. It has been shown that PD, beyond dopaminergic
deficits, might also lead to degeneration of the nucleus basalis of
Meynert (NBM) network and subsequent cortical cholinergic def-
icits (Hall et al., 2014). Accordingly, the reduced connectivity of
precuneus to the anterior hippocampus, which also results in a
hippocampal deficit in relational binding can be viewed as a result
Figure 4. Correlations between bilateral anterior hippocampal functional connectivity changes and memory
scores in Parkinson’s disease (PD) patients (n  28) and controls (n  25). The 3D brain images schematically
display regions showing diminished connectivity in PD patients compared to controls. The peak coordinates of
significant clusters from Figure 3 were selected as targets of the anterior hippocampal connections (MNI: 1237
29 for the right seed; MNI 30 28 56 and 6 34 56 for the left seed). The scatter-plots show positive
correlations between higher connectivity (expressed as r coefficients on the y axes) and better memory
performance. For simplicity, only selected results are shown, while a full list of the significant correlations with
the memory scores can be found in the results section and in Supplemental Table S1 in the online supplemental
material. BVMT-R  Brief Visuospatial Memory Test-Revised; MBT  Memory Binding Test; MNI 
Montreal Neurological Institute. See the online article for the color version of this figure.
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of NBM network degeneration with an affliction of the NBM
pathway connected to MTL structures (Gratwicke, Jahanshahi, &
Foltynie, 2015). These findings support the associative deficit
hypothesis (MBT-TIP and severe recognition deficit). The asso-
ciative deficit is mirrored in the impairment of associative binding
(MBT-PIP), independent of visual attentional or visuospatial com-
ponent (Cohn et al., 2016). Hence the different NBM pathways and
their degeneration in PD could shed light on the reduced connec-
tivity in precuneus/superior parietal cortex and between precuneus
and anterior hippocampus, thus reconciling both hypotheses from
a neural network perspective (Gratwicke et al., 2015).
Of notice is that the reduced hippocampus-precuneus functional
connectivity has been reported to be an early sign of Alzheimer’s
disease (Kim, Kim, & Lee, 2013) and can also be associated with
the true nature of cognitive deficit in PD-MCI (Martinez-Horta &
Kulisevsky, 2011). Limited evidence in PD comes also from
Amboni et al. (2015) who reported a trend between memory and
attention/executive scores and the connectivity in the medial pre-
frontal cortex and from Lebedev et al. (2014), who found that
better memory performance correlated with increased prefronto-
limbic processing in PD, that is, in orbitofrontal, anterior cingulate,
parahippocampal, temporopolar regions (Lebedev et al., 2014).
The dissociation between morphological and functional connec-
tivity changes supports the view of PD as a brain disconnection
syndrome, in which pathophysiological features lead in the first
place to changes in the functional architecture in the brain
(Bezdicek et al., 2018; Warren et al., 2012).
However, the relatively small sample size in our study repre-
sents a limit, possibly explaining the lack of volumetric between-
groups alterations and differences in RAVLT-IRS. Furthermore,
we cannot completely exclude, in PD-MCI, that the patients pres-
ent concomitant PDD 	 AD pathology because amyloid or tau
PET scans or respective biomarkers from the cerebrospinal fluid
are not available in the present study (Irwin et al., 2012; Montine
et al., 2012). However, we found no differences in Schelten’s MTL
scale between the groups, indicating no evidence of AD-like
structural MRI changes in our sample (Supplemental Table S5 in
the online supplemental material).
In conclusion, we propose a comprehensive picture of memory
impairment in PD. We reconcile and refine the retrieval deficit and
the associative deficit hypotheses regarding the nature of memory
impairment in PD coherently, supporting our findings with rigor-
ously defined phenotypes of cognitive impairment in PD and with
brain structural and functional connectivity evidence.
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8 DISCUSSION
Medical imaging, beside other biomarkers, will play an important role
in modern clinical diagnosis. Hence, more and more diagnostic criteria of
neurodegenerative diseases are amended incorporating recent findings of
disease-related brain alterations (Albert et al., 2011; Dubois et al., 2014;
Gorno-Tempini et al., 2011; Rascovsky et al., 2011). MRI scanners are
nearly available in all clinics and imaging is incorporated into clinical rou-
tine for assessing neurodegenerative diseases. Research should take ad-
vantage of this and develop diagnostic criteria including medical imaging.
Yet, diagnostic decision-making still primarily depends on clinical variables.
Hence, we are in need for generalized, quantifiable image-based markers
to independently and accurately diagnose patients. Especially in atypical
parkinsonian syndromes, imaging is applied only as supportive or exclu-
sion criterion. Hence, objectively assessed MRI variables are needed and
expected to lead to more independent, improved medical diagnoses. The
task of research is to develop approaches that can be translated into clini-
cal and radiological routine when assessing and diagnosing patients. This
will be even more important when treatment and medication based on un-
derlying histopathologies is available. As our society ages we need new
approaches to diagnose, monitor progression, and treat diseases. MRI is
an outstanding tool in this case: applied for diagnostics and research pur-
poses in in vivo tissue. The following section discusses the results of my
projects altogether.
8.1 Main Findings
Our aim was to investigate the neural correlates of parkinsonian syn-
dromes. Conducting data-driven meta-analyses, voxel-based morphome-
try analysis, and support-vector machine classification of multi-centric MRI
data, we identified and applied potential neuroimaging biomarkers in the
diseases of Parkinson’s disease, progressive supranuclear palsy, and cor-
ticobasal syndrome.
Studies 1 & 2: Identifying Disease-Specific Patterns by Meta-Analyses.
First part of the thesis concerned quantitative and systematic meta-analyses
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on imaging data, which find convergence of the literature to identify disease-
specific patterns to disentangle parkinsonian syndromes. We investigated
the prototypical neural correlates of Parkinson’s disease (PD) and progres-
sive supranuclear palsy (PSP) (Study 1 & 2, Albrecht et al. (2018, 2019a)).
To reveal disease-affected brain regions across studies we double-validated
results by applying two widely used meta-analytical algorithms considering
only the overlap as significant result. We investigated impaired gray matter,
white matter, and metabolism alterations in 1,767 patients with PD and 210
patients with PSP in comparison with healthy controls. In PSP white mat-
ter studies converged in the bilateral superior/middle cerebellar pedunculi,
cerebral pedunculi, and midbrain and gray matter studies in the midbrain
confirming proposed pathognomonic imaging markers. Subtraction analy-
ses directly comparing the aforesaid regions by integrating white and gray
matter atrophy of PSP and PD patients underline the disease-specificity
of midbrain atrophy by quantitatively comparing atrophy patterns. Further-
more, effect size meta-analyses confirm that midbrain metrics generally
perform very well in separating PSP from multiple system atrophy and PD
yielding strong effect sizes. On the other hand, in PD meta-analyses, struc-
tural MRI showed only minor focal gray matter atrophy in the middle occip-
ital gyrus, indicating that this may not be the optimal method for disease
identification when compared to healthy controls. Interestingly, glucose
metabolism changes seem to be more specific to PD affecting the bilateral
inferior parietal cortex and left caudate nucleus.
Thus, the meta-analytically identified alterations in PSP can be regarded
as disease-specific, as we compared results with whole-brain, region-of-
interest, and subtraction meta-analyses to other neurodegenerative dis-
eases. In PD, structural MRI revealed inconsistent results. The identified
hypometabolism was not unique and is also found in other neurodegener-
ative diseases like Alzheimer’s disease.
Study 3: Obtaining Disease-Related Regions and Classifying the Dis-
ease by Voxel-Based Morphometry and Support-Vector Machine. Sec-
ond part of the thesis focused on multi-centric group data analyses to in-
vestigate neural underpinnings and discriminate disease and clinical syn-
drome in single patients (Study 3, Albrecht et al. (2019b)). In a voxel-
based morphometry analysis - a standard tool in detecting volumetric brain
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changes - we found gray matter volume differences in asymmetric fron-
totemporal and occipital regions, motor areas, and the insulae in patients
with corticobasal syndrome (CBS). Characteristic for an unique disease-
related symptom, alien/ anarchic limb phenomenon, was the frontopari-
etal gyrus including the supplementary motor area contralateral to the side
of the affected limb. A cutting-edge multivariate pattern recognition algo-
rithm – support-vector machine classification – was used to predict pa-
tients with the clinical phenotype of CBS and CBS with alien/anarchic limb
phenomenon. The support-vector machine distinguished (i) patients with
CBS from healthy controls and distinguished (ii) between patients just hav-
ing CBS and patients with CBS having alien/anarchic limb phenomenon.
Whereas the first approach predicts the disease, the second predicts one
important and very interesting clinical syndrome individually. The support-
vector machine classification was trained using whole-brain structural MRI
data and later trained on a disease-specific mask of atrophy pattern ob-
tained by our recent meta-analysis (Appendix, Albrecht et al. (2017)). The
prediction of the disease among controls yielded a high accuracy of 79.0%.
The prediction of the specific syndrome within a disease reached an ac-
curacy of 81.3%. Applying the meta-analytical mask lead to similar stable
results. Due to two groups, 50% represents chance level in both analyses.
Our results highlight that we can identify patients and controls by ob-
jective pattern recognition. Furthermore, we were able to reliably predict a
specific clinical syndrome within a disease. This was shown even in a small
sample of 8 patients. Of note, we successfully applied a disease-specific
mask for prediction: discrimination remained stable when adding the meta-
analytical mask. This mask was obtained from our recent study, which
disentangled the clinical syndrome of CBS and underlying histopathology
of corticobasal degeneration with meta-analyses (Appendix, Albrecht et al.
(2017)). We stratified the analyses according to clinical syndrome, proven
histopathology, and a conjunction of both results. In CBS, we identified
gray matter loss in the basal ganglia/thalamus, frontal, parietal, and tem-
poral lobes. CBD was related to atrophy in the thalamus, frontal, temporal,
and occipital lobes. A conjunction analysis combined the results of both
cohorts by overlaying them. Here, we found the bilateral thalamus, the
bilateral posterior frontomedian cortex, posterior midcingulate cortex and
pre-/ supplementary motor area, and the left posterior superior and middle
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frontal gyrus/ precentral gyrus as affected. After comparing results qual-
itatively with other meta-analysis of neurodegenerative diseases, we pro-
posed the region of the pre-/ supplementary motor area and posterior mid-
cingulate/ frontomedian cortex as an imaging biomarker. Findings of the
voxel-based morphometry analysis in CBS are similar to the comprehen-
sive meta-analyses, thus we replicated the suggested imaging biomarker
from the meta-analyses. It should be mentioned that histopathological
evaluation was only available in one patient, so underlying neurodegen-
eration could not be confirmed for the whole group. CBS can be associated
with various pathologies. Up to now, the multi-centric cohort is clinically
evaluated by experienced experts, which should reduce a bias of misdiag-
noses. Nevertheless, we cannot exclude the possibility that other patholo-
gies influenced the results. Atrophy in our multi-centric cohort overlaps with
frontotemporal lobar degeneration, Alzheimer’s disease, PSP, and PD. All
aforementioned pathologies can possibly underly CBS. Yet, CBD remains
the most frequent pathology of CBS.
8.2 Statistical Approaches to Find Imaging Biomarker
Univariate Approach. Voxel-based morphometry and hence, also meta-
analysis are defined as univariate approaches. Only single variables are
analyzed to describe the data and its pattern, thus the results are not
causes or relationships. We could replicate the resulting regions from
the recent meta-analysis of CBS in our voxel-based morphometry analy-
sis. Still, voxel-based morphometry and meta-analysis are different ap-
proaches. An important difference is the underlying methodical technique.
Meta-analyses integrate single maxima from different studies and do not
consider the combined clusters. On the other hand, voxel-based morphom-
etry analyses also consider maxima but from a single study. Results of both
analyses are interpreted on cluster- and not on maxima-level. Further, the
variance between different studies in meta-analysis is likely to be higher
than between single subjects in a voxel-based morphometry analysis. Nev-
ertheless, one can compare and replicate results of both approaches when
investigating the same variable, namely brain volume differences.
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Multivariate Approach. Machine learning considers multiple variables
and whole patterns - so called multivariate approach - leading to a different
analyses of the data. Indeed, in Study 3 (Albrecht et al., 2019b) voxel-
based morphometry - univariate approach - was not able to detect regional
differences of gray matter volume when comparing patients with and with-
out alien/ anarchic limb phenomenon voxel-wise. Only the comparison of
healthy controls with patients showed regional gray matter volume differ-
ences that underly alien/ anarchic limb phenomenon. Interestingly, support-
vector machine classification was able to detect patterns that identify alien/
anarchic limb phenomenon in a group of patients with CBS. The prediction
not only of a disease but especially of a syndrome yields the potential to in-
form about not obviously detectable symptoms or even treatment selection.
Furthermore, even the whole concept of disease entities and underlying
pathologies can be probed by the means of machine learning. One should
also consider that if a classification model performs poor in distinguishing
between patients and healthy controls or predicting symptoms, it may also
be due to a questionable disease entity model. There are already abun-
dant examples of application of machine learning in the literature. Not only
single-disease classification is possible, more clinical utility is gained when
these classification models also incorporate often confounded diseases.
By the means of [18F]-fluorodeoxyglucose-positron emission tomography it
was already shown that an algorithm can even outperform movement dis-
order specialists in diagnosing PD, multiple system atrophy, and PSP (Tang
et al., 2010). Another promising application is treatment prediction leading
to a precision medicine approach (Study 4, Ballarini et al. (2019)). Treat-
ment can be customized and even adjusted according to brain signatures
of the patients, lowering side effects and unresponsive drug application at
all. Further medical applications remain ongoing research.
8.3 Brain Alterations and their Utility as Imaging Biomarker
In general, our results are completely consistent with the recent move
toward the incorporation of MRI data in the clinical routine and diagnostic
criteria. Nevertheless, the proposed neuroimaging biomarkers still need to
be validated in independent cohorts and on a single-patient level. This kind
of verification and integration of neuroimaging as a criterion is already suc-
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cessfully performed - for example in primary progressive aphasia. Here,
diagnostic imaging criteria were proposed by Gorno-Tempini et al. (2011)
based on previous neuroimaging studies and later statistically validated by
independent meta-analyses (Bisenius et al., 2016). Imaging-supported di-
agnosis is even considered as the higher certainty level of classification: pa-
tients need to meet clinical criteria plus showing the neuroimaging patterns.
Furthermore, Bisenius et al. (2016) independently confirmed in a cohort of
396 patients with conjunction and disjunction meta-analyses the specificity
of the proposed diagnostic neuroimaging criteria. Note that meta-analytical
results suggested to stratify criteria into metabolism and structural changes.
Other studies probed in large, independent, multi-center patient cohorts the
imaging criteria for frontotemporal lobar degeneration and Alzheimer’s dis-
ease (Dukart et al., 2013, 2011). By the means of support-vector machine
classification and the use of regional brain alterations, both diseases could
be reliably distinguished with accuracies up to 100%. Further studies ev-
idence that for both diseases the neuroimaging patterns considerably in-
crease diagnostic accuracy as compared to clinical evaluation (Rascovsky
et al., 2002; Dubois et al., 2007; Kipps et al., 2009). For these reasons,
incorporation into diagnostic criteria is an advisable step toward higher ac-
curacy of diagnosis.
8.4 Limitations
The thesis was done according to good scientific practice standards.
In spite of all our efforts, our studies recognize some limitations. First of
all, the included studies in the meta-analyses and our CBS cohort lack
in histopathological evaluation, as autopsy confirmation is extremely rare.
Hence, we can only infer the underlying neurodegeneration by their typical
clinical representation. Second, methodological and technical differences
exist among the included studies in the meta-analyses and also among
our multi-centric data. Indeed, field-strength of MR scanners, processing
protocols, or data modulation differ among the single studies in the meta-
analyses. However, the impact of these differences on the results should be
minor since within the studies patients and controls have been investigated
by the same protocols and scanner. Further, the meta-analytical algorithms
only take maxima into account and not the cluster size that is more biased
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by this heterogeneity. For the multi-centric data, standard operating proce-
dure protocols ensure comparability of the acquired data minimizing vari-
ance. Accordingly, future validation of the results of our analyses in inde-
pendent cohorts is necessary. Specificity and sensitivity of the suggested
disease-specific brain regions for differential diagnosis should be validated
in large, preferably multi-center, and independent patient cohorts. This ap-
proach has already been successfully applied to other neurodegenerative
diseases such as Alzheimer’s disease and frontotemporal lobar degenera-
tion (Dukart et al., 2013, 2011). Furthermore, we recognize also some lim-
itations in the utility of machine learning. Overall, the generalizablity of the
results needs to be proven in independent cohorts and later on a single-
patient level to serve as an outcome with diagnostic value. Here, ethical
reasons might guide how high the accuracy of a classification model needs
to be and how many false positives are allowed for a valid clinical decision-
making. On the other hand, models 100% accurate may be unrealistic
since also disease diagnosis yet primarily depends on clinical evaluation
by specialists. To enhance interpretability of machine learning outcome, it
is advantageous to compare results to other analytical approaches such
as meta-analyses including samples from various cohorts or voxel-based
morphometry.
8.5 Contributions of the Current Thesis and Future Directions
The current PhD thesis investigates the neural correlates of parkin-
sonian syndromes. We aimed at proposing neuroimaging biomarkers for
parkinsonian syndromes and apply them in subsequent analyses. For PSP
regional atrophy in midbrain and cerebral/ cerebellar pedunculi can be seen
as specific disease-related pattern, supporting the incorporation into diag-
nostic criteria. On the other hand, in PD hypometabolism is more sensitive
than structural atrophy, nevertheless not unique for the disease. By us-
ing disease-specific patterns as mask as well as whole-brain data, we were
able to distinguish patients with CBS from healthy controls and even predict
a syndrome within clinical disease up to 81% accurate.
Still, there are many open questions for future research. Our biomarker
builds a cornerstone for better disease diagnosis. Specifically, the predic-
tion of histopathology will be a necessary step in patient’s appropriate treat-
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ment. Scientists are developing medications targeting the specific patho-
logic protein causing the neurodegeneration. Therefore, an improvement in
ante-mortem diagnosis of each pathology underlying clinical syndromes is
essential. To achieve this, it is from particular interest to fuel a standard in
serial assessments of clinical, psychological, laboratory, and imaging fea-
tures to better understand the natural history of parkinsonian syndromes.
Especially, in rare atypical parkinsonian syndromes such as CBS and PSP
comparable data acquisition is needed to pool data. A first step toward this
goal is the diagnosis according to the recently amended consensus criteria
(Armstrong et al., 2013; Höglinger et al., 2017; Postuma et al., 2015). An-
other step is the development of multi-center studies and consortia applying
standard operating procedure protocols and enabling comparable datasets.
The aforementioned remarks only include some of the challenges future re-
search has to face to accurately diagnose diseases and ease symptoms. In
particular, developing a cure for neurodegenerative diseases remains the
overall goal.
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ARTICLE OPEN
Disentangling the neural correlates of corticobasal syndrome
and corticobasal degeneration with systematic and quantitative
ALE meta-analyses
Franziska Albrecht1, Sandrine Bisenius1, Rodrigo Morales Schaack1, Jane Neumann1,2 and Matthias L. Schroeter1,3
Corticobasal degeneration is a scarce neurodegenerative disease, which can only be conﬁrmed by histopathological examination.
Reported to be associated with various clinical syndromes, its classical clinical phenotype is corticobasal syndrome. Due to the
rareness of corticobasal syndrome/corticobasal degeneration and low numbers of patients included in single studies, meta-analyses
are particularly suited to disentangle features of the clinical syndrome and histopathology. Using PubMed, we identiﬁed 11
magnetic resonance imaging studies measuring atrophy in 22 independent cohorts with 200 patients contrasted to 318 healthy
controls. The anatomic likelihood estimation method was applied to reveal affected brain regions across studies. Corticobasal
syndrome was related to gray matter loss in the basal ganglia/thalamus, frontal, parietal, and temporal lobes. In corticobasal
degeneration patients, atrophy in the thalamus, frontal, temporal, and occipital lobes were found. Finally, in a conjunction analysis,
the bilateral thalamus, the bilateral posterior frontomedian cortex, posterior midcingulate cortex and premotor area/supplementary
motor area, and the left posterior superior and middle frontal gyrus/precentral gyrus were identiﬁed as areas associated with both,
corticobasal syndrome and corticobasal degeneration. Remarkably, atrophy in the premotor area/supplementary motor area and
posterior midcingulate/frontomedian cortex seems to be speciﬁc for corticobasal syndrome/corticobasal degeneration, whereas
atrophy in the thalamus and the left posterior superior and middle frontal gyrus/precentral gyrus are also associated with other
neurodegenerative diseases according to anatomic likelihood estimation method meta-analyses. Our study creates a new
conceptual framework to understand, and distinguish between clinical features (corticobasal syndrome) and histopathological
ﬁndings (corticobasal degeneration) by powerful data-driven meta-analytic approaches. Furthermore, it proposes regional-speciﬁc
atrophy as an imaging biomarker for diagnosis of corticobasal syndrome/corticobasal degeneration ante-mortem.
npj Parkinson’s Disease  (2017) 3:12 ; doi:10.1038/s41531-017-0012-6
INTRODUCTION
Recently, Armstrong et al.1 developed new diagnostic criteria
underlining the use of the term corticobasal syndrome (CBS) only
for clinical representation, whereas the term corticobasal degen-
eration (CBD) should label pathology-proven cases. CBS, as a
scarce clinical phenotype, is associated with its classical histo-
pathology, CBD, but also with other proteinopathies related to tau,
amyloid, and transactive response DNA-binding protein.2 Diag-
nostic criteria of CBS associated with CBD include rigidity or
akinesia, dystonia or myoclonus of limb, cortical sensory deﬁcit,
alien limb phenomena, or orrobuccal/limb apraxia.1 Interestingly,
the disease most often affects the hand.3 When considering a
patient having probable CBS with the pathology of CBD, four of
the mentioned symptoms should be present asymmetrically. The
patient should present at least two symptoms, which can be
symmetric, for possible CBS. Regarding higher cortical features
beside apraxia, the hallmark of CBS, additional cognitive impair-
ments are often described in the literature.1, 3
Patients with CBD show widespread deposition of hyperpho-
sphorylated 4-repeat tau in neurons and glia.4 Neuropathologic
diagnostic criteria require Gallyas/tau-positive lesions, including
neuronal inclusions, threads, coiled bodies, and astrocytic plaques
as well as neuronal loss or additionally ballooned/achromatic
neurons. Tau pathology can be found throughout gray and white
matter, basal ganglia, diencephalon as well as rostral brainstem,
while major lesions are found in superior frontal, pre-central/post-
central and superior parietal gyri, the thalamus as well as the
caudate nucleus.5 Encoded by the microtubule-associated protein
tau (MAPT) gene, tau is responsible for microtubule assembly and
stability. This function is controlled by the status of phosphoryla-
tion of tau protein. In the case of pathological dysfunction,
binding afﬁnity for microtubules decreases. Based on this tau-
histopathology, several clinical phenotypes of CBD may evolve
beside the most frequent syndrome CBS.2 This complex and
highly variable clinical presentation underlines the challenge to
accurately diagnose CBD in a living patient and develop speciﬁc
diagnostic criteria.
Nowadays, physicians and scientists have to face and disen-
tangle this wide range of clinical symptoms and distinct
histopathologies leading to a broad clinicopathological hetero-
geneity. Aiming at a powerful, detailed description and disen-
tanglement of clinical features and neurodegenerative patterns,
here we performed a meta-analysis across voxel-based morpho-
metry (VBM) imaging studies, applying structural magnetic
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resonance imaging (MRI) to detect disease-speciﬁc atrophy
patterns. For the method, we applied anatomical likelihood
estimate (ALE) meta-analyses that have been established as a
standard tool for identifying prototypical neural correlates of
neuropsychiatric diseases.6–12 The analysis was conducted sepa-
rately for the clinical syndrome CBS, and for the (post-mortem)
proven histopathology CBD to disentangle the interplay between
clinical symptoms and underlying histopathology. Note that this
approach enabled a strict dissociation and a subsequent
comparison between the neural correlates of CBS and CBD. This
distinction will be especially relevant for future treatment
strategies aiming at speciﬁc proteinopathies.
We hypothesized that in CBS, severe atrophy will be found
asymmetrically, mainly in the frontal lobe, due to the asymmetric
occurrence of motor symptoms. According to ﬁndings in
neuropathology, we hypothesized CBD lesions in the thalamus,
caudate nucleus, superior frontal regions, regions around pre-
central gyri/post-central gyri, and superior parietal regions. In
addition to ALE meta-analyses conducted separately in CBS and
CBD, we conducted a conjunction analysis to reveal overlapping
regions, which is only speciﬁc for the disease combination of CBS/
CBD.
RESULTS
Figure 1 depicts the ﬂow of information through the different
phases of study selection process according to Moher et al.13
Details of the imaging studies for CBS and CBD that were included
are summarized in Table 1 and Supplementary Table e-1. The
meta-analysis integrated 11 MRI studies including 200 patients
contrasted to 318 healthy controls. Note that two studies
contained more than one cohort, leading to the inclusion of 22
independent patient cohorts. All studies involved reported either
decreased gray matter volume or density, and none reported
increases in gray matter volume or density in patients compared
to control subjects. The CBS patient cohort included 184 patients
with mean age of 66.3 ± 4.3 years (mean ± standard deviation),
disease duration of 5.3 ± 2.0 years, and Mini-Mental State
Examination (MMSE) score of 21.9 ± 2.8. The CBD cohort included
34 patients characterized by an age of 64.4 ± 5.9 years, disease
duration of 7.0 ± 1.4 years, and a mean value in the MMSE of 23.9
± 3.2. Unpaired Student’s t-tests indicate that there is no
signiﬁcant difference in age (t = −0.65, p = 0.54), and MMSE scores
(t = 1.20, p = 0.27) between both cohorts. Note that mean disease
duration was slightly, but non-signiﬁcantly, longer in CBD than
CBS in agreement with the post-mortem deﬁnition of CBD
(t = 1.83, p = 0.09).
The upper part of Fig. 2 and Supplementary Table e-2 illustrate
the results of the ALE meta-analysis identifying the neural
correlates of CBS. The analysis across MRI studies revealed
regional atrophy in the frontal, parietal and temporal lobe, and
the basal ganglia/thalamus. More speciﬁcally, CBS affects the
thalamus, the superior precuneus/postcentral gyrus and the
posterior frontomedian cortex, posterior midcingulate cortex and
premotor area/supplementary motor area bilaterally. In the right
hemisphere, CBS is associated with atrophy in the caudate
Fig. 1 PRISMA statement ﬂow diagram. Flow of information through different phases of the systematic literature search identifying the neural
correlates of CBS and CBD according to the PRISMA statement, as suggested by Moher, Liberati, Tetzlaff and Altman.13 ROI region of interest
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nucleus, the anterior superior temporal gyrus, the anterior
superior insula, the claustrum, as well as putamen, and the
posterior insula. In the left hemisphere, the meta-analysis
additionally identiﬁed the precentral gyrus, posterior superior
frontal sulcus and middle/superior frontal gyrus, a cluster in the
inferior frontal junction area/posterior inferior frontal sulcus and
precentral gyrus, and one cluster in the inferior postcentral sulcus/
superior temporal gyrus.
The results of the ALE meta-analysis that investigated the
neural correlates of CBD are displayed in the middle part of Fig. 2
and Supplementary Table e-2. Note that patients with
histopathological CBD included several clinical symptoms beside
CBS
(see Table 1). CBS was clinically observed in only 53% (18 out of 34
cases). In general, the analysis across MRI studies revealed atrophy
in the thalamus, frontal, temporal and occipital lobes. In detail,
post-mortem proved CBD affects the thalamus, and the posterior
frontomedian cortex, posterior midcingulate cortex and premotor
areas/supplementary motor areas bilaterally. The right hemisphere
shows atrophy in the posterior superior frontal sulcus and middle/
superior frontal gyrus, while the left hemisphere shows gray
matter loss in the medial/lateral occipitotemporal gyrus, the
Table 1. Studies included in the meta-analyses that identiﬁed the neural correlates of CBS and CBD with MRI
Study Pat. (N) Clin. Syn. Hist. Cont. (N) Gender
(m/f)
Age (years) Dis. Dur.
(years)
MMSE Diagnosis of Clin. Syn. Notes
Studies included in the CBS cohort
Borroni 20 CBS NE 21 13/7 62.7± 8.0 2.0± 1.4 25.0± 3.6 Lang et al. 1994 a, b
Boxer 14 CBS NE 80 4/10 64.6± 5.9 5.6± 1.7 19.2± 8.3 (own criteria) a, b
Gross 6 out of 20 CBS NE 12 9/11 67.4± 9.8 3.9± 2.0 22.7± 6.2 NR b, *
Grossman 9 CBS NE 12 NR 64.0± 7.0 3.4± 1.5 18.8± 7.4 (own criteria)
Halpern 5 out of 13 CBS NE 12 7/6 66.8± 10.2 4.2± 1.7 19.6± 5.1 Riley et al. 2000
Huey 48 (1) CBS NE 14 25/23 66.0± 9.0 5.0 NR Boeve et al. 2005 a, b
Koss 5 out of 10 CBS NE 32 5/5 66.2± 8.3 NR 20.9± 6.1 Murray et al. 2007,
(own criteria)
a, b, *
Pardini 25 CBS NE 14 12/13 62.0± 9.0 4.0± 1.8 NR NR b
Lee 7 out of 9 CBS AD 44 5/4 59.2 8.3 18.0 UCSF-MAC b
11 out of 14 CBS CBD 4/10 66.0 6.7 23.9 UCSF-MAC b
4 out of 5 CBS PSP 3/2 69.3 8.1 21.8 UCSF-MAC b
3 out of 5 CBS FTLD-TDP 2/3 72.1 7.9 26.2 UCSF-MAC b
3 out of 5 CBS Mixed (2) 4/1 75.8 5.0 25.0 UCSF-MAC b
Whitwell 6 CBS AD 24 2/4 60.0 7.0 26.0 Boeve et al. 2003 a, b
7 CBS CBD 1/6 68.0 6.0 20.0 Boeve et al. 2003 a, b
6 CBS PSP 3/3 69.0 7.0 27.0 Boeve et al. 2003 a, b
5 CBS FTLD-TDP 3/2 71.0 6.0 22.0 Boeve et al. 2003 a, b
Total CBS 184 265 102/110 66.3± 4.3 5.3± 2.0 21.9± 2.8
Studies included in the CBD cohort
Lee 3 out of 5 bvFTD CBD 44 3/2 65.9 7.9 18.5 Neary et al. 1998 b
11 out of 14 CBS CBD 4/10 66.0 6.7 23.9 UCSF-MAC b
5 out of 7 EM CBD 2/5 64.4 5.6 25.3 (own criteria) b
1 PCA CBD 0/1 54.8 8.6 27.0 McMonagle et al. 2006 b
4 out of 5 PNFA CBD 1/4 71.0 5.6 25.0 Neary et al. 1998, Gorno-
Tempini et al. 2004
b
Rankin 3 out of 5 bvFTD CBD 53 3/2 61.4 7.6 22.0 Neary et al. 1998 a, b
Whitwell 7 CBS CBD 24 1/6 68.0 6.0 20.0 Boeve et al. 2003 a, b
Total CBD 34 121 14/30 64.4± 5.9 7.0± 1.4 23.9± 3.2
Total CBS +
CBD(3)
200 318 111/124 65.8± 4.9 5.7± 2.0 22.5± 3.1
Gender, age, disease duration, and MMSE scores are speciﬁed for patients (mean ± standard deviation). All MRI studies used 1.5T (except for *= 3T). Clinical
data are reported for all patients, whereas in four studies, MRI analyses were performed in a subcohort. Total mean scores were calculated without Rankin and
Whitwell because they reported data as median. Data on references of included studies and diagnostic criteria are available in the Supplementary data
(Supplementary Table e-1). Underline signiﬁes the total score.
a Correction for multiple comparisons
b modulated
(1) Only 5 CBD cases were proven by pathology. (2) Mixed cases showed features of PSP, CBD and FTLD-TDP mixed with possible AD. (3) CBS–CBD cohorts of
Lee and Whitwell were only used once to calculate total CBS + CBD
AD Alzheimer’s disease, bvFTD behavioral variant frontotemporal dementia, CBD corticobasal degeneration, CBS corticobasal syndrome, Clin. Syn. clinical
syndrome, Con. controls, Dis. Dur. disease duration, EM executive-motor, f female, FTLD-TDP frontotemporal lobar degeneration with TAR DNA-binding protein
43 inclusions, Hist. histopathology, m male, MMSE Mini-Mental State Examination, N number of subjects, NE not examined, NR not reported, Pat. patients, PCA
posterior cortical atrophy, PNFA progressive nonﬂuent aphasia, PSP progressive supranuclear palsy, UCSF-MAC University of California, San Francisco Memory
and Aging Center criteria for CBS
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precentral gyrus, posterior superior frontal sulcus and middle/
superior frontal gyrus, the posterior frontal sulcus and middle
frontal sulcus, and the anterior insula.
The lower part of Fig. 2 and Supplementary Table e-2 show the
results of the ALE meta-analysis combining all CBS and CBD
patients. Generally, the results of this analysis revealed that the
Fig. 2 Impaired regions in CBS and CBD. Impaired brain regions in CBS and CBD in comparison with healthy control subjects–anatomical
likelihood estimates meta-analyses. Atrophy was measured by MRI. The CBS analysis (red) included 184 patients from 17 cohorts contrasted to 265
healthy subjects. The CBD analysis (blue) included 34 patients from seven cohorts contrasted to 121 healthy subjects. The analysis of the combined
cohort of CBS and CBD (white) included 200 patients contrasted to 318 healthy control subjects. Coordinates are reported in MNI space. L left
Fig. 3 Conjunction analysis. Conjunction analysis for impaired brain regions in CBS and CBD in comparison with healthy control
subjects–anatomical likelihood estimates meta-analyses. White clusters indicate overlap of both meta-analyses (CBS and CBD). Atrophy was
measured by MRI. Coordinates are reported in MNI space. L left
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basal ganglia/thalamus and frontal lobe are affected. In detail,
atrophy was again identiﬁed in the thalamus, and the posterior
frontomedian cortex, posterior midcingulate cortex and premotor
areas/supplementary motor areas bilaterally. Further, atrophy was
detected in the right insula and claustrum/putamen. Finally, the
left hemisphere showed gray matter loss in the inferior frontal
junction/posterior inferior frontal gyrus and precentral gyrus, the
precentral gyrus/posterior superior frontal sulcus and middle/
superior frontal gyrus, and the anterior superior insula.
Finally, a conjunction analysis was performed by overlaying the
results of the two separate meta-analyses on CBS and CBD to
identify brain regions involved in both, CBS and CBD. Results are
displayed in Fig. 3, where white shading indicates overlap of both
analyses. The analysis revealed that four clusters (1) in the bilateral
thalamus, (2) in the posterior frontomedian cortex/posterior
midcingulate cortex and premotor area/supplementary motor
area, (3) in the left posterior superior frontal sulcus and middle
frontal gyrus/precentral gyrus, and (4) in the left posterior superior
frontal sulcus and middle frontal gyrus were consistently atrophic
in both cohorts, CBS and CBD.
DISCUSSION
To our knowledge, here we present the ﬁrst powerful data-driven
meta-analyses identifying and comparing the neural correlates of
CBS and CBD for MRI measuring atrophy in comparison with
healthy control subjects. The design enabled high validity and
statistical power by including 200 patients with this rare disease
and 318 healthy control subjects. Additionally, the inclusion
criterion of whole brain imaging studies for all meta-analyses
guaranteed a data-driven approach.
Our results reveal that CBS is characterized by gray matter loss
in the basal ganglia/thalamus, frontal, parietal and temporal lobes.
In CBD patients, atrophy in the thalamus, frontal, temporal and
occipital lobes was found. The latter results on CBD agree with
Dickson et al.,4 who described histopathologically atrophy and
tau-immunoreactive lesions in the superior frontal/parietal,
pre- and postcentral gyri, the caudate nucleus, the putamen,
and the thalamus in CBD.
Most remarkably, in a conjunction analysis focusing on common
brain regions affected by both, CBS and CBD, our study identiﬁed
four brain areas with signiﬁcant atrophy: (1) the bilateral anterior
thalamus, and (2) the bilateral posterior frontomedian cortex,
posterior midcingulate cortex and premotor area/supplementary
motor area, and, in the left hemisphere, (3) the posterior superior
frontal sulcus and middle frontal gyrus/precentral gyrus, and (4)
the left posterior superior frontal sulcus and middle frontal gyrus.
As these regions obviously constitute the core hubs for CBS/CBD
according to our meta-analyses, we want to discuss them now
in more detail. With regard to disease speciﬁcity, we will compare
results of our ALE meta-analysis with structural MRI ALE
meta-analyses of other neurodegenerative diseases (Table 2).
Note that the differential diagnosis between CBS/CBD, progressive
supranuclear palsy, multiple system atrophy, Lewy body disease,
and Parkinson’s disease is of paramount interest, as all of these
might be associated with an (atypical or typical) Parkinson’s
syndrome.
Thalamic and left precentral atrophy is not speciﬁc for CBS/CBD
Although the thalamus was altered in both, CBS and CBD, changes
in thalamic structure do not seem to be an exclusive imaging
biomarker for CBS/CBD. Other neurodegenerative diseases, such
as Alzheimer’s disease, progressive supranuclear palsy, behavioral
variant frontotemporal dementia, or Huntington’s disease are
also characterized by thalamic atrophy.14 Atrophy in the thalamus
was also conﬁrmed in recent ALE meta-analyses in Alzheimer’s
disease, progressive supranuclear palsy, and multiple system
atrophy.9, 12, 15, 16 Furthermore, thalamic volume also shrinks in
healthy people throughout life independent from and prior to
total volume loss.17
Table 2. Meta-analytical evidence for biomarker speciﬁcity of regional atrophy in CBS/CBD as measured with MRI
Disease Study Anatomical region
Thalamus Bl. fronto-median
and midcingulate
cortex
Bl. premotor
area and
supplementary
motor area
L. pre-central
gyrus
L. superior
frontal sulcus
and middle
frontal gyrus
Parkinson’s syndromes
Parkinson’s disease 15, 16 − − − + +
Atypical Parkinson’s syndromes
CBD and syndrome Present
meta-analysis
+ + (posterior) + + +
Progressive supranuclear palsy 15 + − − + −
Multiple system atrophy 16 + − − − −
Lewy body dementia 40* (−) (−) (−) (−) (−)
Alzheimer’s disease 9, 12, 41 + − − − −
Behavioral variant frontotemporal dementia 8–11 − + (anterior) − − −
Primary progressive aphasias
Nonﬂuent/ agrammatic variant (progressive non-ﬂuent
aphasia)
9, 10, 42 − − − − +
Semantic variant (semantic dementia) 9, 10, 42, 43 − − − − −
Logopenic variant (logopenic aphasia) 42 − − − − −
Meta-analyses were conducted by calculating ALEs in the gray matter. Other methods, such as effect-size signed differential mapping, were not taken into
account to avoid a bias of different methods.
*Only one study by Zhong et al.40 applying anisotropic effect size version of signed differential mapping (AES-SDM) was included, because no ALE meta-
analysis has been available to date.
Bl bilateral, L left, NR not reported to date
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In our conjunction analysis, the region of the left posterior
superior frontal sulcus and middle frontal gyrus/precentral gyrus
also showed signiﬁcant atrophy. Remarkably, atrophy was located
anterior to the right hand area in the precentral gyrus,18 ﬁtting
well with the clinical ﬁnding that the hand is most often impaired
in CBS.3 The precentral gyrus encompasses parts of primary motor
and premotor cortex. Dorsal premotor regions are responsible for
promoting movements and response selection depending on
spatial cues.19 Ventral premotor regions regulate hand movement
to manipulate and grasp objects, and contain functions related to
cognition such as the comprehension of actions. Goldenberg20
suggested that atrophy in ventral regions of the left hemisphere is
correlated with apraxia, in particular imitating hand postures and
using or pantomiming the use of mechanical tools. Clinically, CBS
is most frequently linked to apraxia21–an impairment in higher
cortical features concerning skillful motoric movement without
motoric deﬁcits per se.
With regard to other neurodegenerative diseases (Table 2),
recent meta-analyses also show atrophy in the left middle frontal
gyrus in Parkinson’s disease, and in the nonﬂuent/agrammatical
variant of primary progressive aphasia, while atrophy in the left
precentral gyrus is shown in Parkinson’s disease and progressive
supranuclear palsy.9, 10, 15, 16 This leads to the conclusion that
atrophy in these brain regions is not disease-speciﬁc for CBS/CBD.
Atrophy in premotor area/supplementary-motor area and posterior
midcingulate/frontomedian cortex is speciﬁc for CBS/CBD
According to the conjunction analysis, the premotor areas and
supplementary motor areas showed atrophy in both CBS and CBD.
These regions are essential for linking cognition to action22 and
their atrophy can lead to the alien limb phenomenon, which is
part of the diagnostic criteria for CBS. Although Parkinson’s
disease patients display less activation or a loss of neurons in this
region,22 ALE meta-analyses have never identiﬁed these brain
regions as affected by atrophy in other neurodegenerative
diseases, including Parkinson’s disease (Table 2; in particular15, 16).
Additionally, the conjunction analysis revealed signiﬁcant gray
matter loss in the posterior frontomedian and midcingulate cortex
in CBS/CBD. Although former ALE meta-analyses have shown
atrophy in behavioral variant frontototemporal dementia in the
anterior frontomedian and midcingulate cortex,8–11 the respective
location was much more posterior in CBS/CBD without any
overlap. In sum, atrophy in the premotor area/supplementary
motor area and posterior midcingulate/frontomedian cortex
seems to be speciﬁc for CBS/CBD, suggesting these brain regions
as candidates for diagnostic and differential diagnostic imaging
biomarkers in CBS/CBD in contrast to other neurodegenerative
diseases (Table 2).
Study’s limitations
Our study identiﬁed consistent ﬁndings of gray matter volume
changes in CBS and CBD, but it also has its limitations. A main
deﬁcit of all included studies is the lack of a common standard in
using special diagnostic criteria for evaluating CBS, where some
studies used idiosyncratic criteria based on clinical expertise
(Table 1). Therefore, slightly differently included clinical symptoms
and, at least partly, imprecise diagnoses are possible. However,
due to the meta-analytical approach, this confounding effect
should be minor and not bias our results decisively. Armstrong
et al.1 built a foundation for new consensus criteria, which should
be employed in clinical studies to help overcome the problem of
not strictly comparable diagnosis. In future, it will be possible to
include only studies based on these new criteria in meta-analyses.
Due to low incidence and ethical issues, MRI studies on autopsy
proven cases of CBD are rare. Hence, results of our CBD analysis
should be handled with caution due to the small cohort of
patients. CBS/CBD patients are characterized by asymmetrical
atrophy and symptoms. Unfortunately, the original studies did not
separate their analyses into patients suffering from left or right-
sided clinical symptoms, although Armstrong et al. (2013) under-
lined the importance of symptom laterality in the new diagnostic
criteria. Studies just reported local maxima of atrophy from whole
CBS/CBD cohorts. Thus, conducting separate meta-analyses for left
and right sided CBS was not possible. An important contributing
factor could be the preference for using either the right or left
hand. We were not able to control for handedness due to
unreported data. One should also consider that there are
methodological differences between VBM studies, for instance,
ﬁeld-strength of scanners, processing protocols, or data modula-
tion. However, these differences would not have confounded our
results, because the ALE method only takes maxima into account
and not cluster sizes. During the literature search, we did not ﬁnd
enough 18F-ﬂuorodeoxyglucose positron emission tomography
(FDG-PET) or diffusion tensor imaging (DTI) studies, which
reported coordinates in stereotactic space, to conduct meaningful
meta-analyses. Thus, our meta-analyses had to be limited to
structural MRI atrophy data. We recommend extending meta-
analyses to other imaging modalities in the future, when more
studies are available. It is well-known that for different imaging
modalities regional alterations might be dissociated in time and
space.8, 12, 23, 24
Furthermore, speciﬁcity and sensitivity of the suggested
disease-speciﬁc brain regions in differentiation of neurodegen-
erative diseases like CBS/CBD have to be validated in large,
preferably multi-centric, and independent patient cohorts. These
patient cohorts should ideally provide information about clinical
and imaging data as well as surrogate markers for histopathology
from serum and cerebrospinal ﬂuid or even post mortem
validation. This approach has already been successfully applied
to other neurodegenerative diseases such as Alzheimer’s disease
and frontotemporal lobar degeneration.25, 26 Validating results of
ALE meta-analyses in independent cohorts is also necessary due
to the fact that these meta-analyses generally include maxima and
not cluster sizes of the various imaging studies. Consequently,
single studies might have shown that dementia diseases may be
regionally more unspeciﬁc than the present meta-analyses
suggest.
CONCLUSION
The meta-analyses build a foundation for a better disentangle-
ment of the clinical phenotype CBS, and the histopathological
type CBD. Results suggest atrophy in the premotor area/
supplementary motor area and posterior midcingulate/frontome-
dian cortex as an imaging biomarker for diagnosis of CBS or CBD
ante-mortem.
MATERIALS AND METHODS
General study selection
Assuring validity and quality, the meta-analysis was conducted according
to preferred reporting items for systematic reviews and meta-analyses
(PRISMA) guidelines13 (also see www.prisma-statement.org). To identify
adequate studies, PubMed was used applying the following search
strategy: (corticobasal degeneration OR CBD OR corticobasal syndrome
OR CBS) AND (voxel* OR gray matter OR VBM). Studies were included if
they fulﬁlled the following criteria: (1) peer-reviewed, (2) diagnosis
according to established diagnostic criteria, (3) original study, (4)
comparison with age-matched healthy control group, (5) results normal-
ized to a stereotactic space such as the Talairach27 or the Montreal
Neurological Institute’s28 (MNI) reference system and respective coordi-
nates available, (6) whole brain study. Region-of-interest analyses or case
studies were excluded to prevent any a priori regional assumptions. Since
we did not ﬁnd enough imaging studies that applied FDG-PET or DTI,
which reported coordinates in stereotactic space, studies were limited to
structural MRI atrophy data. We concentrated on reporting gray matter
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atrophy studies because only two studies analyzed white matter changes.
Literature search was performed between November 2014 and January
2015 reviewing all studies regardless of their publication date. During this
process, we contacted two study authors and obtained data on maxima
from one study.
Statistical analyses
To extract the neural correlates of CBS and CBD, we applied the ALE meta-
analysis method.29–32 This method was ﬁrst invented for meta-analyses of
functional imaging studies with psychological stimulation of participants
(here called activation likelihood estimate). Later, this approach was
extended to imaging studies during rest investigating atrophy or
hypometabolism.6–12
In 2009, Eickhoff et al.33 presented a revised analysis algorithm. The
underlying method transforms extracted peaks into Gaussian probability
distributions around these coordinates. The estimation of the width of
these Gaussian probability distributions is adapted for each study
according to the number of included subjects based on empirical
estimates of between-subject and between-template variability. The
resulting ALE maps are later combined across studies and tested against
the null hypothesis of a random spatial distribution between the modeled
maps. In this step, regions where empirical ALE values are higher than
those expected by chance are identiﬁed. The resulting map is thresholded
with a customized threshold to report only cluster that exceed the number
of voxels corresponding to 5% possible false positives.
The analyses were performed in BrainMap Ginger ALE 2.334 using
extracted peaks of atrophy in CBS/CBD studies. Coordinates reported in the
stereotactic space of Talairach and Tournoux were transformed into the
stereotactic MNI space using the Lancaster transform implemented in
Ginger ALE 2.3.35 As an error corrector for multiple testing we applied the
conservative false discovery rate nonparametric p-value threshold
(FDR pN) correction30, 36 with a threshold of p < 0.05. Clusters with a
minimum size of 374mm3 are reported. Recently, Eickhoff, Laird, Fox,
Lancaster, and Fox (2016)37 reported about implementation errors in
determining thresholds to account for multiple comparisons in older
GingerALE software distributions. Note that ALE scores and peak locations
are unaffected by these errors. We compare our results to other meta-
analyses using also these versions of GingerALE. This way, we ensure
homogeneity and comparability to other previous meta-analyses on
neurodegenerative diseases. Future studies shall apply the new corrected
GingerALE software versions homogeneously for different neurodegen-
erative diseases.
To disentangle the neural correlates for CBS/CBD speciﬁcally, we
performed data analyses in three cohorts: (1) cohort of clinically evaluated
CBS patients (CBS cohort), (2) cohort of histopathologically proven CBD
patients (CBD cohort), and (3) cohort including all CBS and CBD data (CBS
+ CBD cohort). Additionally, we conducted a conjunction analysis between
the results of the separate meta-analyses on CBS and CBD in order to
reveal regions that were consistently atrophied in both cohorts.
For purposes of visualization, results were imported into MRIcron.38
To reveal possible differences in age, disease duration, and MMSE scores
between groups, we performed Student’s t-tests in R39 with a signiﬁcance
threshold at p < 0.05.
Potential bias
Several methods were applied to reduce the risk of bias of single studies
and across studies. To overcome the problem of a bias toward speciﬁc
brain areas, only studies using a quantitative automated whole brain
analysis were included. Studies reporting results of region-of-interest
approaches were not considered. To exclude any impact of age as a
confounding factor on our results, only studies comparing patients with
age-matched healthy controls were included into the meta-analysis.
Studies investigating brain atrophy compared to other neurodegenerative
diseases were also excluded to avoid any bias due to divergent control
groups. According to PRISMA statement, two investigators performed
literature search and selection separately (FA and RMS). As proposed in
Eickhoff’s et al.33 new algorithm, the number of patients included in each
study was taken into account in data synthesis. This leads to a balanced
analysis. Although studies with negative ﬁndings might theoretically have
been omitted, this publication bias is unlikely, because CBS and CBD
patients generally show severe atrophy in comparison with healthy control
subjects.
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